Search

Your search keyword '"Giovanni Damiani"' showing total 285 results
Start Over Author "Giovanni Damiani"
285 results on '"Giovanni Damiani"'

101. Do Sleep Disorders and Western Diet Influence Psoriasis? A Scoping Review

Author

Ilaria Controne, Egeria Scoditti, Alessandra Buja, Alessia Pacifico, Khalaf Kridin, Massimo Del Fabbro, Sergio Garbarino, and Giovanni Damiani

Subjects
Sleep Wake Disorders, Nutrition and Dietetics, Diet, Western, inflammation, Humans, Psoriasis, diet, psoriasis, sleep, sleep disorders, western diet, Sleep, Western, Food Science
Abstract

Western diet may trigger sleep disorders and vice versa, but their single and mutual effects on systemic inflammatory diseases (i.e., psoriasis) are far from being fully elucidated. At the same time, psoriatic patients display a great burden of sleep disorders and dysmetabolisms related to an unhealthy lifestyle (i.e., diet). These patients are also affected by a chronic disorder deeply modulated by environmental factors (i.e., sleep and diet) capable to influence drug-response and disease progression. Thus, we aimed to summarize the evidence in the literature that may highlight a potential link among psoriasis–diet–sleep in order to further promote a multidisciplinary approach to psoriatic patients in the scientific community.

Published
2022

103. Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature

Author

Nicola Luigi Bragazzi, Paolo D. Pigatto, Giovanni Damiani, and Roberto Eggenhöffner

Subjects
Drug, medicine.medical_specialty, media_common.quotation_subject, 0206 medical engineering, Biomedical Engineering, 02 engineering and technology, Article, Biomaterials, Nanodermatology, medicine, lcsh:TA401-492, Nanobiotechnologies, Available drugs, Intensive care medicine, Adverse effect, lcsh:QH301-705.5, media_common, Atopic dermatitis, business.industry, 021001 nanoscience & nanotechnology, medicine.disease, 020601 biomedical engineering, Clinical trial, Safety profile, lcsh:Biology (General), Exudative eczema, lcsh:Materials of engineering and construction. Mechanics of materials, 0210 nano-technology, business, Biotechnology
Abstract

Atopic dermatitis is a chronic, relapsing, non-contiguous, exudative eczema/dermatitis, which represents a complex, multi-factorial disorder, due to an impairment of the stratum corneum barrier. Currently available drugs have a low skin bioavailability and may give rise to severe adverse events. Nanotechnologies, including nano-particles, liposomes, nano-gels, nano-mixtures, nano-emulsions and other nano-carriers, offer unprecedented solutions to these issues, enabling: i) the management of different clinical forms of atopic dermatitis, especially the recalcitrant ones, i) a better bio-availability and trans-dermal drug targeted delivery at the inflammation site, ii) dose control, iii) significant improvements both in clinical symptoms and immune responses, iv) with less adverse events being reported and a better safety profile. However, some nano-sized structures could amplify and even worsen symptoms in particularly susceptible individuals. Furthermore, most studies included in the present systematic review have been conducted in-vitro or in-vivo, with few randomized controlled clinical trials (RCTs). Future investigations should adopt this design in order to enable scholars achieving robust findings and evidence. Therefore, given the above-mentioned shortcomings, further research in the field is urgently warranted., Graphical abstract The effects of nanobiotechnologies-based pharmaceutics in atopic dermatitis.Image 1, Highlights • Atopic dermatitis is a chronic, relapsing eczema/dermatitis, due to an impairment of the stratum corneum barrier. • Currently available drugs have a low skin bioavailability and may give rise to severe adverse events. • Nanotechnologies offer unprecedented solutions, enabling the management of different clinical forms of atopic dermatitis.

Published
2019

104. Sarecycline treatment for acne vulgaris: Rationale for <scp>weight‐based</scp> dosing and limited impact of food intake on clinical efficacy

Author

Ayman Grada, James Q. Del Rosso, Emmy Graber, Christopher G. Bunick, Linda Stein Gold, Angela Y. Moore, Hilary Baldwin, Zaidal Obagi, Giovanni Damiani, Timothy Carrothers, Brian McNamee, and Eva Hanze

Subjects
Eating, Treatment Outcome, Tetracyclines, Acne Vulgaris, Administration, Oral, Humans, Minocycline, Dermatology, General Medicine, Anti-Bacterial Agents
Abstract

Tetracycline-class antibiotics are frequently prescribed by dermatologists, commonly for acne vulgaris. Gastrointestinal absorption of first and second-generation tetracycline-class antibiotics, including doxycycline and minocycline, may be reduced by co-administration with food, resulting in potentially lower clinical efficacy. Development of novel compounds and formulations that are not impacted by diet could improve compliance, absorption, and effectiveness among patients. The objective of this study is to investigate weight-based dosing protocols and the impact of food intake, including high-fat meals, on the absorption, and clinical efficacy of sarecycline, a novel oral narrow-spectrum third-generation tetracycline-class antibiotic approved by the Food and Drug Administration for acne vulgaris treatment. Data from 12 clinical studies were analyzed using population pharmacokinetic modeling, exposure-response modeling and pharmacodynamics to evaluate sarecycline dosing recommendations. The extent of exposure is estimated to decrease by 21.7% following co-administration of a sarecycline tablet with a high-fat meal. Based on the PopPK-PD model, this is equivalent to a decrease in efficacy of 0.9 inflammatory lesions, which is not clinically meaningful. Sarecycline can be administered using weight-based dosing with or without food. Co-administration with high-fat food has a limited impact on clinical efficacy. The pharmacokinetics of oral sarecycline may provide added convenience and support ease of use and improved compliance for acne vulgaris patients.

Published
2021

105. COVID‐19 vaccination and patients with psoriasis under biologics: real‐life evidence on safety and effectiveness from Italian vaccinated healthcare workers

Author

F. Allocco, Giovanni Damiani, and P.o Malagoli

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Outbreak, Dermatology, medicine.disease, Vaccination, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), 030220 oncology & carcinogenesis, Psoriasis, Health care, Medicine, Misinformation, business, Intensive care medicine
Abstract

COVID‐19 outbreak had drastically modified the treatment of chronic inflammatory diseases (i.e. psoriasis) in terms of drug delivery, visits booking and patients’ adherence. Furthermore, during lockdown several patients modified or even discontinued their anti‐psoriatic treatments due to misinformation, COVID‐phobia or even cabin fever syndrome experiencing a psoriatic flare and decreasing the overall daily functionality and quality of life.

Published
2021

106. Effectiveness of community face mask use on COVID-19 epidemiological trends and patterns in Italy: evidence from a 'translational' study

Author

Nicola Luigi Bragazzi, Jianhong Wu, Jude Dzevela Kong, Naim Mahroum, and Giovanni Damiani

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), viruses, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 030106 microbiology, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Epidemiology, Pandemic, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Intensive care medicine, Pandemics, Coronavirus, General Immunology and Microbiology, business.industry, fungi, Masks, COVID-19, virus diseases, General Medicine, body regions, Infectious Diseases, Italy, Communicable Disease Control, Prevention control, business, Infectious agent
Abstract

The novel, emerging coronavirus termed as the ‘Severe Acute Respiratory Syndrome (SARS)-related Coronavirus Type 2’ (SARS-CoV-2) is the infectious agent responsible for the generally mild but somet...

Published
2021

107. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas

Author

Grzegorz Dyduch, Elżbieta Broniatowska, Magdalena Spałkowska, Anna Wojas-Pelc, and Giovanni Damiani

Subjects
Medicine (General), Skin Neoplasms, Nevi and melanomas, medicine.drug_class, precision medicine, Estrogen receptor, Article, Receptors, G-Protein-Coupled, R5-920, melanoma, estrogen, gender, Estrogen Receptor beta, Humans, Medicine, dysplastic nevus, neoplasms, integumentary system, business.industry, Melanoma, Estrogen Receptor alpha, General Medicine, medicine.disease, GPER, Cross-Sectional Studies, Receptors, Estrogen, Estrogen, G-Protein Coupled Estrogen Receptor 1, Dysplastic nevus, Cancer research, business, Dysplastic Nevus Syndrome, Estrogen receptor alpha, estrogen receptor
Abstract

Background and Objectives: Epidemiologic data show significant differences in melanoma incidence and outcomes between sexes. The role of hormonal receptors in the pathogenesis of melanocytic lesions remains unclear, thus we performed this study aiming to assess estrogen receptors expression in different melanocytic lesions. Materials and Methods: We performed a cross-sectional study that included 73 consecutively excised melanocytic lesions. Estrogen receptor alpha (ERα), beta (ERβ), and G-protein coupled estrogen receptor (GPER) expression was analyzed in melanocytes and keratinocytes of common nevi, dysplastic nevi, melanoma, healthy skin margin, and in sebaceous and sweat gland cells. Results: ERβ expression was higher in dysplastic nevi margin melanocytes compared to common nevi (p = 0.046) and in dysplastic nevi keratinocytes compared to melanoma keratinocytes (p = 0.021). ERβ expression was significantly higher in margin melanocytes compared to melanoma melanocytes (p = 0.009). No difference in ERβ expression was shown between melanocytes of three types of lesions. GPER expression was higher in nuclei and cytoplasm of dysplastic nevi (p = 0.02 and p = 0.036 respectively) and at the margin compared to melanoma. GPER expression was lower in sebaceous glands of tissue surrounding common nevi (p = 0.025) compared to dysplastic nevi. GPER expression was higher in skin margin tissue melanocytes (p = 0.016 nuclear, p = 0.029 cytoplasmic) compared to melanoma melanocytes. There were no differences in ERα expression between the melanocytic lesions. Conclusion: Further large-scale studies are warranted to investigate the potential role of ERβ and GPER in the pathogenesis of melanocytic lesions.

Published
2021

108. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis (Preprint)

Author

Roobaea Alroobaea, Saeed Rubaiee, Abdulkader S. Hanbazazah, Haitham Jahrami, Sergio Garbarino, Giovanni Damiani, and Nicola Bragazzi

Abstract

BACKGROUND Atopic dermatitis displays a relevant sleep burden sustained by clinical (i.e., itch), psychological (i.e., inadequate coping strategies) and therapeutic (i.e. frequent loss of drug response) triggers. Dupilumab, the first biologic approved for atopic dermatitis, showed excellent effects on improving pruritus and sleep after only two weeks of treatment but, in some cases, may have paradoxical effects. OBJECTIVE The rate of sleep-related side-effects remains unknown. More specifically, adverse-drug reactions (ADRs) related to dupilumab have been investigated during the safety phase of randomized clinical trials or in small retrospective epidemiological surveys, but little is known about sleep-related ADRs in real-life settings. Therefore, we took advantage of a global large-scale pharmacovigilance database, carrying out a comprehensive data mining analysis to look at different sleep-related ADRs reported among patients under anti IL-4/13 therapy. METHODS We analysed individual case study reports (ICSRs) in VigiBase, the World Health Organization (WHO) global pharmacovigilance database of ADRs collected by national drug authorities in >140 countries (>90% of the world population). We looked for patterns of potentially sleep-related ADRs and we applied a disproportionality analysis based on Bayesian Confidence Propagation Neural Network (BCPNN). A meta-analytical approach was used to synthesize the overall effect size of sleep-related ADRs potentially associated to Dupilumab administration. RESULTS From inception up to March 9, 2021, 94,065 ADRs from 37,848 unique reports were included and analyzed in the present paper: 1,294 of them (1.4%) concerned sleep disturbances (n=27). Most of sleep-related complaints were generic sleep disorders (n=630), followed by insomnia (n=312), somnolence (n=81), lethargy (n=60), night sweats (n=30), middle insomnia (n=39), hypersomnia (n=25), poor quality sleep (n=21), initial insomnia (n=17), sleep apnoea syndrome (n=13), nightmares (n=11) and sleep deficit (n=11). Interestingly, restlessness and restless leg syndrome, nocturnal dyspnoea, narcolepsy and bruxism were reported in 7, 6, 5, 4 and 3 cases, respectively. Only sleep deficit (OR 15.67 [CrI 8.61-28.51]; IC 3.24 [CrI 2.26-3.97]), generic sleep disorder (OR 6.22 [CrI 5.74-6.73]; IC 2.60 [CrI 2.48-2.71]), and nocturnal dyspnoea (OR 3.68 [CrI 1.53-8.87]; IC 1.56 [CrI 0.03-2.56]) achieved the statistical significance threshold. CONCLUSIONS In this work, we identified over 37,000 unique case-reports of Dupilumab side-effects reported on the WHO pharmacovigilance database. We specifically categorised those related to sleep issues, which were 1,294. Our findings from large numbers of cases provide data supporting the clinical observations that Dupilumab is usually effective in improving sleep quality and sleep disturbances/impairments but sometimes may impair circadian rhythm and sleep. Further work is needed to closely scrutinise the impact of Dupilumab on sleep, in terms of underlying mechanisms, and to better understand residual sleep disorders in patients with atopic dermatitis and other allergic diseases treated with Dupilumab. Thus, sleep monitoring may be helpful for dermatologists in managing atopic dermatitis patients treated with dupilumab. The limitations of spontaneous reporting systems including underreporting and reporting bias, heterogeneity of sources and impossibility to infer any causal relationship merit consideration and further research is needed.

Published
2021

109. Switching infliximab in psoriatic patients during COVID‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies

Author

Paolo D. Pigatto, G. Odorici, Giovanni Pellacani, Francesca Farnetani, Giovanni Damiani, Andrea Conti, and Roberta Ruggeri

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Short Report, COVID-19 pandemic, Dermatology, Dermatological referral, biologics, infliximab, interclass switching, intraclass switching, psoriasis, switching, teledermatology, Psoriasis, Internal medicine, Pandemic, Adalimumab, medicine, Humans, Contraindication, Pandemics, Aged, Retrospective Studies, business.industry, SARS-CoV-2, COVID-19, Retrospective cohort study, COVID‐19 pandemic, General Medicine, medicine.disease, Infliximab, humanities, Treatment Outcome, business, medicine.drug
Abstract

During this pandemic, dermatological infusion centers were partially unavailable, suspended or even reconverted to guest COVID‐19 patients, consequently infliximab (IFX) infusions became challenging for their both logistic arrangement and also for patients' COVID‐19 phobia. This 48 weeks follow‐up retrospective observational study included 37 PsO patients that underwent IFX SB2 during pandemic in two primary dermatological referral centers. In 23 (62.1%) we had to switch from IFX to other biologics, not motivated by adverse reactions, contraindication or even loss of response but only to pandemic related conditions. Nine patients underwent interclass switching and 15 underwent intraclass switching; interestingly 2 patients that underwent adalimumab SB‐5 switched back to IFX. Interclass switching was privileged in elder patients and smokers. All patients at week 48 achieved PASI 100. Intra‐ and interclass switchings are both safe and effective strategies in psoriatic patients with COVID‐19 phobia and/or difficulties to undergo infliximab infusions.

Published
2021

110. Diet-Related Phototoxic Reactions in Psoriatic Patients Undergoing Phototherapy: Results from a Multicenter Prospective Study

Author

Paolo D. Pigatto, Egeria Scoditti, Antonio Cristaudo, Rosalynn R Z Conic, Giovanni Damiani, Aldo Morrone, Steven R. Feldman, Khalaf Kridin, Paolo Iacovelli, Alessia Pacifico, Marco Ardigò, Sergio Garbarino, Sara di Gregorio, and Ayman Grada

Subjects
Adult, Male, Diet, Vegan, medicine.medical_specialty, Erythema, Skin type, precision medicine, efficacy, exposome, exposures, Gastroenterology, Article, Internal medicine, Psoriasis, Humans, NB-UVB, Medicine, TX341-641, Prospective Studies, Prospective cohort study, Photosensitizing Agents, Nutrition and Dietetics, business.industry, Nutrition. Foods and food supply, Diet, Vegetarian, vegans, Potential effect, vegetarians, Phytophotodermatitis, omnivores, Ultraviolet b, psoriasis, medicine.disease, Italy, inflammation, Female, medicine.symptom, business, diet, Dermatitis, Phototoxic, Food Science, Phototoxic reactions, phototherapy
Abstract

Vegans and vegetarians often consume foods containing photosensitizers capable of triggering phytophotodermatitis. The potential effect of vegan and vegetarian diets on the response of psoriatic patients undergoing phototherapy is not well characterized. We assessed clinical outcomes of vegan, vegetarian and omnivore adult psoriatic patients undergoing band ultraviolet B phototherapy (NB-UVB). In this multicenter prospective observational study, we enrolled 119 adult, psoriatic patients, of whom 40 were omnivores, 41 were vegetarians and 38 were vegans, with phototherapy indication. After determining the minimum erythemal dose (MED), we performed NB-UVB sessions for 8 weeks. The first irradiation dosage was 70.00% of the MED, then increased by 20.00% (no erythema) or by 10.00% (presence of erythema) until a maximum single dose of 3 J/cm2 was reached and constantly maintained. All the enrolled patients completed the 8 weeks of therapy. Severe erythema was present in 16 (42.11%) vegans, 7 (17.07%) vegetarians and 4 (10.00%) omnivores (p &lt, 0.01). MED was lowest among vegans (21.18 ± 4.85 J/m2), followed by vegetarians (28.90 ± 6.66 J/m2) and omnivores (33.63 ± 4.53 J/m2, p &lt, 0.01). Patients with severe erythema were more likely to have a high furocumarin intake (OR 5.67, 95% CI 3.74–8.61, p &lt, 0.01). Vegans consumed the highest amount of furocumarin-rich foods. A model examining erythema, adjusted for gender, age, skin type, MED, phototherapy type, number of phototherapies and furocumarin intake, confirmed that vegans had a lower number of treatments. Vegans had more frequent severe erythema from NB-UVB, even after adjustment of the phototherapy protocol for their lower MED. Assessing diet information and adapting the protocol for vegan patients may be prudent.

Published
2021

111. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

Author

Matilde Iorizzo, Giovanni Damiani, Alessia Pacifico, and Francesco Pelloni

Subjects
Pemphigoid, 2019-20 coronavirus outbreak, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19, Dermatology, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, Pemphigus, 0302 clinical medicine, Infectious Diseases, 030220 oncology & carcinogenesis, Pemphigoid, Bullous, medicine, Humans, Bullous pemphigoid, business
Published
2021

112. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders

Author

Giovanni Damiani, Rosalynn R.Z. Conic, Wilma F. Bergfeld, and Jalal Maghfour

Subjects
medicine.medical_specialty, business.industry, MEDLINE, Lichen Planus, Atrial fibrillation, Dermatology, Lichen planopilaris, medicine.disease, Coronary artery disease, Infectious Diseases, Metabolic Diseases, Internal medicine, Diabetes mellitus, Hyperlipidemia, Medicine, Humans, Metabolic disease, business
Published
2021

113. COVID‐19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast

Author

Giovanni Damiani, P Malagoli, Paolo D. Pigatto, A d'Arino, and Alessia Pacifico

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dermatology, medicine.disease, Vaccination, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Psoriasis, Correspondence, medicine, Apremilast, business, Letter to the Editor, medicine.drug
Abstract

Although COVID-19 vaccination is warmly suggested for psoriatic patients by several dermatological societies worldwide, only a recently published Italian case-series has sustained a safe and effective role of the vaccine in this patients' subset. Remarkably, vaccines information highlights that limited data are present for immunosuppressed patients and the vaccination should be performed in agreement with the vaccinator.

Published
2021

114. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort study

Author

Dana Tzur Bitan, Yochai Schonmann, Giovanni Damiani, Arnon D. Cohen, Avi Peretz, Khalaf Kridin, and Erez Onn

Subjects
medicine.medical_specialty, Population, Dermatology, Acitretin, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, Internal medicine, Ustekinumab, Medicine, Humans, infection‐ bacterial/fungal/viral, education, education.field_of_study, business.industry, Proportional hazards model, SARS-CoV-2, Tumor Necrosis Factor-alpha, Hazard ratio, COVID-19, General Medicine, Original Articles, medicine.disease, Hospitalization, 030220 oncology & carcinogenesis, Antirheumatic Agents, Methotrexate, Original Article, Tumor Necrosis Factor Inhibitors, business, medicine.drug, Cohort study
Abstract

The risk of coronavirus disease 2019 (COVID-19) and its complications among patients with psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively delineated. We aimed to assess the risk of COVID-19 infection, COVID-19-associated hospitalization, and mortality among Israeli patients with psoriasis treated by TNFi relative to other systemic agents. A population-based cohort study was conducted to compare psoriasis patients treated by TNFi (n=1,943), with those treated by methotrexate (n=1,929), ustekinumab (n=348), and acitretin (n=1,892) regarding COVID-19 outcomes. Risk of investigated outcomes was assessed using uni- and multi-variate Cox regression analyses. The incidence rate of COVID-19, COVID-19-associated hospitalization, and mortality in the TNFi group was 35.8 (95% CI, 26.1-47.9), 0.8 (95% CI, 0.0-4.2), and 0.0 per 1,000 person-years, respectively. Exposure to TNFi was associated with a comparable risk of COVID-19 infection [adjusted hazard ration (HR) for TNFi vs. methotrexate: 1.07 (95% CI, 0.67-1.71); TNFi vs. ustekinumab: 1.07 (95% CI, 0.48-2.40); TNFi vs. acitretin: 0.98 (95% CI, 0.61-1.57)]. TNFi was associated with a decreased risk of COVID-19-associated hospitalization relative to methotrexate (adjusted HR, 0.10; 95% CI, 0.01-0.82) and ustekinumab (adjusted HR, 0.04; 95% CI, 0.00-0.64), but not to acitretin (adjusted HR, 1.00; 95% CI, 0.16-6.16). No significant difference in COVID-19-associated mortality was found between the four different groups. TNFi was associated with a decreased risk of admissions due to COVID-19. Our findings substantiate the continuation of TNFi treatment during the pandemic. TNFi may be positively considered in patients with moderate-to-severe psoriasis warranting systemic treatment during the pandemic. This article is protected by copyright. All rights reserved.

Published
2021

115. Safe distance, safe patients! Therapeutic management of oncological patients affected by cutaneous and mucosal adverse events during the COVID-19 pandemic: an Italian experience

Author

Claudio Marasca, Giovanni Damiani, Eleonora Cinelli, Davide Fattore, Maria Carmela Annunziata, Gabriella Fabbrocini, Cinelli, E., Fabbrocini, G., Fattore, D., Marasca, C., Damiani, G., and Annunziata, M. C.

Subjects
Male, Pruritu, Teledermatology, 0302 clinical medicine, Neoplasms, Surveys and Questionnaires, Pandemic, Surveys and Questionnaire, 030212 general & internal medicine, Skin, Rash, Telemedicine, Italy, Oncology, 030220 oncology & carcinogenesis, Drug Eruptions, medicine.symptom, Coronavirus Infections, Human, Adverse event, Administration, Cutaneou, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pain medicine, Physical Distancing, Pneumonia, Viral, Administration, Cutaneous, Betacoronavirus, 03 medical and health sciences, medicine, Mucositis, Humans, Intensive care medicine, Adverse effect, Pandemics, Mucous Membrane, Betacoronaviru, Coronavirus Infection, SARS-CoV-2, business.industry, Pruritus, COVID-19, Exanthema, medicine.disease, Drug Eruption, Adverse events, Commentary, Neoplasm, Differential diagnosis, business
Abstract

Stringent measures have been taken to contain COVID-19 spread, limiting access only for urgent visits, surgery procedures, or hospitalizations and using teledermatology services for non-urgent cases. Management of oncological patients affected by chemo-, immune-, and radiotherapy-related cutaneous and mucosal adverse events is a challenge. Firstly because of the differential diagnosis of cutaneous rash (e.g., drug-related rash or paraviral exanthema). Secondly, oncological patients can suffer from xerosis, pruritus, and mucositis that contribute to cutaneous and mucosal barrier lesions, thus becoming vulnerable site for viral or bacterial colonization. These lesions can also be aggravated by the use of protective mask and gloves. Here, we report also our results of a teledermatological survey on 87 oncological patients, where the health status of oncological patients referred to our dedicated clinic was assessed during the COVID-19 pandemic. Therefore, it is fundamental that oncological patients are followed up by their dermatologists even if the clinics are closed. Teledermatology represents a crucial means of communication. Patients can contact the dermatological staff by emails and telephone, 24 h a day, 7 days a week, for video calls and dermatological consultations.

Published
2020

116. Psoriatic and psoriatic arthritis patients with and without jet-lag: does it matter for disease severity scores? Insights and implications from a pilot, prospective study

Author

Piergiorgio Malagoli, Mohammad Adawi, Rosalynn R.Z. Conic, Abdulla Watad, Colin M. Shapiro, Alessia Pacifico, Paolo D. Pigatto, Sergio Garbarino, Nicola Luigi Bragazzi, Giovanni Damiani, Vijay Kumar Chattu, and Danica Tiodorovic

Subjects
Adult, Male, medicine.medical_specialty, Physiology, Visual analogue scale, 030209 endocrinology & metabolism, Article, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Disease severity, Physiology (medical), Internal medicine, Psoriasis, Linear regression, medicine, Humans, Prospective cohort study, Jet Lag Syndrome, business.industry, Arthritis, Psoriatic, Dermatology Life Quality Index, Middle Aged, medicine.disease, Circadian Rhythm, Female, Observational study, business, 030217 neurology & neurosurgery
Abstract

BACKGROUND: Jet-lag may affect air-travelers crossing at least 2 time-zones and has several healthcare implications. It occurs when the human biological rhythms are out of synch with respect to the day-night cycle at the country destination. Its effect in psoriasis is missing. We aimed to evaluate the effect of Jet-lag in psoriatic patients’ management. METHODS: This is a prospective observational study that enrolled psoriatic patients that underwent a flight: patients who experienced jet-lag were compared to patients who did not experience jet-lag. Before the flight, a dermatologist recorded clinical and demographical data with particular attention to Psoriasis Area Severity Index (PASI) and Disease Activity in PSoriatic Arthritis (DAPSA). Patients performed Self-Administered Psoriasis Area Severity Index (SAPASI), the Dermatology Life Quality Index (DLQI) and the pruritus Visual Analog Scale (VAS) scores. After the flight, patients completed the SAPASI, DLQI and pruritus-VAS scores. RESULTS: The sample recruited comprised of 70 psoriatic patients aged 42.4 ± 9.7 years (median 42.5 years). Thirty (42.9%) were males, mean BMI was 25.5 ± 2.2 kg/m(2). Average disease duration was 15.2 ±7.1 years, and 20 (28.6%) subjects had developed PsA. Average hours of flight were 5.4 ±3.5 (median 3.5 hours), with 34 (48.6%) subjects reporting jet-lag. At the multivariate regression analysis, the change in the SAPASI score resulted correlated with jet-lag (regression coefficient 1.63, p = 0.0092), as well the change in the DLQI score (regression coefficient = 1.73, p = 0.0009), but no change on the pruritus VAS scale was found. CONCLUSIONS: The present study suggests that jet-lag may influence disease severity and DLQI scores, but not itch in psoriatic patients.

Published
2019

117. Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival

Author

Stephanie Saridakis, Giovanni Damiani, Rosalynn R.Z. Conic, Jennifer S. Ko, Brian R. Gastman, Allison T. Vidimos, and Pauline Funchain

Subjects
Male, Oncology, medicine.medical_specialty, Skin Neoplasms, Databases, Factual, Lymphovascular invasion, Sentinel lymph node, Dermatology, Metastasis, Immunocompromised Host, 030207 dermatology & venereal diseases, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, Sex Factors, 0302 clinical medicine, Risk Factors, Internal medicine, Biopsy, medicine, Humans, Neoplasm Invasiveness, Aged, Proportional Hazards Models, Retrospective Studies, medicine.diagnostic_test, Sentinel Lymph Node Biopsy, Merkel cell carcinoma, Proportional hazards model, business.industry, Hazard ratio, Age Factors, Odds ratio, Middle Aged, medicine.disease, Carcinoma, Merkel Cell, Survival Rate, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Blood Vessels, Female, Sentinel Lymph Node, business
Abstract

Merkel cell carcinoma (MCC) is a rare, aggressive malignancy with high rates of recurrence and metastasis.To evaluate predictors of sentinel lymph node (SLN) positivity in MCC using the National Cancer Database.The National Cancer Database, from 2012 to 2014, was used to identify 3048 patients with MCC, of whom 1174 received an SLN biopsy. Predictors of SLN positivity were evaluated using logistic regression. Overall survival was evaluated using a Cox proportional hazards model.Of patients who underwent SLN biopsy, those with primary lesions on the trunk (odds ratio, 1.98; 95% confidence interval [CI], 1.23-3.17; P = .004), tumor-infiltrating lymphocytes (odds ratio, 1.58; 95% CI, 1.01-2.46; P = .04), or lymphovascular invasion (odds ratio, 3.45; 95% CI, 2.51-4.76; P .001) were more likely to have positive SLNs on multivariate analysis. Overall survival was negatively affected by age ≥75 years (hazard ratio [HR], 2.55; 95% CI, 1.36-4.77; P = .003), male sex (HR, 1.78; 95% CI, 1.09-2.91, P = .022), immunosuppression (HR, 3.51; 95% CI, 1.72-7.13; P = .001), and SLN positivity (HR, 3.15; 95% CI, 1.98-5.04; P .001).Lack of disease-specific survival and potential selection bias from a retrospective data set.Truncal MCC, tumor-infiltrating lymphocytes, and presence of lymphovascular invasion were independent predictors of positive SLNs. Overall survival was negatively affected by advancing age, male sex, immunosuppression, and SLN positivity.

Published
2019

118. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases

Author

Enrique Esteve-Valverde, Abdulla Watad, Mohammed Adawi, Mariana Quaresma, Jaume Alijotas-Reig, Howard Amital, Yehuda Shoenfeld, Giovanni Damiani, Nicola Luigi Bragazzi, Dennis McGonagle, and Charlie Bridgewood

Subjects
Adult, Male, 0301 basic medicine, Adolescent, medicine.medical_treatment, Giant Cell Arteritis, Immunology, Connective tissue, Autoimmune Diseases, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Immune system, Adjuvants, Immunologic, Humans, Immunology and Allergy, Medicine, Hepatitis B Vaccines, Autoinflammatory disease, Israel, Child, Connective Tissue Diseases, Autoimmune/inflammatory syndrome induced by adjuvants, Aged, Aged, 80 and over, Inflammation, business.industry, Vaccination, Infant, Newborn, Infant, Syndrome, Middle Aged, 030104 developmental biology, medicine.anatomical_structure, Influenza Vaccines, Child, Preschool, Female, business, Mixed pattern, Adjuvant, Autoinflammatory Disorders, 030215 immunology
Abstract

Background: We investigated the pattern of reported immune diseases in the international ASIA syndrome registry. Methods: Data from 500 subjects exposed to adjuvants from the ASIA syndrome international registry were analysed. Results: The patient mean age was 43 ± 17 years and 89% were female. Within the reported immune diseases, 69% were well-defined immune diseases (autoimmune, autoinflammation, and mixed pattern diseases). Among the well-defined immune diseases following the exposure to adjuvants, polygenic autoimmune diseases were significantly higher than autoinflammatory disorders (92.7% vs 5.8%, respectively, p < 0.001). Polygenic autoimmune diseases such as connective tissue diseases were significantly linked to the exposure to HBV vaccine (OR 3.15 [95%CI 1.08–9.23], p = 0.036). Polygenic autoinflammatory diseases were significantly associated with the exposure to influenza vaccination (OR 10.98 [95%CI 3.81–31.67], p < 0.0001). Conclusions: Immune conditions following vaccination are rare, and among these, polygenic autoimmune diseases represent the vast majority of the well-defined immune diseases reported under the umbrella ASIA syndrome. However, vaccines benefit outweighs their autoimmune side effects.

Published
2019

119. Melasma and thyroid disorders: a systematic review and meta‐analysis

Author

Mahmood Moosazadeh, Mahdi Afshari, Giovanni Damiani, Saeid Abediankenari, and Motahhareh Kheradmand

Subjects
Male, Thyroid Hormones, endocrine system, medicine.medical_specialty, Melasma, Dermatology, Iodide Peroxidase, Melanosis, 030207 dermatology & venereal diseases, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, medicine, Humans, In patient, Antithyroglobulin antibody, Autoantibodies, business.industry, Thyroid, medicine.disease, Thyroid Diseases, Confidence interval, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Meta-analysis, Female, Thyroid function, business, Hormone
Abstract

Background Thyroid hormones may play a key role in melasma; however, melasma link with thyroid disorders remains controversial. Objectives To compare the serum levels of thyroid-stimulating hormone (TSH), T4, T3, anti-thyroid peroxidase (anti-TPO), and antithyroglobulin between patients with melasma and control group using meta-analysis. Methods We screened 10 databanks and search engines, searched mesh and nonmesh terms. The identified evidences were reviewed and quality assessed using the Newcastle-Ottawa Scale (NOS). The heterogeneity between the primary results was investigated using Cochrane and I-square indices. Random effect model was applied to combine the standardized mean differences of thyroid function indicators between patients with and without melasma. P values meta-analysis was used to investigate the association between anti-TPO and melasma. Results We included seven studies, 473 cases, and 379 controls that had been investigated. The total standardized mean differences (95% confidence intervals) of TSH, T3, T4, and antithyroglobulin antibody between cases and controls were estimated to be 0.33 (0.18, 0.47), -0.01 (-0.20, 0.19), -1.50 (-2.96, -0.04), and 0.62 (0.14, 1.11), respectively. The corresponding figures among women were 0.35 (0.17, 0.52), 0.10 (-0.17, 0.38), -2.75 (-6.30, 0.81), and 0.99 (0.14, 1.83), respectively. P value of meta-analysis showed a significant relationship between anti-TPO serum level and melasma (Fisher = 26.80, P = 0.020). Conclusion Serum levels of TSH, anti-TPO, and antithyroglobulin antibody were significantly higher in patients with melasma than those without melasma. Moreover, these differences were more severe among women with melasma.

Published
2019

120. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis

Author

Rosalynn R.Z. Conic, Kristen Fajgenbaum, Paolo D. Pigatto, Sebastiano Leone, Emilio Berti, Alessia Pacifico, Nicola Luigi Bragazzi, Maria Caterina Pace, Vincenzo Bettoli, P. P. Poli, Carlo Maiorana, Giovanni Damiani, Piergiorgio Malagoli, Marco Fiore, Damiani, G., Leone, S., Fajgenbaum, K., Bragazzi, N. L., Pacifico, A., Conic, R. R. Z., Pigatto, P. D. M., Maiorana, C., Poli, P., Berti, E., Pace, M. C., Malagoli, P., Bettoli, V., and Fiore, M.

Subjects
medicine.medical_specialty, End stage liver disease, Observational Study, digestive system, 03 medical and health sciences, 0302 clinical medicine, Non-alcoholic fatty liver, Internal medicine, Nonalcoholic fatty liver disease, medicine, Retrospective analysis, Hidradenitis suppurativa, Non-alcoholic steatohepatitis, Hepatology, business.industry, nutritional and metabolic diseases, medicine.disease, digestive system diseases, humanities, body regions, 030220 oncology & carcinogenesis, Cohort, 030211 gastroenterology & hepatology, business, Non-alcoholic steatohepatiti
Abstract

BACKGROUND Nonalcoholic fatty liver disease (NAFLD) includes two distinct conditions, with different histologic features and prognosis: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Furthermore, NASH is the more aggressive necro-inflammatory form, which may accumulate fibrosis and result in End stage liver disease (ESLD). NAFLD is also linked to systemic inflammatory conditions such as psoriasis. NAFLD is currently the most common cause of ESLD in Western countries, becoming a serious public health concern. Hidradenitis suppurativa (HS) is a systemic inflammatory/autoinflammatory disease of the terminal follicular epithelium of the apocrine gland with a prevalence of 0.05% to 4.10%. Due to its systemic inflammatory behavior several comorbidities were recently associated, however liver ones were scarcely assessed. AIM To evaluate the prevalence and characteristics of NASH/NAFL in HS patients. METHODS This retrospective study is a sub-analysis of a larger study carried out in 4 Italian dermatological centers. In this cohort, there were 83 patients: 51 patients with HS only, 20 patients with HS/NAFL and 12 with HS/NASH. RESULTS Inflammatory comorbidities were present in 3.9% of HS only patients, 25% of HS/NAFL patients and 58.3% of HS/NASH patients (P < 0.001). Similarly, mean Autoinflammatory Disease Damage Index (ADDI) was significantly higher among patients with HS/NASH (5.3 ± 2.2, P < 0.001) compared to patients with HS/NAFL or HS only (2.8 ± 1.6 and 2.6 ± 1.4 respectively). Furthermore, ADDI correlates with IHS4 in HS, HS/NAFL and HS/NASH. Diabetic patients have higher Hurley score than not diabetic ones. Ultrasound examination was significantly different in the three groups. CONCLUSION HS patients displayed a high prevalence of NASH/NAFLD and ultrasound examination should be particularly addressed to patients that display high ADDI scores.

Published
2019

121. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database

Author

Thomas Knackstedt, Jennifer S. Ko, Giovanni Damiani, Allison T. Vidimos, Alok Vij, Brian R. Gastman, Pauline Funchain, and Rosalynn R.Z. Conic

Subjects
Adult, Male, Skin Neoplasms, Multivariate analysis, Databases, Factual, Sentinel lymph node, Dermatology, computer.software_genre, Risk Assessment, Breslow Thickness, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Predictive Value of Tests, Biopsy, medicine, Humans, Neoplasm Invasiveness, Melanoma, Neoplasm Staging, Retrospective Studies, American Cancer Society, Database, medicine.diagnostic_test, business.industry, Biopsy, Needle, Age Factors, Cancer, Odds ratio, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Survival Analysis, United States, 030220 oncology & carcinogenesis, Cutaneous melanoma, Female, Sentinel Lymph Node, business, computer
Abstract

Sentinel lymph node biopsy (SLNB) specimens are often obtained from patients for further staging after these patients have undergone melanoma excision. Limited data regarding predictors of SLNB positivity in thin melanoma are available.We sought to evaluate predictors of SLNB positivity in thin melanoma.Patients with cutaneous melanoma with a Breslow thickness ≤1.00 mm who received a SLNB were identified from the National Cancer Database between 2004 and 2014 (n = 9186). Predictors of SLNB positivity were analyzed using logistic regression.In a multivariate analysis, patients60 years of age (P .001) and Breslow thickness0.8 mm (P = .03) were at increased risk for positive sentinel lymph node (SLN). Moreover, on multivariate analysis, the presence of dermal mitoses increased the odds of SLN positivity by 95% (odds ratio [OR] 1.95 [95% confidence interval {CI} 1.53-2.5], P .001), ulceration by 63% (OR 1.63 [95% CI 1.21-2.18], P .001), and Clark level IV to V by 48% (OR 1.48 [95% CI 1.19-1.85]). Patients without ulceration but with dermal mitoses had 92% (OR 1.92 [95% CI 1.5-2.48], P .001) increased SLN positivity.Limited survival data are available.Younger age, a Breslow thickness0.8 mm, the presence of dermal mitoses, ulceration, and Clark level IV to V are positive predictors of positive SLN. While the new American Joint Committee on Cancer system has removed dermal mitotic rate from staging, continued evaluation of dermal mitotic rate could be valuable for guiding surgical decision making about SLNB.

Published
2019

123. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Author

Giovanni Damiani, Naim Mahroum, Mohammad Adawi, Abdulla Watad, Luca Giacomelli, Mahmud Mahamid, Roberto Eggenhöffner, Dennis McGonagle, Rosalynn R.Z. Conic, Hussein Mahagna, Charlie Bridgewood, Samaa Watad, Howard Amital, Nicola Luigi Bragazzi, and Paolo D. Pigatto

Subjects
0301 basic medicine, medicine.medical_specialty, Systematic review and meta-analysis, Immunology, Anti-pneumococcal vaccination, PRISMA guidelines, Systemic lupus erythematosus, Humans, Lupus Erythematosus, Systemic, Pneumococcal Vaccines, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Immunology and Allergy, Adverse effect, 030203 arthritis & rheumatology, Lupus Erythematosus, business.industry, Immunogenicity, Systemic, medicine.disease, Belimumab, Vaccination, 030104 developmental biology, Pneumococcal vaccine, Tolerability, Meta-analysis, Pneumococcal pneumonia, business, medicine.drug
Abstract

The immunological perturbations associated with systemic lupus erythematosus (SLE) put many patients at a higher risk of infections, including pneumococcal pneumonia. However, the uptake and utility of anti-pneumococcal vaccines in SLE patient is both controversial and not completely agreed upon. Indeed, several epidemiological studies of anti-pneumococcal vaccine safety and efficacy in SLE have reported short-term immunogenicity with elevated anti-pneumococcal antibody titres but inconsistent long-term findings, with some studies finding poor responses, mainly for long-term immune protection. Moreover, the safety and efficacy of the pneumococcal vaccine in SLE patients remains controversial due to the different types of anti-pneumococcal vaccines, and the heterogeneity of SLE patients. Several reviews addressing anti-pneumococcal vaccination in SLE patients exist, however, to the best of our knowledge, the present is the first systematic review and meta-analysis. To better understand the efficacy and safety of pneumococcal vaccination in SLE, a comprehensive literature search was performed identifying 18 studies, which have been included in the present systematic review and meta-analysis. All studies were designed as longitudinal investigations, 2, in particular, were of high quality, being randomized, double-blind trials (RCTs). Four studies had control groups. Total sample size included 601 participants. Vaccine immunogenicity in terms of subjects with protective antibody titers ranged from 36% to 97.6%. According to our systematic review and metanalysis, high erythrocyte sedimentation rate (ESR), older age, earlier SLE onset, high disease activity, and immunosuppressive therapy were predictors of poor immunogenicity, although belimumab was found to have no significant impact. With regard to safety, no serious adverse events were found, with up to one third of cases reporting mild/low-grade complaints. In conclusion, due to the high risk of pneumococcal infection in SLE patients and given the safety and, at least partial, effectiveness, according to our systematic review and meta-analysis, in such patients, preventive strategies mainly by immunization, are required in all age groups and, in those needing immunosuppressive therapy, immunization should be given prior the initiation of the treatment. PROSPERO registration code CRD42018103605.

Published
2019

124. ‘High dose’ vs. ‘medium dose’ UVA1 phototherapy in italian patients with severe atopic dermatitis

Author

Carmela Ferraro, Alessia Pacifico, Simone Cazzaniga, Rosalynn R.Z. Conic, Aldo Morrone, Giovanni Leone, Paolo Iacovelli, and Giovanni Damiani

Subjects
Adult, Male, medicine.medical_specialty, Skin type, Dark skin, Skin Pigmentation, Dermatology, Severity of Illness Index, Article, Dermatitis, Atopic, law.invention, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Severity of illness, Severe atopic dermatitis, Humans, Medicine, Young adult, business.industry, Radiotherapy Dosage, Middle Aged, Regimen, Treatment Outcome, Infectious Diseases, Italy, 030220 oncology & carcinogenesis, Comparison study, Female, Ultraviolet Therapy, business
Abstract

BACKGROUND: the current evidences attest UVA1 phototherapy as effective in the treatment of severe atopic dermatitis (AD). Furthermore in this indication, “medium dose” is as effective as “high dose” regimen in this indication. To date, a randomized comparison study evaluating the effectiveness as well as safety of different UVA1 protocols in different skin types in the treatment of adult patients with severe AD is still lacking. OBJECTIVE: The aim of the present study was to compare the safety and the efficacy of medium and high dose UVA1 either in fair or in dark skin types. which are more common among Italian population. METHODS: Twenty-seven adult patients with severe AD were consecutively included in a randomized, controlled, open, two arms trial prospective, open, randomized, 2 arms study. Severity of AD was determined by means of SCORAD index and clinical improvement was also monitored. A total of 13/27 patients were treated with High Dose (130 J/cm(2)) UVA1 protocol while 14/27 patients received Medium Dose (60 J/cm(2)) UVA1 protocol. Phototherapy was performed 5 times weekly up to 3 weeks. Before and after UVA1 treatment each patient was evaluated for skin pigmentation through Melanin Index (MI) quantitative evaluation. RESULTS: Skin status improved in all patients resulting in a reduction of SCORAD index in all groups. Our results demonstrated that among patients with darker skin types and higher MI, High dose UVA1 was significantly more effective than Medium Dose (p < 0.0001) while within the groups with skin type II, no significant differences between high and medium dose protocols were observed. CONCLUSION: Our study, further confirms previous observations that UVA1 phototherapy should be considered among the first approaches in the treatment of patients with severe generalized atopic dermatitis and also demonstrates that in darker skin types, high dose UVA1 phototherapy is more effective than medium dose in the treatment of adult patients with severe AD.

Published
2018

125. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation

Author

Giovanni Damiani, S. Ken Tanaka, Nika Furey, Jonette E. Keri, Jodi L. Johnson, Christopher G. Bunick, and Ayman Grada

Subjects
0301 basic medicine, Microbiology (medical), antibiotic resistance, medicine.drug_class, 030106 microbiology, Antibiotics, Review, Biochemistry, Microbiology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, In vivo, antibiotic, medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, acne, Doxycycline, biology, business.industry, lcsh:RM1-950, sarecycline, Minocycline, tetracyclines, medicine.disease, biology.organism_classification, animal models, infection, Infectious Diseases, lcsh:Therapeutics. Pharmacology, narrow-spectrum, inflammation, Antibacterial activity, business, Dysbiosis, Bacteria, medicine.drug
Abstract

Prolonged broad-spectrum antibiotic use is more likely to induce bacterial resistance and dysbiosis of skin and gut microflora. First and second-generation tetracycline-class antibiotics have similar broad-spectrum antibacterial activity. Targeted tetracycline-class antibiotics are needed to limit antimicrobial resistance and improve patient outcomes. Sarecycline is a narrow-spectrum, third-generation tetracycline-class antibiotic Food and Drug Administration (FDA)-approved for treating moderate-to-severe acne. In vitro studies demonstrated activity against clinically relevant Gram-positive bacteria but reduced activity against Gram-negative bacteria. Recent studies have provided insight into how the structure of sarecycline, with a unique C7 moiety, interacts with bacterial ribosomes to block translation and prevent antibiotic resistance. Sarecycline reduces Staphylococcus aureus DNA and protein synthesis with limited effects on RNA, lipid, and bacterial wall synthesis. In agreement with in vitro data, sarecycline demonstrated narrower-spectrum in vivo activity in murine models of infection, exhibiting activity against S. aureus, but reduced efficacy against Escherichia coli compared to doxycycline and minocycline. In a murine neutropenic thigh wound infection model, sarecycline was as effective as doxycycline against S. aureus. The anti-inflammatory activity of sarecycline was comparable to doxycycline and minocycline in a rat paw edema model. Here, we review the antibacterial mechanisms of sarecycline and report results of in vivo studies of infection and inflammation.

Published
2021

126. Can intermittent, <scp>time‐restricted</scp> circadian fasting modulate cutaneous severity of dermatological disorders? Insights from a multicenter, observational, prospective study

Author

Khalaf Kridin, Hamdi Chtourou, Nicola Luigi Bragazzi, Achraf Ammar, Hristina Kocic, Rosalynn R.Z. Conic, Khaled Trabelsi, Giovanni Damiani, Alessia Pacifico, Piergiorgio Malagoli, Sergio Garbarino, and Paolo D. Pigatto

Subjects
Adult, Male, medicine.medical_specialty, Biological clock, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Weight loss, Internal medicine, Intermittent fasting, Humans, Medicine, Prospective Studies, Circadian rhythm, Dermatological disorders, Prospective cohort study, Skin, business.industry, Weight change, Fasting, General Medicine, Middle Aged, Circadian Rhythm, 030220 oncology & carcinogenesis, Observational study, medicine.symptom, business, human activities
Abstract

The impact of intermittent circadian fasting (ICF) on skin disorders is far to be plenty deciphered. However, the circadian rhythm seems to exert a modulation on dermatoses severity, drug-response, and drug-related side effects. We aimed to evaluate ICF effect in the daily management of dermatological diseases. In this multicenter, prospective observational study we enrolled patients willing to undergo the 2018 ICF (from May 16 to June 14). Dermatoses severity were evaluated at the beginning of ICF (T0) and at the end of ICF (T1) by two independent board-certified dermatologists. Seventy-two patients suffering from different dermatoses volunteered to take part into the study. They displayed a mean age of 40.38 ± 12.46 years (median 41.0 years), 25 subjects were males (34.7% of the entire sample). The median weight change was 0 kg. The overall ICF effect size was -0.58 ([95% CI -0.83 to -0.33], P < .0001, medium effect size). Since in the present investigation no weight loss occurred, we could speculate that the impact of fasting in terms of improvements in the clinical symptoms could be rather due to the perturbation of the human biological clock. Despite our data remain preliminary, a chronobiological approach should be incorporated in the dermatological armamentarium.

Published
2021

129. Patient‐reported outcomes of topical therapies in actinic keratosis: A systematic review

Author

Steven R. Feldman, Ayman Grada, Giovanni Damiani, and Nicola Luigi Bragazzi

Subjects
safety, medicine.medical_specialty, Ingenol Mebutate Gel, Treatment adherence, Imiquimod, Review Article, Dermatology, compliance, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Patient satisfaction, systematic review, Quality of life, actinic keratosis, medicine, Humans, Patient Reported Outcome Measures, adherence, topical, tolerability, Review Articles, business.industry, Actinic keratosis, General Medicine, medicine.disease, Keratosis, Actinic, Clinical trial, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Quality of Life, Diterpenes, patient‐reported outcomes, business, medicine.drug
Abstract

Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field‐directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient‐reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter‐duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well‐tolerated, short‐duration topical treatment for actinic keratosis.

Published
2021

130. COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study

Author

Paola Savoia, Paolo D. Pigatto, Alessandra Buja, Renata Finelli, Nicola Luigi Bragazzi, Khalaf Kridin, Giovanni Damiani, Ayman Grada, and Laura Cristina Gironi

Subjects
Adult, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), maskne, Dermatology, pandemics, Imcas: Original Article, rosacea due to masks, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, COVID‐19, Acne Vulgaris, medicine, Humans, Imcas: Original Articles, Prospective Studies, Prospective cohort study, Acne, SARS-CoV-2, mask rosacea, business.industry, Masks, COVID-19, acne due to masks, General Medicine, Middle Aged, medicine.disease, Rosacea, 030220 oncology & carcinogenesis, Communicable Disease Control, Quality of Life, Facial Dermatosis, Observational study, business, Grading scale
Abstract

Masks are essential for COVID‐19 prevention, but recently they were suggested to modify cutaneous facial microenvironment and trigger facial dermatoses. To evaluate mask‐related rosacea and acne (maskne) in untreated patients during lockdown. In this multi‐center, real‐life, observational prospective study, we enrolled stable, untreated acne and rosacea patients that wore masks during lockdown at least 6 h/day. They underwent two teledermatological consultations, at the baseline and after 6 weeks. Clinical, pharmacological, and psychological data were recorded. A total 66 patients, 30 (median age: 34.0 [30.25‐29.75] yoa) with acne and 36 patients (median age: 48 [43‐54] years) with rosacea, were enrolled in this study. After 6 weeks of mask and quarantine, patients with acne displayed an increased Global Acne Grading Scale (GAGS) score in mask‐related areas (P

Published
2021

131. NB‐UVB plus oral Polypodium leucotomos extract display higher efficacy than NB‐UVB alone in patients with vitiligo

Author

Alessia Pacifico, Giovanni Damiani, Salvador González, Paolo Iacovelli, Rosalynn R.Z. Conic, and Aldo Morrone

Subjects
medicine.medical_specialty, Polypodium, Vitiligo, Placebo-controlled study, Skin Pigmentation, Dermatology, Placebo, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Combined treatment, Psoriasis, medicine, Humans, In patient, Prospective Studies, skin and connective tissue diseases, Polypodium Leucotomos, integumentary system, Plant Extracts, business.industry, General Medicine, medicine.disease, Combined Modality Therapy, Narrow band, Treatment Outcome, 030220 oncology & carcinogenesis, Ultraviolet Therapy, business
Abstract

Polypodium leucotomos displayed a synergic effect with NB-UVB in psoriasis, but its application on vitiligo remains understudied. The aim of this study was to investigate whether oral supplementation with leaves extract of Polypodium leucotomos (PL) improves narrow band (NB) UVB phototherapy-induced repigmentation. Forty-four patients with generalized vitiligo were enrolled in this randomized, prospective, placebo controlled study. Twenty-three patients were randomly selected to receive combined treatment with NB-UVB phototherapy and 480 mg oral PL twice daily while 21 patients received NB-UVB phototherapy combined with placebo. All subjects were treated with NB-UVB twice weekly for 6 months. Our results demonstrated that oral PL combined with NB-UVB improved repigmentation as well as increased the response rate compared with patients treated with NB-UVB alone (47.8% vs 22%). Our study suggests that oral supplementation of PL and NB-UVB phototherapy enhance the extent of repigmentation.

Published
2021

132. Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics

Author

Magdalena Spałkowska, Khalaf Kridin, Alessia Pacifico, Alessandra Buja, Pierachille Santus, Nicola Luigi Bragazzi, Laura Cristina Gironi, Giovanni Damiani, Paola Savoia, and Paolo D. Pigatto

Subjects
medicine.medical_specialty, Impetigo, Population, Koebner phenomenon, Dermatology, Vitiligo, surgical masks, Imcas: Original Article, facial dermatoses, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, Psoriasis, medicine, Koebner clinical phenotypes, Humans, COVID-19, Koebner mask induced, personal protective equipment, psoriasis, telemedicine, Prospective Studies, Imcas: Original Articles, education, Pandemics, Referral and Consultation, education.field_of_study, Molluscum contagiosum, business.industry, SARS-CoV-2, Masks, General Medicine, Atopic dermatitis, medicine.disease, Phenotype, Italy, Rosacea, 030220 oncology & carcinogenesis, business
Abstract

During COVID‐19 pandemic, wearing masks for prevention became mandatory but evidence suggest that is also detrimental for skin. Although facial dermatoses due to masks increase in both healthcare workers and general population, a pathogenetic hypothesis remains still elusive. We aimed to evaluate the prevalence of dermatological consultations due to Koebner triggered dermatoses In this prospective, multicenter, real life study carried out in Italy from March 11th to December 11th 2020 during COVID‐19 pandemics, dermatological consultations (in‐person and telemedicine) to study the prevalence of Koebner (KB) phenomenon due to masks were evaluated. Boyd and Nelder classification was adopted for Koebner phenomenon and Bizzozero's for KB intensity. A total of 229/873 (26.2%) dermatological consultations were KB triggered dermatoses and lesions were located in mask‐covered ear area (76 [33.2%]), malar area (73 [31.8%]), perioral area (53 [23.1%]), and nose (27 [11.8%]). The first KB category grouped 142 patients (psoriasis, vitiligo, maskne, and mask rosacea), the second one 24 (warts, molluscum contagiosum, and impetigo), the third one 46 (atopic dermatitis), and the fourth one 17 (eczema). Among previously KB negative psoriatic patients that became KB positive, 9/13 (69.2%) had discontinued or modified the prescribed antipsoriatic treatment. Mask‐related Koebner phenomenon is an important clinical sign to orient clinician's therapeutic protocols during COVID‐19 pandemic, especially in patients with psoriasis.

Published
2021

133. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients

Author

Giovanni Damiani, Emanuela Martina, Paolo D. Pigatto, Teresa Grieco, Annamaria Offidani, and Caterina Foti

Subjects
Pediatrics, medicine.medical_specialty, Urticaria, Dermatology, Omalizumab, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Anti-Allergic Agents, Medicine, Humans, Chronic Urticaria, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Retrospective cohort study, General Medicine, medicine.disease, Comorbidity, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Chronic Disease, Quality of Life, Observational study, Metabolic syndrome, business, medicine.drug
Abstract

BACKGROUND: Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients > 65 years old (yoa) treated with omalizumab are rare. METHODS: In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65yoa. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab. RESULTS: 63 patients, with a mean age of 72.3 ± 5.6 years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an "early complete response" profile, which means the achievement of a UAS7 score of "0" within the first 7 days of therapy. The most frequent comorbidity was hypertension, which affected 26/63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities. CONCLUSIONS: omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities. This article is protected by copyright. All rights reserved.

Published
2021

134. Higher Rates of COVID-19 but Less Severe Infections Reported for Patients on Il-4/Il-13 Blocker: A Big Data Analysis of the WHO Vigibase

Author

Abdulla Watad, Haijiang Dai, Naim Mahroum, Jianhong Wu, Jude Dzevela Kong, Nicola Luigi Bragazzi, Giovanni Damiani, Dennis McGonagle, Charlie Bridgewood, and Howard Amital

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, medicine.disease, Dupilumab, Asymptomatic, Pneumonia, Infectious disease (medical specialty), Internal medicine, Pharmacovigilance, Interleukin 13, medicine, medicine.symptom, business, Interleukin 4
Abstract

Background: Dupilumab (Dupixent®) is a monoclonal antibody that inhibits IL-4 and IL-13 signaling used for the treatment of allergic diseases. Whilst biological therapy is generally associated with an increased risk of infectious disease, prior studies have suggested Dupilumab may be protective. Objective: We investigated the link between Dupilumab therapy and SARS-CoV-2 infection. Methods: We carryied out a comprehensive data-mining and disproportionality analysis of the WHO global pharmacovigilance database. One asymptomatic COVID-19 case, 106 cases of symptomatic COVID-19, and 2 cases of severe COVID-19 pneumonia were found. Results: Dupilumab treated patients were at higher risk of COVID-19 (with an IC0.25 of 3.05), even though infections were less severe (IC0.25 of -1.71). The risk of developing COVID-19 was significant both among males and females (with an IC0.25 of 0.24 and 0.58, respectively). The risk of developing COVID-19 was significant in the age-group of 45-64 years (with an IC0.25 of 0.17). Limitations: Limitations include: the heterogeneous nature of the database sources. Furthermore, a direct causal relationship cannot be inferred from the current investigation. Conclusion: Dupilumab use was found to reduce COVID-19 related severity. Further studies are needed to better understand the immunological mechanisms and clinical implications of these findings.

Published
2021

135. Photopatch Testing

Author

Paolo Daniele Maria Pigatto, Alessia Pacifico, Giovanni Damiani, and Antonio Cristaudo

Published
2021

136. Dermatoscopy of nodular/plaque-type primary cutaneous T- and B-cell lymphomas: A retrospective comparative study with pseudolymphomas and tumoral/inflammatory mimickers by the International Dermoscopy Society

Author

Alejandro Lobato-Berezo, Ruzica Jurakic Toncic, Elena Sotiriou, Małgorzata Sokołowska-Wojdyło, Giovanni Damiani, Paola Vitiello, Teresa Russo, Martyna Sławińska, Patricia L. Myskowski, Enzo Errichetti, Piergiacomo Calzavara-Pinton, Bengü Nisa Akay, Ayşe Tülin Güleç, Aimilios Lallas, Giuseppe Argenziano, Caterina Longo, Giuseppe Stinco, Zorana Kremic, Iris Zalaudek, Jaka Radoš, Camilla Reggiani, Shamir Geller, Michał Sobjanek, Vincenzo Piccolo, Athanassios Kyrgidis, Pedro Zaballos, Vincenzo Maione, Grażyna Kamińska-Winciorek, Romana Čeović, Sven Lanssens, Zoe Apalla, Daniela Ledić Drvar, Errichetti, E., Geller, S., Zalaudek, I., Longo, C., Kyrgidis, A., Akay, B. N., Piccolo, V., Myskowski, P., Vitiello, P., Russo, T., Argenziano, G., Slawinska, M., Sokolowska-Wojdylo, M., Sobjanek, M., Toncic, R. J., Rados, J., Drvar, D. L., Ceovic, R., Kaminska-Winciorek, G., Zaballos, P., Reggiani, C., Kremic, Z., Lanssens, S., Gulec, A. T., Lobato-Berezo, A., Damiani, G., Maione, V., Calzavara-Pinton, P., Sotiriou, E., Stinco, G., Apalla, Z., Lallas, A., Errichetti, Enzo, Geller, Shamir, Zalaudek, Iri, Longo, Caterina, Kyrgidis, Athanassio, Akay, Bengu Nisa, Piccolo, Vincenzo, Myskowski, Patricia, Vitiello, Paola, Russo, Teresa, Argenziano, Giuseppe, Sławińska, Martyna, Sokołowska-Wojdyło, Małgorzata, Sobjanek, Michał, Toncic, Ruzica Jurakic, Rados, Jaka, Drvar, Daniela Ledic, Ceovic, Romana, Kaminska-Winciorek, Grażyna, Zaballos, Pedro, Reggiani, Camilla, Kremic, Zorana, Lanssens, Sven, Güleç, Ayşe Tülin, Lobato-Berezo, Alejandro, Damiani, Giovanni, Maione, Vincenzo, Calzavara-Pinton, Piergiacomo, Sotiriou, Elena, Stinco, Giuseppe, Apalla, Zoe, and Lallas, Aimilios

Subjects
tumors, Pathology, medicine.medical_specialty, tumor, Lymphoma, B-Cell, Skin Neoplasms, pseudolymphoma, Dermoscopy, Breast Neoplasms, lymphoma, Dermatology, dermatoscopy, lymphomas, infiltrative dermatose, Retrospective Studie, hemic and lymphatic diseases, dermatoscopyinfiltrative dermatosesinflammatory dermatoseslymphomaspseudolymphomastumors, Medicine, Humans, Lymphoma, T-Cell, Cutaneou, B cell, Retrospective Studies, Dermatoscopy, infiltrative dermatoses, inflammatory dermatoses, pseudolymphomas, Case-Control Studies, Female, Lymphoma, T-Cell, Cutaneous, Pseudolymphoma, medicine.diagnostic_test, business.industry, Primary cutaneous lymphoma, B-Cell, T-Cell, humanities, medicine.anatomical_structure, Cutaneous, Correlation analysis, Plaque type, business, Case-Control Studie, inflammatory dermatose, Retrospective design, Breast Neoplasm, Human
Abstract

Background Limited data on dermatoscopy of nodular/plaque-type T-/B-cell primary cutaneous lymphomas (PCLs) is available. Objective To describe dermatoscopic features of nodular/plaque-type PCLs, comparing them with those of clinical mimickers (pseudolymphomas, tumors, and inflammatory lesions) and investigating possible differences according to histologic subtypes. Methods Participants were invited to join this retrospective, multicenter case-control study by submitting histologically/immunohistochemically confirmed instances of nodular/plaque-type PCLs and controls. Standardized assessments of the dermatoscopic images and comparative analyses were performed. Results A total of 261 lesions were included (121 PCLs and 140 controls). Orange structureless areas were the strongest PCL dermatoscopic predictor on multivariate analysis compared with tumors and noninfiltrative inflammatory dermatoses. On the other hand, a positive association was found between PCLs and either unfocused linear vessels with branches or focal white structureless areas compared with infiltrative inflammatory dermatoses, whereas white lines were predictive of PCLs over pseudolymphomas. Differences in the vascular pattern were also seen between B- and T-cell PCLs and among B-cell PCL subtypes. Limitations Retrospective design and the lack of a dermatoscopic-pathologic correlation analysis. Conclusion Nodular/plaque-type PCLs display dermatoscopic clues, which may partially vary according to histologic subtype and whose diagnostic relevance depends on the considered clinical differential diagnoses.

Published
2021

137. Platelet-Rich Plasma for Wound Healing

Author

Rosalynn R.Z. Conic, Massimo Del Fabbro, Silvio Taschieri, Giovanni Damiani, Sourav Panda, and Paolo D. Pigatto

Subjects
medicine.medical_specialty, business.industry, Regeneration (biology), Surgery, law.invention, Randomized controlled trial, Private practice, law, Platelet-rich plasma, medicine, Long term outcomes, Platelet, Prospective cohort study, business, Wound healing
Abstract

Wound healing is a multistep regeneration process that requires immunological and microenvironmental conditions occurring simultaneously. Since platelets and their granules play a pivotal role in wound healing, their use as medication is extensively been evaluated in several fields, spacing from chronic wounds to aesthetics. In this chapter, we focused on wound healing and specifically on the contribution exerted by platelet-rich plasma (PRP) in different wounds. We performed a comprehensive literature review, including randomized clinical trials, prospective studies, case--control, and case series, to investigate clinical long-term outcomes (>12 months) of topical PRP. Our results suggest that PRP improves healing, sustaining a faster tissue regeneration, reducing scar formation, improving neo-vascularization, and decreasing recurrences. Remarkably, patients display lower pain and discomfort resulting in an increased satisfaction. Since this effective technique is ideal to be performed in hospital as well as in private practice, authors encourage the use of PRP in all patients with wounds, both chronic and acute.

Published
2021

138. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019

Author

Mohsen Naghavi, Saman Esmaeilnejad, Irena Ilic, Chhabi Lal Ranabhat, Hubert Amu, Jalil Jaafari, Walter Mendoza, Yanzhong Wang, Atta Abbas Naqvi, Mahesh P A, Afshin Maleki, Songhomitra Panda-Jonas, Akila Prashant, Jessica Y Islam, Ali H. Mokdad, Rahmatollah Moradzadeh, Roman Shrestha, Muhammad Naveed, Andre M. N. Renzaho, Santi Martini, Reza Rawassizadeh, Chisom Joyqueenet Akunna, Tudorel Andrei, Jason A. Anderson, Martin McKee, Iffat Elbarazi, Golnaz Heidari, Abdollah Mohammadian-Hafshejani, Soewarta Kosen, Davood Anvari, Randah R. Hamadeh, G. K. Mini, Emerito Jose A. Faraon, Farhad Islami, Yasir Waheed, Fahad Alanezi, Maciej Banach, Sheikh Mohammed Shariful Islam, Ismaeel Yunusa, Suresh Mehata, Tarun Gupta, Mavra A Riaz, Derrick A Bennett, Nithin Kumar, Ali Soroush, Kurt Straif, Muhammad Aziz Rahman, Hasan Yusefzadeh, Avirup Guha, Catalina Liliana Andrei, Muhammed Shahriar Zaman, Arief Hargono, Sandhya Neupane Kandel, Adam E. Berman, Giulia Carreras, Ali Bijani, Christoph Nowak, Rafael Alves Guimarães, Aziz Sheikh, Kamal Hezam, Carlo Eduardo Medina-Solís, Simon I. Hay, Deborah Carvalho Malta, Rahman Shiri, Ashok Pandey, Ramesh Holla, Gyu Ri Kim, Aidin Abedi, Sharath Burugina Nagaraja, Andem Effiong, Samad Azari, Bhaskar Thakur, Mohsen Mazidi, Vahid Yazdi-Feyzabadi, Prashant Mathur, Bay Vo, Robert Ancuceanu, Eun-Kee Park, Mehdi Fazlzadeh, Thomas Hsiao, Richard G Pestell, Sindhura Lakshmi Koulmane Laxminarayana, Doo Woong Lee, Bayew Kelkay, Erkin M. Mirrakhimov, Hualiang Lin, Mohsen Bayati, Florian Fischer, Wei Liu, Stefan Stortecky, Javad Nazari, Fatemeh Pashazadeh Kan, Virginia Núñez-Samudio, Nitish Naik, Sreenivas Narasimha Swamy, Rajat Gupta, Rakhi Dandona, Hermann Brenner, Chandrashekhar T Sreeramareddy, Mohammad Ali Mansournia, Yuichiro Yano, Pankaj Bhardwaj, Samath D Dharmaratne, Constantine I. Vardavas, Gabriela Fernanda Gil, Azeem Majeed, Akram Pourshams, Nachimuthu Senthil Kumar, Florentino Luciano Caetano dos Santos, Juan Sanabria, Iván Landires, Parkes J Kendrick, Dinh-Toi Chu, Asma Tahir Awan, Khem Narayan Pokhrel, Siddharudha Shivalli, Omid Shafaat, Shankar Prasad Nagaraju, Manu Raj Mathur, Rachel L Updike, Mohammad Ebrahimi Kalan, Ryan David Kennedy, Alessandra Lugo, Olalekan A. Uthman, Tarek Tawfik Amin, Jiregna Darega Gela, Zhi-Jiang Zhang, Yeshambel T. Nigatu, Bedanta Roy, Arielle Wilder Eagan, Jalal Arabloo, Milena Ilic, Mehdi Hosseinzadeh, Jost B. Jonas, Dian Kusuma, Shahrzad Bazargan-Hejazi, Yo Han Lee, Mohammed Shannawaz, Mohammad Ali Moni, Valery L. Feigin, Himal Kandel, Lalit Dandona, Milena Santric-Milicevic, Jasvinder A. Singh, Till Bärnighausen, Neeraj Bhala, Sara Sheikhbahaei, Alireza Ansari-Moghaddam, Borhan Mansouri, Narayana Manjunatha, Giuseppe Gorini, Saif Ullah, Sheikh M. Alif, Giang Thu Vu, Ai Koyanagi, Mahaveer Golechha, Ingan Ukur Tarigan, Sumaira Mubarik, Naohiro Yonemoto, Ahmad Ghashghaee, Yves Miel H Zuniga, Bach Xuan Tran, Sorin Hostiuc, Catherine P. Benziger, Ritesh G. Menezes, Leonardo Roever, Xiaochen Dai, Meghnath Dhimal, Medhat Farwati, Chenwen Zhong, Seyed Sina Naghibi Irvani, G Anil Kumar, Jaya Prasad Tripathy, Amirhossein Sahebkar, Simiao Chen, Zubair Kabir, Meseret Derbew Molla, Tilahun Ali, Animut Tagele Tamiru, Negussie Boti Sidemo, Monika Sawhney, Bright Opoku Ahinkorah, Ruxandra Irina Negoi, Segun Emmanuel Ibitoye, Vin Gupta, Mona Pathak, Lorenzo Monasta, Andrew T Olagunju, Nermin Ghith, Nuwan Darshana Wickramasinghe, Kazumasa Yamagishi, Virendra Singh, Takahiro Tabuchi, Gholamreza Roshandel, Andre R. Brunoni, Hayley D. Tymeson, Madhur Verma, Eyayou Girma Tadesse, Adrian Pana, Isabela M. Benseñor, Abdullah Al Mamun, Jianrong Zhang, Hai Quang Pham, Mihaela Hostiuc, Sung-In Jang, Vinay Nangia, Luca Ronfani, Rizwan Suliankatchi Abdulkader, Dhirendra N Sinha, Josip Car, Sohail Ahmad, Rekha Thapar, Salman Rawaf, Joanna L Whisnant, Sanjay Basu, Abdallah M. Samy, Michal Grivna, Zahid A Butt, Abera Getachew Obsa, Mahdi Nalini, Ted R. Miller, Sanjeev Misra, Utsav Parekh, Budi Aji, Saeed Amini, João Pedro Silva, Felix Akpojene Ogbo, Mihajlo Jakovljevic, Demosthenes B. Panagiotakos, Baye Dagnew, Yousef Khader, Atif Amin Baig, Habib Benzian, Keivan Ahmadi, Marco Vacante, Brijesh Sathian, Akshaya Srikanth Bhagavathula, Savita Lasrado, Maryam Khayamzadeh, Darshan B B, Mohammad Rifat Haider, Yonas Akalu, Irmina Maria Michalek, Simone Vidale, Getie Lake Aynalem, Rosa A. S. Couto, Yigizie Yeshaw, Syed Mohamed Aljunid, Pradhum Ram, Shrikant Pawar, Kevin Welding, Suzanne Barker-Collo, Hamideh Salimzadeh, Luisa Sorio Flor, Priya Rathi, Hiba Jawdat Barqawi, Marcos Roberto Tovani-Palone, K M Shivakumar, Gebiyaw Wudie Tsegaye, Fares Alahdab, Vafa Rahimi-Movaghar, Om P Kurmi, Nataliya Foigt, André Karch, Marina Pinheiro, Basema Saddik, Paschalis Steiropoulos, Chuanhua Yu, Graeme J. Hankey, Panniyammakal Jeemon, Abdul-Aziz Seidu, Ramaiah Itumalla, Befikadu Legesse Wubishet, Vera Marisa Costa, Shanshan Li, Ambrish Singh, Yuming Guo, Reza Malekzadeh, Nikha Bhardwaj, Mikhail Sergeevich Zastrozhin, Maryam Zamanian, Onyema greg Chido-Amajuoyi, Ibtihal Fadhil, Sabina O Nduaguba, Turki Alanzi, Eun-Cheol Park, Nicholas Arian, Salah Eddin Karimi, Parnaz Daneshpajouhnejad, Minale Tareke, Paramjit Gill, Chukwudi A Nnaji, Haroon Ahmed, Irina Filip, Juwel Rana, Aziz Rezapour, Huong Lan Thi Nguyen, Ashish Badiye, Kewal Krishan, Nima Hafezi-Nejad, Masood Ali Shaikh, Tanuj Kanchan, Shilpashree Madhava Kunjathur, Reza Ghanei Gheshlagh, Thomas R. Hird, Yousef Mohammad, Soraya Siabani, Falk Schwendicke, Ziyad Al-Aly, Desta Debalkie Atnafu, Krittika Bhattacharyya, Mika Kivimäki, Ayodipupo Sikiru Oguntade, Zabihollah Yousefi, Neeti Kapoor, Syed Mahboob Shah, Kavumpurathu Raman Thankappan, Mika Shigematsu, Ben Lacey, Ireneous N. Soyiri, Amir Radfar, Lemma Getacher, Sameer Vali Gopalani, David Laith Rawaf, Amir Masoud Rahmani, Birhan Gebresillassie Gebregiorgis, Morenike Oluwatoyin Folayan, Salime Goharinezhad, Ambuj Roy, Ruth W Kimokoti, Nuworza Kugbey, Getinet Ayano, Mohammad Hifz Ur Rahman, Benny Antony, Katrin Burkart, Christopher J L Murray, Khalid F. AlHabib, Mariam Molokhia, Mansour Ghafourifard, Abebaw Alemayehu Desta, Tariku Tesfaye Bekuma, Shailesh Advani, Kiomars Sharafi, Kurnia Dwi Artanti, E S Abhilash, Ejaz Ahmad Khan, Sana Salehi, Dan J. Stein, Pankaj Chaturvedi, Mahmoud A. Alomari, Kawkab Shishani, Dejana Braithwaite, Jung-Chen Chang, Rajeev Gupta, Giovanni Damiani, Maha El Tantawi, Maria Sofia Sofia Cattaruzza, Amir Abdoli, Narayanaswamy Venketasubramanian, Rakibul M Islam, Ibrahim Abdelmageed Ginawi, Victor Aboyans, Ganesh Kumar Saya, Silvano Gallus, João Mauricio Castaldelli-Maia, Vardhmaan Jain, Masoud Foroutan, Janni Leung, Mohammad Abdollahi, Mohammed Zewdu Yimmer, Vahid Alipour, Wondwossen Niguse Asmare, Ravi Prakash Jha, Gerhard Sulo, Brigid Unim, Sheng-Chia Chung, Sadaf G. Sepanlou, Hamed Mirzaei, Anna Aleksandrovna Skryabina, In-Hwan Oh, Rannveig Sigurvinsdottir, Oladimeji Adebayo, Farshad Farzadfar, Anasthasia Zastrozhina, Shafiu Mohammed, Johan Sundström, Ali Kabir, Paolo Lauriola, Tilahun Belete Mossie, Sadia Bibi, Bartosz Miazgowski, Erin C Mullany, Keyvan Pakshir, Srikanta Banerjee, Mowafa Househ, Mohamed M. Gad, Leila R Kalankesh, Mikk Jürisson, Ismail Tareque, Albertino Damasceno, Musliu Adetola Tolani, Andrea Werdecker, Shane D. Morrison, Inga Dora Sigfusdottir, Marcel Ausloos, Monika Arora, Marissa B Reitsma, Filippos Filippidis, Biniyam Sahiledengle Geberemariyam, Bruno Piassi Sao Jose, Leeberk Raja Inbaraj, Antonio Biondi, Mohsen Abbasi-Kangevari, Junjie Huang, Mohammad Mahdi Zamani, Jean Jacques Noubiap, Emmanuela Gakidou, Valentin Yurievich Skryabin, Mayowa O. Owolabi, Shubha Jayaram, Hiroyasu Iso, Charles Ugochukwu Ibeneme, Molly R Nixon, Rachel Feldman, Liliana G Ciobanu, Kristina Edvardsson, Claudiu Herteliu, Andreea Mirica, Kindie Mitiku Kebede, Department of Public Health, Collaborators, GBD 2019 Chewing Tobacco, and Lacey, B

Subjects
Male, Health Status, Smoking Prevention, DETERMINANTS, Global Health, 01 natural sciences, Global Burden of Disease, SMOKELESS TOBACCO, 0302 clinical medicine, Risk Factors, Global health, Prevalence, 030212 general & internal medicine, 610 Medicine & health, RISK, High prevalence, WOMEN, Public Health, Global Health, Social Medicine and Epidemiology, Articles, Middle Aged, 3142 Public health care science, environmental and occupational health, Chewing tobacco, Smokeless tobacco, Population Surveillance, A990 Medicine and Dentistry not elsewhere classified, Female, Quality-Adjusted Life Years, Burden of disease, Adult, medicine.medical_specialty, Tobacco, Smokeless, Adolescent, WHO Framework Convention on Tobacco Control, VALIDATION, 03 medical and health sciences, Young Adult, Age Distribution, SDG 3 - Good Health and Well-being, Environmental health, medicine, Humans, 0101 mathematics, Sex Distribution, Chewing tobacco, Prevalence, Global Burden, Smokeless tobacco, business.industry, Public health, Smoking Tobacco, 010102 general mathematics, Public Health, Environmental and Occupational Health, Global Burden, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, STATES, Socioeconomic Factors, Smoking Cessation, business
Abstract

Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. Findings In 2019, 273 center dot 9 million (95% uncertainty interval 258 center dot 5 to 290 center dot 9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 center dot 72% (4 center dot 46 to 5 center dot 01). 228 center dot 2 million (213 center dot 6 to 244 center dot 7; 83 center dot 29% [82 center dot 15 to 84 center dot 42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global agestandardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 center dot 21% [-1 center dot 26 to -1 center dot 16]), similar progress was not observed for chewing tobacco (0 center dot 46% [0 center dot 13 to 0 center dot 79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 center dot 94% [-1 center dot 72 to -0 center dot 14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Summary Background Chewing tobacco and other types of smokeless tobacco use have had less attention from the global health community than smoked tobacco use. However, the practice is popular in many parts of the world and has been linked to several adverse health outcomes. Understanding trends in prevalence with age, over time, and by location and sex is important for policy setting and in relation to monitoring and assessing commitment to the WHO Framework Convention on Tobacco Control. Methods We estimated prevalence of chewing tobacco use as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 using a modelling strategy that used information on multiple types of smokeless tobacco products. We generated a time series of prevalence of chewing tobacco use among individuals aged 15 years and older from 1990 to 2019 in 204 countries and territories, including age-sex specific estimates. We also compared these trends to those of smoked tobacco over the same time period. Findings In 2019, 273 & middot;9 million (95% uncertainty interval 258 & middot;5 to 290 & middot;9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 & middot;72% (4 & middot;46 to 5 & middot;01). 228 & middot;2 million (213 & middot;6 to 244 & middot;7; 83 & middot;29% [82 & middot;15 to 84 & middot;42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global age standardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 & middot;21% [-1 & middot;26 to -1 & middot;16]), similar progress was not observed for chewing tobacco (0 & middot;46% [0 & middot;13 to 0 & middot;79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 & middot;94% [-1 & middot;72 to -0 & middot;14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. For complete list of authors see http://dx.doi.org/10.1016/S2468-2667(21)00065-7

Published
2021

139. MAsks use and facial dermatitis during COVID-19 outbreak: Is there a difference between CEand non-CEapproved masks? Multi-center, real-life data from a large Italian cohort

Author

Pierachille Santus, Antonio Cristaudo, Piergiorgio Malagoli, Paola Savoia, Alessia Pacifico, Nicola Luigi Bragazzi, Paolo D. Pigatto, Alessandra Buja, Dennis Linder, Laura Cristina Gironi, Francesca Allocco, and Giovanni Damiani

Subjects
medicine.medical_specialty, Population, Sars-cov-2, Dermatitis, Dermatology, Facial dermatoses, law.invention, Disease Outbreaks, law, Personal protective equipment, Quarantine, Medicine, Humans, Prospective Studies, Prospective cohort study, education, education.field_of_study, business.industry, Incidence (epidemiology), Masks, Outbreak, COVID-19, medicine.disease, Occupational, Infectious Diseases, Dermatitis, Occupational, Italy, Cohort, Irritant contact dermatitis, Covid-19, Facial Dermatoses, Personal Protective Equipment, business
Abstract

BACKGROUND: During the recent COVID-19 outbreak, masks became mandatory and shortages frequent, therefore the prevalence of non-CE (European Conformity Mark) approved masks increased in the general population. We aimed to quantify the prevalence of mask-related cutaneous side effects and the differences between CE and non-CE approved masks. METHODS: In this multicenter prospective observational study conducted from March 20, 2020 to May 12, 2020(during and after quarantine), patients attending emergency departments for a dermatological consult were clinically assessed and their masks were inspected to detect CE marks and UNI (Italian National Unification Entity) norms. Patients with history of facial dermatoses or under current treatment for facial dermatoses were excluded. RESULTS: We enrolled 412 patients (318 during quarantine and 94 after quarantine). CE-approved masks were observed 52.8% vs. 24.5%, whilst subsets of non-CE approved masks were 9.7% vs. 14.9% (Personal protective equipment (PPE)-masks), 16.4% vs. 12.8% (surgical masks [SM]), and 21.1% vs. 47.9%(non-PPE) and (non-SM masks), respectively during and after quarantine. Remarkably, non-CE-approved masks resulted in patients displaying a statistically significant higher incidence of facial dermatoses and irritant contact dermatitis compared to CE-approved masks, and these differences were mainly driven by non-PPE non-SM masks. Comparing quarantine and after quarantine periods, no statistically significant differences were found for CE-approved masks, whilst differences were detected in non-CE-approved masks regarding incidence of facial dermatoses (P

Published
2021

140. Italian expert consensus on clinical and therapeutic management of multiple chemical sensitivity (Mcs)

Author

Daniela Caccamo, Andrea Cormano, Marco Alessandrini, Andrea Mazzatenta, Paolo D. Pigatto, Ottaviano Tapparo, Giovanni Damiani, Alessandro Micarelli, Alba Piroli, Gianpaolo Guzzi, Margherita Bianca, and Alberto Migliore

Subjects
Neurological signs, medicine.medical_specialty, 2019-20 coronavirus outbreak, Consensus, Health, Toxicology and Mutagenesis, Population, behavioral disciplines and activities, Article, Settore MED/06, Age and gender, Chemical intolerance, Threshold limit value, Multiple chemical sensitivity (MCS), Health care, Neurogenic inflammation, medicine, Hypersensitivity, Humans, Intensive care medicine, education, education.field_of_study, business.industry, chemical intolerance, environmental exposure, multiple chemical sensitivity (MCS), neurogenic inflammation, threshold limit value, Public Health, Environmental and Occupational Health, Expert consensus, Environmental exposure, medicine.disease, humanities, Italy, Solvents, Medicine, Multiple Chemical Sensitivity, business, Multiple chemical sensitivity
Abstract

Multiple chemical sensitivity (MCS) is a multisystem, recurrent, environmental disorder that flares in response to different exposures (i.e., pesticides, solvents, toxic metals and molds) under the threshold limit value (TLV) calculated for age and gender in the general population. MCS is a syndrome characterized by cutaneous, allergic, gastrointestinal, rheumatological, endocrinological, cardiological and neurological signs and symptoms. We performed a systematic review of the literature to summarize the current clinical and therapeutic evidence and then oriented an eDelphi consensus. Four main research domains were identified (diagnosis, treatment, hospitalization and emergency) and discussed by 10 experts and an MCS patient. Thus, the first Italian MCS consensus had the double aim: (a) to improve MCS knowledge among healthcare workers and patients by standardizing the clinical and therapeutic management to MCS patients, and (b) to improve and shed light on MCS misconceptions not supported by evidence-based medicine (EBM).

Published
2021

141. Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning

Author

Elizabeth A. Cromwell, Joshua C.P. Osborne, Thomas R. Unnasch, María Gloria Basáñez, Katherine M. Gass, Kira A. Barbre, Elex Hill, Kimberly B. Johnson, Katie M. Donkers, Shreya Shirude, Chris A. Schmidt, Victor Adekanmbi, Olatunji O. Adetokunboh, Mohsen Afarideh, Ehsan Ahmadpour, Muktar Beshir Ahmed, Temesgen Yihunie Akalu, Ziyad Al-Aly, Fahad Mashhour Alanezi, Turki M. Alanzi, Vahid Alipour, Catalina Liliana Andrei, Fereshteh Ansari, Mustafa Geleto Ansha, Davood Anvari, Seth Christopher Yaw Appiah, Jalal Arabloo, Benjamin F. Arnold, Marcel Ausloos, Martin Amogre Ayanore, Atif Amin Baig, Maciej Banach, Aleksandra Barac, Till Winfried Bärnighausen, Mohsen Bayati, Krittika Bhattacharyya, Zulfiqar A. Bhutta, Sadia Bibi, Ali Bijani, Somayeh Bohlouli, Mahdi Bohluli, Oliver J. Brady, Nicola Luigi Bragazzi, Zahid A. Butt, Félix Carvalho, Souranshu Chatterjee, Vijay Kumar Chattu, Soosanna Kumary Chattu, Natalie Maria Cormier, Saad M.A. Dahlawi, Giovanni Damiani, Farah Daoud, Aso Mohammad Darwesh, Ahmad Daryani, Kebede Deribe, Samath Dhamminda Dharmaratne, Daniel Diaz, Hoa Thi Do, Maysaa El Sayed Zak, Maha El Tantawi, Demelash Abewa Elemineh, Anwar Faraj, Majid Fasihi Harandi, Yousef Fatahi, Valery L. Feigin, Eduarda Fernandes, Nataliya A. Foigt, Masoud Foroutan, Richard Charles Franklin, Mohammed Ibrahim Mohialdeen Gubari, Davide Guido, Yuming Guo, Arvin Haj‐mirzaian, Kanaan Hamagharib Abdullah, Samer Hamidi, Claudiu Herteliu, Hagos Degefa De Hidru, Tarig B. Higazi, Naznin Hossain, Mehdi Hosseinzadeh, Mowafa Househ, Olayinka Stephen Ilesanmi, Milena D. Ilic, Irena M. Ilic, Usman Iqbal, Seyed Sina Naghibi Irvani, Ravi Prakash Jha, Farahnaz Joukar, Jacek Jerzy Jozwiak, Zubair Kabir, Leila R. Kalankesh, Rohollah Kalhor, Behzad Karami Matin, Salah Eddin Karimi, Amir Kasaeian, Taras Kavetskyy, Gbenga A. Kayode, Ali Kazemi Karyani, Abraham Getachew Kelbore, Maryam Keramati, Rovshan Khalilov, Ejaz Ahmad Khan, Md Nuruzzaman Nuruzzaman Khan, Khaled Khatab, Mona M. Khater, Neda Kianipour, Kelemu Tilahun Kibret, Yun Jin Kim, Soewarta Kosen, Kris J. Krohn, Dian Kusuma, Carlo La Vecchia, Charles Lansingh Van, Paul H. Lee, Kate E. Legrand, S. (Shanshan) Li, Joshua Longbottom, Hassan Magdy Abd El Razek, Muhammed Magdy Abd El Razek, Afshin Maleki, Abdullah Mamun, Ali Manafi, Navid Manafi, Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, Mohsen Mazidi, Colm McAlinden, Birhanu Geta Meharie, Walter Mendoza, Endalkachew Worku Mengesha, Desalegn Tadese Mengistu, Seid Tiku Mereta, Tomislav Mestrovic, Ted R. Miller, Mohammad Miri, Masoud Moghadaszadeh, Abdollah Mohammadian Hafshejani, Reza Mohammadpourhodki, Shafiu Mohammed, Salahuddin Mohammed, Masoud Moradi, Rahmatollah Moradzadeh, Paula Moraga, Jonathan F. Mosser, Mehdi Naderi, Ahamarshan Jayaraman Nagarajan, Gurudatta Naik, Ionut Negoi, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Trang Huyen Nguyen, Rajan Nikbakhsh, Bogdan Oancea, Tinuke O. Olagunju, Andrew T. Olagunju, Ahmed Omar Bali, Obinna E. Onwujekwe, Adrian Pana, Hadi Pourjafar, Fakher Rahim, Mohammad Hifz Ur Rahman, Priya Rathi, Salman Rawaf, David Laith Rawaf, Reza Rawassizadeh, Serge Resnikoff, Melese Abate Reta, Aziz Rezapour, Enrico Rubagotti, Salvatore Rubino, Ehsan Sadeghi, Abedin Saghafipour, S. Mohammad Sajadi, Abdallah M. Samy, Rodrigo Sarmiento-Suárez, Monika Sawhney, Megan F. Schipp, Amira A. Shaheen, Masood Ali Shaikh, Morteza Shamsizadeh, Kiomars Sharafi, A (Aziz) Sheikh, B. Suresh Kumar Shetty, Jae Il Shin, K. M. Shivakumar, Biagio Simonetti, Jasvinder A. Singh, Eirini Skiadaresi, Amin Soheili, Shahin Soltani, Emma Elizabeth Spurlock, Mu'awiyyah Babale Sufiyan, Takahiro Tabuchi, Leili Tapak, Robert L. Thompson, Alan J. Thomson, Eugenio Traini, Bach Xuan Tran, Irfan Ullah, Saif Ullah, Chigozie Jesse Uneke, Bhaskaran Unnikrishnan, Olalekan A. Uthman, Natalie V.S.Vinkeles Melchers, Francesco S. Violante, Haileab Fekadu Wolde, Tewodros Eshete Wonde, Tomohide Yamada, Sanni Yaya, Vahid Yazdi Feyzabadi, Paul Yip, Naohiro Yonemoto, Hebat Allah Salah A. Yousof, Chuanhua Yu, Yong Yu, Hasan Yusefzadeh, Leila Zaki, Sojib Bin Zaman, Maryam Zamanian, Zhi Jiang Zhang, Yunquan Zhang, Arash Ziapour, Simon I. Hay, David M. Pigott, Elizabeth A. Cromwell, Joshua C.P. Osborne, Thomas R. Unnasch, María Gloria Basáñez, Katherine M. Gass, Kira A. Barbre, Elex Hill, Kimberly B. Johnson, Katie M. Donkers, Shreya Shirude, Chris A. Schmidt, Victor Adekanmbi, Olatunji O. Adetokunboh, Mohsen Afarideh, Ehsan Ahmadpour, Muktar Beshir Ahmed, Temesgen Yihunie Akalu, Ziyad Al-Aly, Fahad Mashhour Alanezi, Turki M. Alanzi, Vahid Alipour, Catalina Liliana Andrei, Fereshteh Ansari, Mustafa Geleto Ansha, Davood Anvari, Seth Christopher Yaw Appiah, Jalal Arabloo, Benjamin F. Arnold, Marcel Ausloos, Martin Amogre Ayanore, Atif Amin Baig, Maciej Banach, Aleksandra Barac, Till Winfried Bärnighausen, Mohsen Bayati, Krittika Bhattacharyya, Zulfiqar A. Bhutta, Sadia Bibi, Ali Bijani, Somayeh Bohlouli, Mahdi Bohluli, Oliver J. Brady, Nicola Luigi Bragazzi, Zahid A. Butt, Félix Carvalho, Souranshu Chatterjee, Vijay Kumar Chattu, Soosanna Kumary Chattu, Natalie Maria Cormier, Saad M.A. Dahlawi, Giovanni Damiani, Farah Daoud, Aso Mohammad Darwesh, Ahmad Daryani, Kebede Deribe, Samath Dhamminda Dharmaratne, Daniel Diaz, Hoa Thi Do, Maysaa El Sayed Zak, Maha El Tantawi, Demelash Abewa Elemineh, Anwar Faraj, Majid Fasihi Harandi, Yousef Fatahi, Valery L. Feigin, Eduarda Fernandes, Nataliya A. Foigt, Masoud Foroutan, Richard Charles Franklin, Mohammed Ibrahim Mohialdeen Gubari, Davide Guido, Yuming Guo, Arvin Haj‐mirzaian, Kanaan Hamagharib Abdullah, Samer Hamidi, Claudiu Herteliu, Hagos Degefa De Hidru, Tarig B. Higazi, Naznin Hossain, Mehdi Hosseinzadeh, Mowafa Househ, Olayinka Stephen Ilesanmi, Milena D. Ilic, Irena M. Ilic, Usman Iqbal, Seyed Sina Naghibi Irvani, Ravi Prakash Jha, Farahnaz Joukar, Jacek Jerzy Jozwiak, Zubair Kabir, Leila R. Kalankesh, Rohollah Kalhor, Behzad Karami Matin, Salah Eddin Karimi, Amir Kasaeian, Taras Kavetskyy, Gbenga A. Kayode, Ali Kazemi Karyani, Abraham Getachew Kelbore, Maryam Keramati, Rovshan Khalilov, Ejaz Ahmad Khan, Md Nuruzzaman Nuruzzaman Khan, Khaled Khatab, Mona M. Khater, Neda Kianipour, Kelemu Tilahun Kibret, Yun Jin Kim, Soewarta Kosen, Kris J. Krohn, Dian Kusuma, Carlo La Vecchia, Charles Lansingh Van, Paul H. Lee, Kate E. Legrand, S. (Shanshan) Li, Joshua Longbottom, Hassan Magdy Abd El Razek, Muhammed Magdy Abd El Razek, Afshin Maleki, Abdullah Mamun, Ali Manafi, Navid Manafi, Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, Mohsen Mazidi, Colm McAlinden, Birhanu Geta Meharie, Walter Mendoza, Endalkachew Worku Mengesha, Desalegn Tadese Mengistu, Seid Tiku Mereta, Tomislav Mestrovic, Ted R. Miller, Mohammad Miri, Masoud Moghadaszadeh, Abdollah Mohammadian Hafshejani, Reza Mohammadpourhodki, Shafiu Mohammed, Salahuddin Mohammed, Masoud Moradi, Rahmatollah Moradzadeh, Paula Moraga, Jonathan F. Mosser, Mehdi Naderi, Ahamarshan Jayaraman Nagarajan, Gurudatta Naik, Ionut Negoi, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Trang Huyen Nguyen, Rajan Nikbakhsh, Bogdan Oancea, Tinuke O. Olagunju, Andrew T. Olagunju, Ahmed Omar Bali, Obinna E. Onwujekwe, Adrian Pana, Hadi Pourjafar, Fakher Rahim, Mohammad Hifz Ur Rahman, Priya Rathi, Salman Rawaf, David Laith Rawaf, Reza Rawassizadeh, Serge Resnikoff, Melese Abate Reta, Aziz Rezapour, Enrico Rubagotti, Salvatore Rubino, Ehsan Sadeghi, Abedin Saghafipour, S. Mohammad Sajadi, Abdallah M. Samy, Rodrigo Sarmiento-Suárez, Monika Sawhney, Megan F. Schipp, Amira A. Shaheen, Masood Ali Shaikh, Morteza Shamsizadeh, Kiomars Sharafi, A (Aziz) Sheikh, B. Suresh Kumar Shetty, Jae Il Shin, K. M. Shivakumar, Biagio Simonetti, Jasvinder A. Singh, Eirini Skiadaresi, Amin Soheili, Shahin Soltani, Emma Elizabeth Spurlock, Mu'awiyyah Babale Sufiyan, Takahiro Tabuchi, Leili Tapak, Robert L. Thompson, Alan J. Thomson, Eugenio Traini, Bach Xuan Tran, Irfan Ullah, Saif Ullah, Chigozie Jesse Uneke, Bhaskaran Unnikrishnan, Olalekan A. Uthman, Natalie V.S.Vinkeles Melchers, Francesco S. Violante, Haileab Fekadu Wolde, Tewodros Eshete Wonde, Tomohide Yamada, Sanni Yaya, Vahid Yazdi Feyzabadi, Paul Yip, Naohiro Yonemoto, Hebat Allah Salah A. Yousof, Chuanhua Yu, Yong Yu, Hasan Yusefzadeh, Leila Zaki, Sojib Bin Zaman, Maryam Zamanian, Zhi Jiang Zhang, Yunquan Zhang, Arash Ziapour, Simon I. Hay, and David M. Pigott

Abstract

Recent evidence suggests that, in some foci, elimination of onchocerciasis from Africa may be feasible with mass drug administration (MDA) of ivermectin. To achieve continental elimination of transmission, mapping surveys will need to be conducted across all implementation units (IUs) for which endemicity status is currently unknown. Using boosted regression tree models with optimised hyperparameter selection, we estimated environmental suitability for onchocerciasis at the 5 × 5-km resolution across Africa. In order to classify IUs that include locations that are environmentally suitable, we used receiver operating characteristic (ROC) analysis to identify an optimal threshold for suitability concordant with locations where onchocerciasis has been previously detected. This threshold value was then used to classify IUs (more suitable or less suitable) based on the location within the IU with the largest mean prediction. Mean estimates of environmental suitability suggest large areas across West and Central Africa, as well as focal areas of East Africa, are suitable for onchocerciasis transmission, consistent with the presence of current control and elimination of transmission efforts. The ROC analysis identified a mean environmental suitability index of 0.71 as a threshold to classify based on the location with the largest mean prediction within the IU. Of the IUs considered for mapping surveys, 50.2% exceed this threshold for suitability in at least one 5×5-km location. The for

Published
2021
Full Text
View/download PDF

142. Tetracyclines in <scp>COVID</scp> ‐19 patients quarantined at home: Literature evidence supporting <scp>real‐world</scp> data from a multicenter observational study targeting inflammatory and infectious dermatoses

Author

Paolo Pigatto, Paola Savoia, Pierachille Santus, Laura Cristina Gironi, Alessia Pacifico, Ottavio Cremona, Giovanni Damiani, Elisa Zavattaro, Gironi, Laura Cristina, Damiani, Giovanni, Zavattaro, Elisa, Pacifico, Alessia, Santus, Pierachille, Pigatto, Paolo Daniele Maria, Cremona, Ottavio, and Savoia, Paola

Subjects
Adult, medicine.medical_specialty, Teledermatology, Coronavirus disease 2019 (COVID-19), SARS-Cov-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anosmia, Dermatology, Skin Diseases, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, minocycline, 0302 clinical medicine, COVID‐19, Internal medicine, medicine, Humans, Prospective Studies, Aged, drug re‐proposal, doxycycline, SARS-CoV-2, business.industry, COVID-19, Outbreak, Original Articles, General Medicine, Minocycline, tetracyclines, Middle Aged, Ageusia, inflammatory dermatoses, SARS‐Cov‐2, drug re-proposal, 030220 oncology & carcinogenesis, Original Article, Observational study, medicine.symptom, business, medicine.drug
Abstract

Background Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential anti-viral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. Methods We performed a multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC. Results We enrolled 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]). During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. Conclusions TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms. This article is protected by copyright. All rights reserved.

Published
2020

143. Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)

Author

Angelo Cattaneo, C. Carrera, Dennis Linder, Nicola Luigi Bragazzi, C. Franchi, Giovanni Damiani, Paolo D. Pigatto, Piergiorgio Malagoli, Enzo Grossi, Rosalynn R.Z. Conic, and Radhakrishna Uppala

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Injections, Subcutaneous, Drug Resistance, Physical examination, Induction Phase, Pilot Projects, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Efficacy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Deep Learning, Predictive Value of Tests, Internal medicine, Psoriasis, medicine, Humans, Prospective Studies, Biological Products, medicine.diagnostic_test, Artificial neural network, business.industry, Deep learning, Models, Immunological, Complete blood count, General Medicine, Middle Aged, medicine.disease, Prognosis, Treatment Outcome, 030220 oncology & carcinogenesis, Secukinumab, Female, Artificial intelligence, business, Biomarkers
Abstract

Background Drug resistance to biologics in psoriasis therapy can occur n it may be acquired during a treatment or else present itself from the beginning. To date, no biomarkers are known that may reliably guide clinicians in predicting responsiveness to biologics. Biologics may pose a substantial economic burden. Secukinumab efficiently targets IL-17 in the treatment of psoriasis. Objective To assess the lfast responderr patient profile, predicting it from the preliminary complete blood count (CBC) and clinical examination. Materials and methods From November 2016 to May 2017 we performed a multicenter prospective open label pilot study in three Italian reference centers enrolling bio-naive plaque psoriasis patients, undergoing the initiation phase secukinumab treatment (300mg subcutaneous at week 0,1,2,3,4). We define fast responders as patients having achieved at least PASI 75 at the end of secukinumab induction phase. Clinical and CBC data at week 0 and at week 4 were analyzed with linear statistics, principal component analysis, and artificial neural networks (ANNs), also known as deep learning. Two different ANNs were employed: Auto Contractive Map (Auto-CM), an unsupervised ANNs, to study how this variables cluster and a supervised ANNs, Training with Input Selection and Testing (TWIST), to build the predictive model. Results We enrolled 23 plaque psoriasis patients: 19 patients were responders and 4 were non-responders. 30 attributes were examined by Auto-CM, creating a semantic map for three main profiles: responders, non-responders and an intermediate profile. The algorithm yielded 5 of the 30 attributes to describe the 3 profiles. This allowed us to set up the predictive model. It displayed after training testing protocol an overall accuracy of 91.88% (90% for responders and 93,75% for non-responders). Conclusions The present study is possibly the first approach employing ANNs to predict drug efficacy in dermatology; a wider use of ANNs may be conducive to useful both theoretical and clinical insight. J Drugs Dermatol. 2020;19(12) doi:10.36849/JDD.2020.5006.

Published
2020

144. The impact of autoimmune systemic inflammation and associated medications on male reproductive health in patients with chronic rheumatological, dermatological, and gastroenterological diseases: A systematic review

Author

Salvatore De Masi, Renata Finelli, Giovanni Damiani, Kristian Leisegang, Federica Finocchi, and Ashok Agarwal

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Gastrointestinal Diseases, Immunology, Disease, medicine.disease_cause, Skin Diseases, Autoimmunity, Autoimmune Diseases, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Psoriasis, Internal medicine, Rheumatic Diseases, Immunology and Allergy, Medicine, Humans, Hidradenitis suppurativa, Infertility, Male, Inflammation, Ankylosing spondylitis, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics and Gynecology, medicine.disease, 030104 developmental biology, Reproductive Health, Reproductive Medicine, Rheumatoid arthritis, Chronic inflammatory response, business
Abstract

Autoimmune disorders currently affect 5%-8% of the global population, characterized by an aberrant chronic inflammatory response to self-antigens. The aim of this study was to systematically review the current available evidence investigating the impact of systemic autoimmune diseases and associated immunosuppressive treatment on fertility parameters of adult men. Clinical trials, observational studies, and case reports written in English and reporting semen analysis, evaluation of seminal oxidative stress, and/or sperm DNA fragmentation in patients affected by psoriasis and psoriatic arthritis, celiac disease, inflammatory bowel diseases, systemic lupus erythematosus, ankylosing spondylitis, hidradenitis suppurativa, uveitis, dermatomyositis, and rheumatoid arthritis were collected by searching on PubMed, EMBASE, OVID, Scopus, and Cochrane Library databases, with no limit of time. The study quality and the extent of bias in design, methods, and outcome assessment were evaluated by applying the Joanna Briggs Institute Critical Appraisal tools. Evidence suggested that various autoimmune diseases or relevant medications can adversely affect male fertility parameters and that patients may benefit of counseling and sperm cryopreservation. Clinical trials further investigating any adverse effect of autoimmunity and related thereby on male infertility are warranted, to develop appropriate guidelines for males diagnosed and treated for autoimmune disorders.

Published
2020

145. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Author

Soufiane Boufous, Yousef Veisani, Mehran Asadi-Aliabadi, Sharath Burugina Nagaraja, Maziar Moradi-Lakeh, Getachew Mullu Kassa, Edward J Mills, Dimas Ria Angga Pribadi, William James Dangel, Mohamad-Hani Temsah, Catherine O. Johnson, Gregory A. Roth, Giuseppe Gorini, Fariborz Mansour-Ghanaei, Alberto Ortiz, Samad Azari, Assefa Ayalew Ayalew Ayalew Gebreslassie, Salime Goharinezhad, Stephanie R. M. Zimsen, Peng Zheng, Michael Assmus, Elisabetta Pupillo, Bach Xuan Tran, Lal B. Rawal, Narayanaswamy Venketasubramanian, Noushin Mohammadifard, Stephen S Lim, Ata Rafiee, Maria Inês Schmidt, Vincent C. Iannucci, Suzanne Lyn Barker-Collo, Leah E. Cahill, Tauseef Ahmad, Platon D. Lopukhov, Kazumasa Yamagishi, Abdullah Al Mamun, Iqbal R. F. Elyazar, Giovanni Damiani, Mohammad Hossein Bakhshaei, Mehdi Fazlzadeh, Virginia Núñez-Samudio, Alyssa Pennini, Dietrich Plass, Atkilt Esaiyas Etisso, Gebre Teklemariam Demoz, Alexandrea Watson, Arvin Haj-Mirzaian, Paul S Briant, Frank B. Osei, Blair R. Bumgarner, Maciej Banach, Ravensara S. Travillian, Kai-Lan Chang, Shirin Djalalinia, Hasan Yusefzadeh, Silvano Gallus, Seyyed Meysam Mousavi, Bernhard T. Baune, Aaron van Donkelaar, Azeem Majeed, Hans Kromhout, Robert Ancuceanu, Blessing J. Akombi, Pushpendra Singh, Nayu Ikeda, William M. Gardner, Zahid A Butt, Mohammad Abdollahi, Temesgen Yihunie Akalu, Rahman Shiri, Benn Sartorius, Ai-Min Wu, Bing Fang Hwang, Flavia M. Cicuttini, Hiroyasu Iso, Luis Camera, Amin Soheili, Félix Carvalho, Yun Jin Kim, Caleb Mackay Salpeter Irvine, Mehdi Mirzaei-Alavijeh, Iman Halvaei, Saqib Ali, Giulio Castelpietra, Catalina Liliana Andrei, Ali Kazemi Karyani, Parkes J Kendrick, Hamidreza Haririan, Lucas Guimarães Abreu, Mukhammad David Naimzada, Jeff T. Zhao, Samiah Alam, Sorin Hostiuc, Shaun Wen Huey Lee, João Mauricio Castaldelli-Maia, Behzad Karami Matin, Cyrus Alinia, Takahiro Tabuchi, Manu Raj Mathur, Søren Thorgaard Skou, Thomas Khaled Dwayne Classen, Reza Heidari-Soureshjani, Massimo Cirillo, Nikita Otstavnov, Mehdi Bohluli, Ruth W. Kimokoti, Animut Tagele Tamiru, Masoumeh Sadeghi, Mohammad Ali Jahani, Itamar S. Santos, Mekdes Tigistu Yilma, Lars Johansson, Arielle Wilder Eagan, Nevine El Nahas, Silvia Schiavolin, Kevin D. Shield, Dinh-Toi Chu, Shiva Borzouei, Paul S. F. Yip, Beatrix Haddock, Gianfranco Alicandro, Vasily Vlassov, Deanna Anderlini, Giuseppe Remuzzi, Khalid A Altirkawi, Farahnaz Joukar, Aso Mohammad Darwesh, Ratilal Lalloo, Panniyammakal Jeemon, Rohollah Kalhor, Daniel Youngwhan Cho, Weijia Fu, João Pedro Silva, Rodrigo Sarmiento-Suarez, Seth Christopher Yaw Appiah, Mehdi Ahmadi, Jacob Olusegun Olusanya, José Neves, Gaorui Guo, Tomas Y. Yeheyis, John S. Ji, Charles D. H. Parry, Maryam Ghadimi, Seyed-Mohammad Fereshtehnejad, Serge Resnikoff, Anna E. Torre, Vinod C Nayak, Jamileh Shadid, Susanne Breitner, Mohammad Khammarnia, Mathilde Touvier, Ensiyeh Jenabi, Hosna Janjani, Floriane Ausloos, Irmina Maria Michalek, Alexandra S. Boon-Dooley, Jessica A. Cruz, Syed Mohamed Aljunid, Abiodun M. Adeoye, André Faro, Bartosz Miazgowski, Jobert Richie Nansseu, Erin C Mullany, Giannina Ferrara, Martin McKee, Emmanuel Peprah, Oommen John, Reza Saeedi, Yasser Vasseghian, Dragos Virgil Davitoiu, Sarah Wulf Hanson, Yingxi Zhao, Omid Shafaat, Ali Rajabpour-Sanati, Farid Najafi, Ana Maria Mantilla Herrera, Fatemeh Rajati, Tarun Gupta, Łukasz Szumowski, Mohammed Ibrahim Mohialdeen Gubari, Peter Njenga Keiyoro, Dharmesh Kumar Lal, Zhi Jiang Zhang, Osayomwanbo Osarenotor, Tanvir M. Huda, Perminder S. Sachdev, Farhad Ghamari, Era Upadhyay, Vivek Kumar, Guoqing Hu, Vinay Nangia, Vladimir Andreevich Korshunov, Saeed Shahabi, Golnaz Heidari, Ashraf Nabhan, Robert C. Reiner, Aziz Rezapour, Justin J. Lang, Rakhi Dandona, Josephine W. Ngunjiri, Anna-Karin Danielsson, André Karch, Filippo Ariani, Ahmed Abdelalim, Masih Tajdini, Stefanos Tyrovolas, Mohamed Hsairi, Jae Il Shin, Jasvinder A. Singh, Meghan D. Mooney, Fiona B. Bennitt, Hesam Alizade, Segun Emmanuel Ibitoye, Pradhum Ram, Soraya Siabani, Evanson Z. Sambala, Reza Malekzadeh, Falk Schwendicke, Lalit Dandona, Masoud Moradi, Molly R Nixon, Roya Mirzaei, Rachel Feldman, Hosni Salem, Alberto L. García-Basteiro, Lorainne Tudor Car, Sharareh Eskandarieh, Ramesh Holla, Ritesh G. Menezes, Taraneh Yousefinezhadi, Hai Quang Pham, Hamideh Salimzadeh, Luisa Sorio Flor, Priya Rathi, Ali Bijani, Harvey Whiteford, Shanshan Li, Aleksandr Y. Aravkin, Joshua A. Salomon, Franz Castro, Lisa M. Force, Abdilahi Yousuf Yousuf, Mina Anjomshoa, Ken Takahashi, Maigeng Zhou, Telma Zahirian Moghadam, Maseer Khan, Irina Filip, Santi Martini, Randah R. Hamadeh, Somayeh Bohlouli, Joana Morgado-da-Costa, Tim Driscoll, Jingkai Wei, Hermann Brenner, Reza Rawassizadeh, Radoslaw Sierpinski, Saman Esmaeilnejad, Emmanuel Wandera Okunga, Marisa Freitas, Srikanta Banerjee, Feleke Mekonnen Demeke, Shahin Soltani, Naser Mohammad Gholi Mezerji, Reed J D Sorensen, Elena V. Gnedovskaya, Johan Ärnlöv, Ivo Rakovac, Reza Mohammadpourhodki, Hussain Jafari, Atte Meretoja, Yasir Waheed, Fahad Alanezi, Arya Haj-Mirzaian, Sezer Kisa, Jaifred Christian F. Lopez, Khalid F. Alhabib, Basema Saddik, Michael R. Phillips, Vishnu Renjith, Yafeng Wang, Kevan R. Polkinghorne, Liliana G Ciobanu, Jacek Jerzy Jozwiak, Gelin Xu, Richard C. Franklin, Junjie Wu, Thomas R. Hird, Mohammad Zamani, Diana Silva, Fotis Topouzis, Irena Ilic, Jeffrey D. Stanaway, Hadi Pourjafar, Huong Lan Thi Nguyen, Khaled Khatab, Ammas Siraj Mohammed, Ziyad Al-Aly, A. A. Fomenkov, Charlie Ashbaugh, Mowafa Househ, Paul I. Dargan, Endalkachew Worku Mengesha, Shaimaa I. El-Jaafary, Ernoiz Antriyandarti, Iffat Elbarazi, Dara K. Mohammad, Naznin Hossain, Reza Shirkoohi, João M. Furtado, Arash Ziapour, Morteza Jafarinia, M. Mofizul Islam, Anamika Pandey, Ahmed I. Hasaballah, Tanuj Kanchan, Lee Ling Lim, Muktar Omer Omer, Charles D.A. Wolfe, Ulrich O Mueller, Helen Bitew, V. Prakash, Fereshteh Mehri, Randall V. Martin, Claudiu Herteliu, Constance D. Pond, Min Jeong Shin, Morteza Oladnabi, Antonio Maria Borzì, Yousef Mohammad, Yuichiro Yano, Luke D. Knibbs, Kevin S Ikuta, Maryam Mirzaei, Andreea Mirica, Sofia Boston Redford, Siamak Sabour, Mariya Vladimirovna Titova, Davood Anvari, Ghobad Moradi, Jordi Alonso, Shiwei Liu, Theo Vos, Tuomo J. Meretoja, Ireneous N. Soyiri, Owen R. Cooper, Seyed Sina Naghibi Irvani, Kejia Hu, Hannah J. Henrikson, Sanni Yaya, Robert P. Dellavalle, Chidozie Declan Iwu, Sergey Soshnikov, Jee-Young Jasmine Choi, Satinath Mukhopadhyay, Zabihollah Yousefi, Iman El Sayed, Biresaw Wassihun Alemu, Neeti Kapoor, Ahmad Daryani, Cathleen Keller, Ibrahim Abdollahpour, Nuno Taveira, Masoud Foroutan, Fatemeh Amiri, Mariam Molokhia, Songhomitra Panda-Jonas, Amy E. Peden, Rufus Akinyemi, Ejaz Ahmad Khan, Mostafa Amini-Rarani, J. Becker, Hamidreza Pazoki Toroudi, Ben Lacey, Kidanemaryam Berhe, Simon Yadgir, Spencer L. James, Cory N. Spencer, Aletta E. Schutte, Mu'awiyyah Babale Sufiyan, Arash Tehrani-Banihashemi, Govinda Prasad Dhungana, Fereshteh Ansari, Rixing Xu, Jonathan F. Mosser, Josep Maria Haro, Enrico Rubagotti, Anurag Agrawal, Zahiruddin Quazi Syed, Hoa Thi Do, Ettore Beghi, Seyed Mohammad Kazem Aghamir, Abraham Geremew, Alireza Esteghamati, Paramjit Gill, Farzad Jalilian, J. Jason West, Mikhail Sergeevich Zastrozhin, Albertino Damasceno, Bruce Bartholow Duncan, Nazir Fattahi, Daniel Cury Ribeiro, Michael Brauer, Mark A. Stokes, Veincent Christian Filipino Pepito, Lidia Morawska, Fiona J Charlson, Babak Moazen, Dejana Braithwaite, Jonathan M. Kocarnik, Sergio I. Prada, Andrea Farioli, Zahra Atafar, Heather Orpana, Daniela Balzi, Marco Vacante, Rahmatollah Moradzadeh, Jacek A. Kopec, Iván Landires, Robert G. Weintraub, Leonardo Roever, Yannick Béjot, Markus P. Schlaich, Hamed Zandian, Subramanian Senthilkumaran, Klara Dokova, Vahid Alipour, Sowmya J. Rao, Rakesh Ghosh, Omar Mukhtar Salman, Faris Lami, Marcos Roberto Tovani-Palone, Hamid Reza Tohidinik, Seyed Mohammad Riahi, Adnan Kisa, Ghasem Azarian, Caroline Stein, Zulfiqar A. Bhutta, Sinead Langan, Kunihiro Matsushita, Lauren E. Schaeffer, Kathryn H. Jacobsen, Mehdi Naderi, Mehdi Hosseinzadeh, Nizal Sarrafzadegan, Bahram Armoon, Dan J. Stein, Jessica Fanzo, Morenike Oluwatoyin Folayan, Luca Ronfani, Phetole Walter Mahasha, Nicholas J K Breitborde, Adrian Oţoiu, Arash Sarveazad, Marc L. Serre, Mostafa Hosseini, Nicolas Cherbuin, George D. Thurston, Jalal Arabloo, Mokhtar Mahdavi, Andre Rodrigues Duraes, Ana Laura Manda, Ahmed Abualhasan, Nima Rezaei, Yuan-Pang Wang, Theodore Patrick Younker, Alireza Ansari-Moghaddam, Borhan Mansouri, Adam E. Berman, Khezar Hayat, Rosario Cárdenas, Bolajoko O. Olusanya, Tommi Vasankari, Simon I. Hay, Fatemeh Ghaffarifar, Leo Stockfelt, Ai Koyanagi, Giorgia Giussani, Yuming Guo, Sonia Saxena, Deborah Carvalho Malta, Mehedi Hasan, Negar Rezaei, Maja Pasovic, Jukka Takala, Bogdan Oancea, Sare Safi, A. Werdecker, Florian Fischer, Beatriz Paulina Ayala Quintanilla, Muhammad Shahdaat Bin Sayeed, Takeshi Fukumoto, Maha Atout, Brijesh Sathian, Cristina Bosetti, Mitchell T. Wallin, Agegnehu Bante, Helen Ippolito, Anthony Masaka, Chantal Huynh, Justin Lo, Jordan Weiss, Joemer C. Maravilla, Alberto Raggi, Peter W. Gething, Cristiana Abbafati, Daniela Ribeiro, Mohammad Farahmand, Yetunde O. John-Akinola, Isabela M. Benseñor, Emilie R Maddison, John J. McGrath, Salman Khazaei, Scott B. Patten, Jean Jacques Noubiap, Emmanuela Gakidou, Celine M. Barthelemy, Ashish Badiye, George C. Patton, Obinna Onwujekwe, Peter Allebeck, Victor Aboyans, Olayinka Stephen Ilesanmi, Mousa Yaminfirooz, Neeraj Bedi, Nicholas L S Roberts, Joht Singh Chandan, Hans W. Hoek, Usman Iqbal, Nima Hafezi-Nejad, Haley Lescinsky, Naohiro Yonemoto, Ahmad Ghashghaee, Anders Larsson, David C. Schwebel, Milena Ilic, Richard T. Burnett, Yang Liu, Carlo La Vecchia, Felix Akpojene Ogbo, Morteza Naserbakht, Sangram Kishor Patel, Melanie S. Hammer, Prasanna Mithra, Mohammad Amin Bahrami, Kanyin L. Ong, Mona Pathak, Afshin Maleki, Saeid Safiri, Masood Ali Shaikh, Kate Causey, Michael R.M. Abrigo, Jost B. Jonas, Dian Kusuma, Jagadish Rao Padubidri, Mihajlo Jakovljevic, Ali S. Shalash, Abdiwahab Hashi, Ionut Negoi, Nataliya A. Foigt, Andrey Nikolaevich Briko, François Alla, Giuseppe Grosso, Houman Goudarzi, Di H. Cross, Vera Marisa Costa, Eduarda Fernandes, Chandrashekhar T Sreeramareddy, Odgerel Chimed-Ochir, Sonia Rodríguez-Ramírez, Bo Norrving, Kerem Shuval, Jacob L. Stubbs, Muhammad Ali, Shuhei Nomura, Man Mohan Mehndiratta, Chisom Joyqueenet Akunna, Abdollah Mohammadian-Hafshejani, Navid Rabiee, Dana Bryazka, Hussen Mohammed, Asadollah Gholamian, Ashley Marks, Rizwan Kalani, Molly E. Herbert, Islam Y. Elgendy, Moritz U. G. Kraemer, Chuanhua Yu, Suzanne Polinder, Pascual R. Valdez, Jennifer Rickard, Kylie Ball, Turki Alanzi, Mohsen Bayati, Hamed Mirzaei, Christopher M Odell, Amira Shaheen, Ziad A. Memish, Thirunavukkarasu Sathish, Michael A. Piradov, Hamed Kalani, Lorenzo Monasta, Christopher S Yilgwan, Desalegn Getnet Demsie, Riaz Uddin, Rizwan Suliankatchi Abdulkader, Vinay Srinivasan, Hamid Ahmadieh, Claudio Alberto Dávila-Cervantes, Raffaele Palladino, Chukwudi A Nnaji, Mika Shigematsu, Stein Emil Vollset, Abbas Sheikhtaheri, Paulo A. Lotufo, Nasir Salam, Binyam Minuye Birihane, Mohammad Ali Mansournia, Tomislav Mestrovic, Samer Hamidi, Rajesh Sagar, Mayowa O. Owolabi, Kara Estep, Ester Cerin, Michael T. Chung, Simon Øverland, Amir Taherkhani, Sheng Chia Chung, Martin Amogre Ayanore, Nikolaos Dervenis, Joan B. Soriano, Tahereh Javaheri, Victor Adekanmbi, Seid Tiku Mereta, Gbenga A. Kayode, Christopher R. Cederroth, Razique Anwer, Rajan Nikbakhsh, Kaja Abbas, Fatemeh Heydarpour, Louisa Degenhardt, Tahiya Alam, Mohammad Miri, Alibek Mereke, David Laith Rawaf, Ippazio Cosimo Antonazzo, Erkin M. Mirrakhimov, Seyed Hossein Yahyazadeh Jabbari, Desta Debalkie Atnafu, Davide Sattin, Moslem Soofi, Edris Hasanpoor, Krittika Bhattacharyya, Mika Kivimäki, Nikolay Ivanovich Briko, Joanna L Whisnant, Christopher J L Murray, Simin Mouodi, Alize J. Ferrari, Damian Santomauro, Katrin Burkart, Tudorel Andrei, Alberto Baldasseroni, Hafiz Ansar Rasul Suleria, Valery L. Feigin, Nauman Khalid, Ewerton Cousin, S. Mohammad Sajadi, Francisco Rogerlândio Martins-Melo, Shankar M Bakkannavar, Themba G.G. Ginindza, Sadaf G. Sepanlou, Sheikh Mohammed Shariful Islam, Sanjay Basu, Getinet Ayano, Paula Moraga, Soheil Hassanipour, Jason A. Anderson, Catherine Bisignano, Iyad Sultan, Deepak Kumar Pasupula, Keivan Ahmadi, Fariba Dorostkar, Rajeev Gupta, David M. Pereira, Mustafa Z. Younis, Adel Spotin, Rasmus Havmoeller, Yeshambel T. Nigatu, Barthelemy Kuate Defo, Mithila Faruque, Alan D. Lopez, Shailesh Advani, Behshad Naghshtabrizi, Shane D. Morrison, Inga Dora Sigfusdottir, Konrad Pesudovs, Anna Gershberg Hayoon, Raaj Kishore Biswas, Reshmi Bhageerathy, H. Dean Hosgood, Giulia Carreras, Sarika Chaturvedi, James L. Fisher, In-Hwan Oh, G Anil Kumar, Christoph Nowak, Vijay Kumar Chattu, Puja C Rao, Marcel Ausloos, Ali Kabir, Rannveig Sigurvinsdottir, Leeberk Raja Inbaraj, Edgar Denova-Gutiérrez, Rafael Tabarés-Seisdedos, Minh Nguyen, Ashkan Afshin, Payman Salamati, Colin Angus, Mona M. Khater, Ehsan Sadeghi, Mahalaqua Nazli Khatib, Antonio Biondi, Valentin Yurievich Skryabin, Mohsen Abbasi-Kangevari, Andrew T Olagunju, Amir Radfar, Laith J. Abu-Raddad, Marcello Tonelli, Hesam Ghiasvand, Hanne Christensen, Juan Jesus Carrero, Maryam Adabi, Saravanan Muthupandian, Kurt Straif, Hossein Samadi Kafil, Lope H Barrero, Harish Chander Gugnani, Mohammad Fareed, Morteza Shamsizadeh, Jemal Abdu Mohammed, Juan A Rivera, Shai Linn, Saad M.A. Dahlawi, Janni Leung, Shokofeh Maleki, Mohd Anisul Karim, Kamarul Imran Musa, Farshad Pourmalek, Dietrich Rothenbacher, Kiomars Sharafi, Alessandra C. Goulart, Leila Doshmangir, Gabriele Nagel, Helena Manguerra, Olatunji O. Adetokunboh, Srinivasa Vittal Katikireddi, Nermin Ghith, Maha El Tantawi, Awoke Misganaw, Yunquan Zhang, Carl Abelardo T. Antonio, Vahid Rashedi, Mehran Shams-Beyranvand, Bhaskaran Unnikrishnan, Holly E. Erskine, Ann Kristin Knudsen, Marissa B Reitsma, Getayeneh Antehunegn Tesema, Javad Javidnia, Ismael R. Campos-Nonato, Biniyam Sahiledengle Geberemariyam, Godfrey Mutashambara Rwegerera, Alaa Badawi, James Leigh, Morteza Arab-Zozani, Kyle E. Simpson, Muluken Bekele Sorrie, Roghiyeh Faridnia, Vivekanand Jha, Tomasz Miazgowski, Aaron J Cohen, Chukwuma David Umeokonkwo, Alessandra Lugo, Adhanom Gebreegziabher Baraki, Akshaya Srikanth Bhagavathula, Caitlyn Steiner, Gholamreza Roshandel, Cuong Tat Nguyen, Tania G Sánchez-Pimienta, Ahamarshan Jayaraman Nagarajan, Laura Kemmer, Ihoghosa Osamuyi Iyamu, Seyedeh Zahra Masoumi, Vivian Chia-Rong Hsieh, Kris J. Krohn, Phoebe Anne Rhinehart, Sarah Wozniak, Sahar Saeedi Moghaddam, Kate E. LeGrand, Christian Kieling, Vahid Yazdi-Feyzabadi, Robin Room, Zelalem Nigussie Azene, Kelly Cercy, Paul H. Lee, Stanislav S. Otstavnov, Dinesh Bhandari, Rafael Alves Guimarães, Zemenu Tadesse Tessema, Aziz Sheikh, Michellr L. Bell, Marwa Rashad Salem, Kirsten E. Wiens, Emma U.R. Smith, Hassan Abolhassani, Cristiano Piccinelli, Kedir Hussein Abegaz, G.K. Mini, Christian Razo, Manuela L. Ferreira, Diego De Leo, Francesco Saverio Violante, Aristidis Tsatsakis, Zahra Sadat Dibaji Forooshani, Tea Lallukka, Dickson A. Amugsi, Anna Poznańska, Graeme J. Hankey, Kewal Krishan, Maryam Zamanian, Eirini Skiadaresi, Jai K Das, Felix Greaves, Tessa M. Pilz, Sameer Vali Gopalani, Mansour Ghafourifard, M. DeLang, Morteza Mahmoudi, Alton Lu, Brian J. Hall, Ravi Prakash Jha, David Edvardsson, Xiu Ju George Zhao, Farshad Farzadfar, Hadi Hassankhani, Samuel M. Ostroff, Gerhard Sulo, Keyghobad Ghadiri, Neeraj Bhala, Stefan Lorkowski, Mohammad Rabiee, Sivan Yegnanarayana Iyer Saraswathy, Amirhossein Sahebkar, Rashid Abdi Guled, Abdallah M. Samy, Roman Topor-Madry, Michal Grivna, Afsaneh Arzani, Ayesha Humayun, Simin Liu, Maryam Khayamzadeh, Davoud Adham, Ahad Bakhtiari, Shafiu Mohammed, Paolo Lauriola, Abbas Mosapour, Sophia Emmons-Bell, Khurshid Alam, Rajat Das Gupta, Matilde Leonardi, Muktar Beshir Ahmed, Jeffrey V. Lazarus, Mohamed M. Gad, Kelly Compton, Leila R Kalankesh, Abdelrahman Ibrahim Abushouk, Mikk Jürisson, Catherine M. Antony, Ali A. Asadi-Pooya, Daniel Diaz, Salman Rawaf, Gina Agarwal, Ted R. Miller, Rebecca Ivers, João Vasco Santos, Savita Lasrado, Abdul Moiz Hafiz, Amir Almasi-Hashiani, Praveen Hoogar, Fares Alahdab, Om P Kurmi, Anbissa Muleta Senbeta, Tomi Akinyemiju, Boris Bikbov, Muhammad Aziz Rahman, Amin Mousavi Khaneghah, Yahya Safari, Guilherme Borges, Carlos A Castañeda-Orjuela, Kenji Shibuya, Bahman Yousefi, Berrin Serdar, Karen M. Tabb, Sonali Kochhar, Till Bärnighausen, Kala M. Mehta, Mostafa Dianatinasab, Arash Etemadi, Melissa Y. Wei, Kiana Ramezanzadeh, Lingkan Barua, Zubair Kabir, Rade Vukovic, Hesham M. Al-Mekhlafi, Shoshana H. Ballew, Miriam Levi, Zainab Samad, Florentino Luciano Caetano dos Santos, Juan Sanabria, Ramu Rawat, Chinwe Juliana Iwu, Gabrielle B. Britton, Colm McAlinden, Mohsen Naghavi, Maarten J. Postma, Chhabi Lal Ranabhat, Jalil Jaafari, Walter Mendoza, Mahesh P A, Pallab K. Maulik, Ali H. Mokdad, Andre M. N. Renzaho, Milena Santric-Milicevic, Parvaiz A Koul, Foad Abd-Allah, Mihaela Hostiuc, Richard G. Cowden, Ronny Westerman, Meghdad Pirsaheb, Department of Earth Observation Science, UT-I-ITC-ACQUAL, Faculty of Geo-Information Science and Earth Observation, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Microbes in Health and Disease (MHD), Tampere University, Tays Research Services, Health Sciences, Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., Abegaz, K. H., Abolhassani, H., Aboyans, V., Abreu, L. G., Abrigo, M. R. M., Abualhasan, A., Abu-Raddad, L. J., Abushouk, A. I., Adabi, M., Adekanmbi, V., Adeoye, A. M., Adetokunboh, O. O., Adham, D., Advani, S. M., Agarwal, G., Aghamir, S. M. K., Agrawal, A., Ahmad, T., Ahmadi, K., Ahmadi, M., Ahmadieh, H., Ahmed, M. B., Akalu, T. Y., Akinyemi, R. O., Akinyemiju, T., Akombi, B., Akunna, C. J., Alahdab, F., Al-Aly, Z., Alam, K., Alam, S., Alam, T., Alanezi, F. M., Alanzi, T. M., Alemu, B. W., Alhabib, K. F., Ali, M., Ali, S., Alicandro, G., Alinia, C., Alipour, V., Alizade, H., Aljunid, S. M., Alla, F., Allebeck, P., Almasi-Hashiani, A., Al-Mekhlafi, H. M., Alonso, J., Altirkawi, K. A., Amini-Rarani, M., Amiri, F., Amugsi, D. A., Ancuceanu, R., Anderlini, D., Anderson, J. A., Andrei, C. L., Andrei, T., Angus, C., Anjomshoa, M., Ansari, F., Ansari-Moghaddam, A., Antonazzo, I. C., Antonio, C. A. T., Antony, C. M., Antriyandarti, E., Anvari, D., Anwer, R., Appiah, S. C. Y., Arabloo, J., Arab-Zozani, M., Ariani, F., Armoon, B., Arnlov, J., Arzani, A., Asadi-Aliabadi, M., Asadi-Pooya, A. A., Ashbaugh, C., Assmus, M., Atafar, Z., Atnafu, D. D., Atout, M. M. W., Ausloos, F., Ausloos, M., Ayala Quintanilla, B. P., Ayano, G., Ayanore, M. A., Azari, S., Azarian, G., Azene, Z. N., Badawi, A., Badiye, A. D., Bahrami, M. A., Bakhshaei, M. H., Bakhtiari, A., Bakkannavar, S. M., Baldasseroni, A., Ball, K., Ballew, S. H., Balzi, D., Banach, M., Banerjee, S. K., Bante, A. B., Baraki, A. G., Barker-Collo, S. L., Barnighausen, T. W., Barrero, L. H., Barthelemy, C. M., Barua, L., Basu, S., Baune, B. T., Bayati, M., Becker, J. S., Bedi, N., Beghi, E., Bejot, Y., Bell, M. L., Bennitt, F. B., Bensenor, I. M., Berhe, K., Berman, A. E., Bhagavathula, A. S., Bhageerathy, R., Bhala, N., Bhandari, D., Bhattacharyya, K., Bhutta, Z. A., Bijani, A., Bikbov, B., Bin Sayeed, M. S., Biondi, A., Birihane, B. M., Bisignano, C., Biswas, R. K., Bitew, H., Bohlouli, S., Bohluli, M., Boon-Dooley, A. S., Borges, G., Borzi, A. M., Borzouei, S., Bosetti, C., Boufous, S., Braithwaite, D., Breitborde, N. J. K., Breitner, S., Brenner, H., Briant, P. S., Briko, A. N., Briko, N. I., Britton, G. B., Bryazka, D., Bumgarner, B. R., Burkart, K., Burnett, R. T., Burugina Nagaraja, S., Butt, Z. A., Caetano dos Santos, F. L., Cahill, L. E., Camera, L. L. A., Campos-Nonato, I. R., Cardenas, R., Carreras, G., Carrero, J. J., Carvalho, F., Castaldelli-Maia, J. M., Castaneda-Orjuela, C. A., Castelpietra, G., Castro, F., Causey, K., Cederroth, C. R., Cercy, K. M., Cerin, E., Chandan, J. S., Chang, K. -L., Charlson, F. J., Chattu, V. K., Chaturvedi, S., Cherbuin, N., Chimed-Ochir, O., Cho, D. Y., Choi, J. -Y. J., Christensen, H., Chu, D. -T., Chung, M. T., Chung, S. -C., Cicuttini, F. M., Ciobanu, L. G., Cirillo, M., Classen, T. K. D., Cohen, A. J., Compton, K., Cooper, O. R., Costa, V. M., Cousin, E., Cowden, R. G., Cross, D. H., Cruz, J. A., Dahlawi, S. M. A., Damasceno, A. A. M., Damiani, G., Dandona, L., Dandona, R., Dangel, W. J., Danielsson, A. -K., Dargan, P. I., Darwesh, A. M., Daryani, A., Das, J. K., Das Gupta, R., das Neves, J., Davila-Cervantes, C. A., Davitoiu, D. V., De Leo, D., Degenhardt, L., Delang, M., Dellavalle, R. P., Demeke, F. M., Demoz, G. T., Demsie, D. G., Denova-Gutierrez, E., Dervenis, N., Dhungana, G. P., Dianatinasab, M., Dias da Silva, D., Diaz, D., Dibaji Forooshani, Z. S., Djalalinia, S., Do, H. T., Dokova, K., Dorostkar, F., Doshmangir, L., Driscoll, T. R., Duncan, B. B., Duraes, A. R., Eagan, A. W., Edvardsson, D., El Nahas, N., El Sayed, I., El Tantawi, M., Elbarazi, I., Elgendy, I. Y., El-Jaafary, S. I., Elyazar, I. R., Emmons-Bell, S., Erskine, H. E., Eskandarieh, S., Esmaeilnejad, S., Esteghamati, A., Estep, K., Etemadi, A., Etisso, A. E., Fanzo, J., Farahmand, M., Fareed, M., Faridnia, R., Farioli, A., Faro, A., Faruque, M., Farzadfar, F., Fattahi, N., Fazlzadeh, M., Feigin, V. L., Feldman, R., Fereshtehnejad, S. -M., Fernandes, E., Ferrara, G., Ferrari, A. J., Ferreira, M. L., Filip, I., Fischer, F., Fisher, J. L., Flor, L. S., Foigt, N. A., Folayan, M. O., Fomenkov, A. A., Force, L. M., Foroutan, M., Franklin, R. C., Freitas, M., Fu, W., Fukumoto, T., Furtado, J. M., Gad, M. M., Gakidou, E., Gallus, S., Garcia-Basteiro, A. L., Gardner, W. M., Geberemariyam, B. S., Gebreslassie, A. A. A. A., Geremew, A., Gershberg Hayoon, A., Gething, P. W., Ghadimi, M., Ghadiri, K., Ghaffarifar, F., Ghafourifard, M., Ghamari, F., Ghashghaee, A., Ghiasvand, H., Ghith, N., Gholamian, A., Ghosh, R., Gill, P. S., Ginindza, T. G. G., Giussani, G., Gnedovskaya, E. V., Goharinezhad, S., Gopalani, S. V., Gorini, G., Goudarzi, H., Goulart, A. C., Greaves, F., Grivna, M., Grosso, G., Gubari, M. I. M., Gugnani, H. C., Guimaraes, R. A., Guled, R. A., Guo, G., Guo, Y., Gupta, R., Gupta, T., Haddock, B., Hafezi-Nejad, N., Hafiz, A., Haj-Mirzaian, A., Hall, B. J., Halvaei, I., Hamadeh, R. R., Hamidi, S., Hammer, M. S., Hankey, G. J., Haririan, H., Haro, J. M., Hasaballah, A. I., Hasan, M. M., Hasanpoor, E., Hashi, A., Hassanipour, S., Hassankhani, H., Havmoeller, R. J., Hay, S. I., Hayat, K., Heidari, G., Heidari-Soureshjani, R., Henrikson, H. J., Herbert, M. E., Herteliu, C., Heydarpour, F., Hird, T. R., Hoek, H. W., Holla, R., Hoogar, P., Hosgood, H. D., Hossain, N., Hosseini, M., Hosseinzadeh, M., Hostiuc, M., Hostiuc, S., Househ, M., Hsairi, M., Hsieh, V. C. -R., Hu, G., Hu, K., Huda, T. M., Humayun, A., Huynh, C. K., Hwang, B. -F., Iannucci, V. C., Ibitoye, S. E., Ikeda, N., Ikuta, K. S., Ilesanmi, O. S., Ilic, I. M., Ilic, M. D., Inbaraj, L. R., Ippolito, H., Iqbal, U., Irvani, S. S. N., Irvine, C. M. S., Islam, M. M., Islam, S. M. S., Iso, H., Ivers, R. Q., Iwu, C. C. D., Iwu, C. J., Iyamu, I. O., Jaafari, J., Jacobsen, K. H., Jafari, H., Jafarinia, M., Jahani, M. A., Jakovljevic, M., Jalilian, F., James, S. L., Janjani, H., Javaheri, T., Javidnia, J., Jeemon, P., Jenabi, E., Jha, R. P., Jha, V., Ji, J. S., Johansson, L., John, O., John-Akinola, Y. O., Johnson, C. O., Jonas, J. B., Joukar, F., Jozwiak, J. J., Jurisson, M., Kabir, A., Kabir, Z., Kalani, H., Kalani, R., Kalankesh, L. R., Kalhor, R., Kanchan, T., Kapoor, N., Karami Matin, B., Karch, A., Karim, M. A., Kassa, G. M., Katikireddi, S. V., Kayode, G. A., Kazemi Karyani, A., Keiyoro, P. N., Keller, C., Kemmer, L., Kendrick, P. J., Khalid, N., Khammarnia, M., Khan, E. A., Khan, M., Khatab, K., Khater, M. M., Khatib, M. N., Khayamzadeh, M., Khazaei, S., Kieling, C., Kim, Y. J., Kimokoti, R. W., Kisa, A., Kisa, S., Kivimaki, M., Knibbs, L. D., Knudsen, A. K. S., Kocarnik, J. M., Kochhar, S., Kopec, J. A., Korshunov, V. A., Koul, P. A., Koyanagi, A., Kraemer, M. U. G., Krishan, K., Krohn, K. J., Kromhout, H., Kuate Defo, B., Kumar, G. A., Kumar, V., Kurmi, O. P., Kusuma, D., La Vecchia, C., Lacey, B., Lal, D. K., Lalloo, R., Lallukka, T., Lami, F. H., Landires, I., Lang, J. J., Langan, S. M., Larsson, A. O., Lasrado, S., Lauriola, P., Lazarus, J. V., Lee, P. H., Lee, S. W. H., Legrand, K. E., Leigh, J., Leonardi, M., Lescinsky, H., Leung, J., Levi, M., Li, S., Lim, L. -L., Linn, S., Liu, S., Liu, Y., Lo, J., Lopez, A. D., Lopez, J. C. F., Lopukhov, P. D., Lorkowski, S., Lotufo, P. A., Lu, A., Lugo, A., Maddison, E. R., Mahasha, P. W., Mahdavi, M. M., Mahmoudi, M., Majeed, A., Maleki, A., Maleki, S., Malekzadeh, R., Malta, D. C., Mamun, A. A., Manda, A. L., Manguerra, H., Mansour-Ghanaei, F., Mansouri, B., Mansournia, M. A., Mantilla Herrera, A. M., Maravilla, J. C., Marks, A., Martin, R. V., Martini, S., Martins-Melo, F. R., Masaka, A., Masoumi, S. Z., Mathur, M. R., Matsushita, K., Maulik, P. K., Mcalinden, C., Mcgrath, J. J., Mckee, M., Mehndiratta, M. M., Mehri, F., Mehta, K. M., Memish, Z. A., Mendoza, W., Menezes, R. G., Mengesha, E. W., Mereke, A., Mereta, S. T., Meretoja, A., Meretoja, T. J., Mestrovic, T., Miazgowski, B., Miazgowski, T., Michalek, I. M., Miller, T. R., Mills, E. J., Mini, G. K., Miri, M., Mirica, A., Mirrakhimov, E. M., Mirzaei, H., Mirzaei, M., Mirzaei, R., Mirzaei-Alavijeh, M., Misganaw, A. T., Mithra, P., Moazen, B., Mohammad, D. K., Mohammad, Y., Mohammad Gholi Mezerji, N., Mohammadian-Hafshejani, A., Mohammadifard, N., Mohammadpourhodki, R., Mohammed, A. S., Mohammed, H., Mohammed, J. A., Mohammed, S., Mokdad, A. H., Molokhia, M., Monasta, L., Mooney, M. D., Moradi, G., Moradi, M., Moradi-Lakeh, M., Moradzadeh, R., Moraga, P., Morawska, L., Morgado-da-Costa, J., Morrison, S. D., Mosapour, A., Mosser, J. F., Mouodi, S., Mousavi, S. M., Mousavi Khaneghah, A., Mueller, U. O., Mukhopadhyay, S., Mullany, E. C., Musa, K. I., Muthupandian, S., Nabhan, A. F., Naderi, M., Nagarajan, A. J., Nagel, G., Naghavi, M., Naghshtabrizi, B., Naimzada, M. D., Najafi, F., Nangia, V., Nansseu, J. R., Naserbakht, M., Nayak, V. C., Negoi, I., Ngunjiri, J. W., Nguyen, C. T., Nguyen, H. L. T., Nguyen, M., Nigatu, Y. T., Nikbakhsh, R., Nixon, M. R., Nnaji, C. A., Nomura, S., Norrving, B., Noubiap, J. J., Nowak, C., Nunez-Samudio, V., Otoiu, A., Oancea, B., Odell, C. M., Ogbo, F. A., Oh, I. -H., Okunga, E. W., Oladnabi, M., Olagunju, A. T., Olusanya, B. O., Olusanya, J. O., Omer, M. O., Ong, K. L., Onwujekwe, O. E., Orpana, H. M., Ortiz, A., Osarenotor, O., Osei, F. B., Ostroff, S. M., Otstavnov, N., Otstavnov, S. S., Overland, S., Owolabi, M. O., P A, M., Padubidri, J. R., Palladino, R., Panda-Jonas, S., Pandey, A., Parry, C. D. H., Pasovic, M., Pasupula, D. K., Patel, S. K., Pathak, M., Patten, S. B., Patton, G. C., Pazoki Toroudi, H., Peden, A. E., Pennini, A., Pepito, V. C. F., Peprah, E. K., Pereira, D. M., Pesudovs, K., Pham, H. Q., Phillips, M. R., Piccinelli, C., Pilz, T. M., Piradov, M. A., Pirsaheb, M., Plass, D., Polinder, S., Polkinghorne, K. R., Pond, C. D., Postma, M. J., Pourjafar, H., Pourmalek, F., Poznanska, A., Prada, S. I., Prakash, V., Pribadi, D. R. A., Pupillo, E., Quazi Syed, Z., Rabiee, M., Rabiee, N., Radfar, A., Rafiee, A., Raggi, A., Rahman, M. A., Rajabpour-Sanati, A., Rajati, F., Rakovac, I., Ram, P., Ramezanzadeh, K., Ranabhat, C. L., Rao, P. C., Rao, S. J., Rashedi, V., Rathi, P., Rawaf, D. L., Rawaf, S., Rawal, L., Rawassizadeh, R., Rawat, R., Razo, C., Redford, S. B., Reiner, R. C., Reitsma, M. B., Remuzzi, G., Renjith, V., Renzaho, A. M. N., Resnikoff, S., Rezaei, N., Rezapour, A., Rhinehart, P. -A., Riahi, S. M., Ribeiro, D. C., Ribeiro, D., Rickard, J., Rivera, J. A., Roberts, N. L. S., Rodriguez-Ramirez, S., Roever, L., Ronfani, L., Room, R., Roshandel, G., Roth, G. A., Rothenbacher, D., Rubagotti, E., Rwegerera, G. M., Sabour, S., Sachdev, P. S., Saddik, B., Sadeghi, E., Sadeghi, M., Saeedi, R., Saeedi Moghaddam, S., Safari, Y., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sajadi, S. M., Salam, N., Salamati, P., Salem, H., Salem, M. R. R., Salimzadeh, H., Salman, O. M., Salomon, J. A., Samad, Z., Samadi Kafil, H., Sambala, E. Z., Samy, A. M., Sanabria, J., Sanchez-Pimienta, T. G., Santomauro, D. F., Santos, I. S., Santos, J. V., Santric-Milicevic, M. M., Saraswathy, S. Y. I., Sarmiento-Suarez, R., Sarrafzadegan, N., Sartorius, B., Sarveazad, A., Sathian, B., Sathish, T., Sattin, D., Saxena, S., Schaeffer, L. E., Schiavolin, S., Schlaich, M. P., Schmidt, M. I., Schutte, A. E., Schwebel, D. C., Schwendicke, F., Senbeta, A. M., Senthilkumaran, S., Sepanlou, S. G., Serdar, B., Serre, M. L., Shadid, J., Shafaat, O., Shahabi, S., Shaheen, A. A., Shaikh, M. A., Shalash, A. S., Shams-Beyranvand, M., Shamsizadeh, M., Sharafi, K., Sheikh, A., Sheikhtaheri, A., Shibuya, K., Shield, K. D., Shigematsu, M., Shin, J. I., Shin, M. -J., Shiri, R., Shirkoohi, R., Shuval, K., Siabani, S., Sierpinski, R., Sigfusdottir, I. D., Sigurvinsdottir, R., Silva, J. P., Simpson, K. E., Singh, J. A., Singh, P., Skiadaresi, E., Skou, S. T. S., Skryabin, V. Y., Smith, E. U. R., Soheili, A., Soltani, S., Soofi, M., Sorensen, R. J. D., Soriano, J. B., Sorrie, M. B., Soshnikov, S., Soyiri, I. N., Spencer, C. N., Spotin, A., Sreeramareddy, C. T., Srinivasan, V., Stanaway, J. D., Stein, C., Stein, D. J., Steiner, C., Stockfelt, L., Stokes, M. A., Straif, K., Stubbs, J. L., Sufiyan, M. B., Suleria, H. A. R., Suliankatchi Abdulkader, R., Sulo, G., Sultan, I., Szumowski, Tabares-Seisdedos, R., Tabb, K. M., Tabuchi, T., Taherkhani, A., Tajdini, M., Takahashi, K., Takala, J. S., Tamiru, A. T., Taveira, N., Tehrani-Banihashemi, A., Temsah, M. -H., Tesema, G. A., Tessema, Z. T., Thurston, G. D., Titova, M. V., Tohidinik, H. R., Tonelli, M., Topor-Madry, R., Topouzis, F., Torre, A. E., Touvier, M., Tovani-Palone, M. R. R., Tran, B. X., Travillian, R., Tsatsakis, A., Tudor Car, L., Tyrovolas, S., Uddin, R., Umeokonkwo, C. D., Unnikrishnan, B., Upadhyay, E., Vacante, M., Valdez, P. R., van Donkelaar, A., Vasankari, T. J., Vasseghian, Y., Veisani, Y., Venketasubramanian, N., Violante, F. S., Vlassov, V., Vollset, S. E., Vos, T., Vukovic, R., Waheed, Y., Wallin, M. T., Wang, Y., Wang, Y. -P., Watson, A., Wei, J., Wei, M. Y. W., Weintraub, R. G., Weiss, J., Werdecker, A., West, J. J., Westerman, R., Whisnant, J. L., Whiteford, H. A., Wiens, K. E., Wolfe, C. D. A., Wozniak, S. S., Wu, A. -M., Wu, J., Wulf Hanson, S., Xu, G., Xu, R., Yadgir, S., Yahyazadeh Jabbari, S. H., Yamagishi, K., Yaminfirooz, M., Yano, Y., Yaya, S., Yazdi-Feyzabadi, V., Yeheyis, T. Y., Yilgwan, C. S., Yilma, M. T., Yip, P., Yonemoto, N., Younis, M. Z., Younker, T. P., Yousefi, B., Yousefi, Z., Yousefinezhadi, T., Yousuf, A. Y., Yu, C., Yusefzadeh, H., Zahirian Moghadam, T., Zamani, M., Zamanian, M., Zandian, H., Zastrozhin, M. S., Zhang, Y., Zhang, Z. -J., Zhao, J. T., Zhao, X. -J. G., Zhao, Y., Zhou, M., Ziapour, A., Zimsen, S. R. M., Brauer, M., Afshin, A., Lim, S. S., Lacey, B, Sartorius, B, Abbafati, C, Abbas, K, Abbasi-Kangevari, M, Abd-Allah, F, Abdelalim, A, Abdollahi, M, Abdollahpour, I, Abegaz, K, Abolhassani, H, Aboyans, V, Abreu, L, Abrigo, M, Abualhasan, A, Abu-Raddad, L, Abushouk, A, Adabi, M, Adekanmbi, V, Adeoye, A, Adetokunboh, O, Adham, D, Advani, S, Afshin, A, Agarwal, G, Aghamir, S, Agrawal, A, Ahmad, T, Ahmadi, K, Ahmadi, M, Ahmadieh, H, Ahmed, M, Akalu, T, Akinyemi, R, Akinyemiju, T, Akombi, B, Akunna, C, Alahdab, F, Al-Aly, Z, Alam, K, Alam, S, Alam, T, Alanezi, F, Alanzi, T, Alemu, B, Alhabib, K, Ali, M, Ali, S, Alicandro, G, Alinia, C, Alipour, V, Alizade, H, Aljunid, S, Alla, F, Allebeck, P, Almasi-Hashiani, A, Al-Mekhlafi, H, Alonso, J, Altirkawi, K, Amini-Rarani, M, Amiri, F, Amugsi, D, Ancuceanu, R, Anderlini, D, Anderson, J, Andrei, C, Andrei, T, Angus, C, Anjomshoa, M, Ansari, F, Ansari-Moghaddam, A, Antonazzo, I, Antonio, C, Antony, C, Antriyandarti, E, Anvari, D, Anwer, R, Appiah, S, Arabloo, J, Arab-Zozani, M, Aravkin, A, Ariani, F, Armoon, B, Arnlov, J, Arzani, A, Asadi-Aliabadi, M, Asadi-Pooya, A, Ashbaugh, C, Assmus, M, Atafar, Z, Atnafu, D, Atout, M, Ausloos, F, Ausloos, M, Ayala Quintanilla, B, Ayano, G, Ayanore, M, Azari, S, Azarian, G, Azene, Z, Badawi, A, Badiye, A, Bahrami, M, Bakhshaei, M, Bakhtiari, A, Bakkannavar, S, Baldasseroni, A, Ball, K, Ballew, S, Balzi, D, Banach, M, Banerjee, S, Bante, A, Baraki, A, Barker-Collo, S, Barnighausen, T, Barrero, L, Barthelemy, C, Barua, L, Basu, S, Baune, B, Bayati, M, Becker, J, Bedi, N, Beghi, E, Bejot, Y, Bell, M, Bennitt, F, Bensenor, I, Berhe, K, Berman, A, Bhagavathula, A, Bhageerathy, R, Bhala, N, Bhandari, D, Bhattacharyya, K, Bhutta, Z, Bijani, A, Bikbov, B, Bin Sayeed, M, Biondi, A, Birihane, B, Bisignano, C, Biswas, R, Bitew, H, Bohlouli, S, Bohluli, M, Boon-Dooley, A, Borges, G, Borzi, A, Borzouei, S, Bosetti, C, Boufous, S, Braithwaite, D, Brauer, M, Breitborde, N, Breitner, S, Brenner, H, Briant, P, Briko, A, Briko, N, Britton, G, Bryazka, D, Bumgarner, B, Burkart, K, Burnett, R, Burugina Nagaraja, S, Butt, Z, Caetano Dos Santos, F, Cahill, L, Camera, L, Campos-Nonato, I, Cardenas, R, Carreras, G, Carrero, J, Carvalho, F, Castaldelli-Maia, J, Castaneda-Orjuela, C, Castelpietra, G, Castro, F, Causey, K, Cederroth, C, Cercy, K, Cerin, E, Chandan, J, Chang, K, Charlson, F, Chattu, V, Chaturvedi, S, Cherbuin, N, Chimed-Ochir, O, Cho, D, Choi, J, Christensen, H, Chu, D, Chung, M, Chung, S, Cicuttini, F, Ciobanu, L, Cirillo, M, Classen, T, Cohen, A, Compton, K, Cooper, O, Costa, V, Cousin, E, Cowden, R, Cross, D, Cruz, J, Dahlawi, S, Damasceno, A, Damiani, G, Dandona, L, Dandona, R, Dangel, W, Danielsson, A, Dargan, P, Darwesh, A, Daryani, A, Das, J, Das Gupta, R, das Neves, J, Davila-Cervantes, C, Davitoiu, D, De Leo, D, Degenhardt, L, Delang, M, Dellavalle, R, Demeke, F, Demoz, G, Demsie, D, Denova-Gutierrez, E, Dervenis, N, Dhungana, G, Dianatinasab, M, Dias da Silva, D, Diaz, D, Dibaji Forooshani, Z, Djalalinia, S, Do, H, Dokova, K, Dorostkar, F, Doshmangir, L, Driscoll, T, Duncan, B, Duraes, A, Eagan, A, Edvardsson, D, El Nahas, N, El Sayed, I, El Tantawi, M, Elbarazi, I, Elgendy, I, El-Jaafary, S, Elyazar, I, Emmons-Bell, S, Erskine, H, Eskandarieh, S, Esmaeilnejad, S, Esteghamati, A, Estep, K, Etemadi, A, Etisso, A, Fanzo, J, Farahmand, M, Fareed, M, Faridnia, R, Farioli, A, Faro, A, Faruque, M, Farzadfar, F, Fattahi, N, Fazlzadeh, M, Feigin, V, Feldman, R, Fereshtehnejad, S, Fernandes, E, Ferrara, G, Ferrari, A, Ferreira, M, Filip, I, Fischer, F, Fisher, J, Flor, L, Foigt, N, Folayan, M, Fomenkov, A, Force, L, Foroutan, M, Franklin, R, Freitas, M, Fu, W, Fukumoto, T, Furtado, J, Gad, M, Gakidou, E, Gallus, S, Garcia-Basteiro, A, Gardner, W, Geberemariyam, B, Ayalew Gebreslassie, A, Geremew, A, Gershberg Hayoon, A, Gething, P, Ghadimi, M, Ghadiri, K, Ghaffarifar, F, Ghafourifard, M, Ghamari, F, Ghashghaee, A, Ghiasvand, H, Ghith, N, Gholamian, A, Ghosh, R, Gill, P, Ginindza, T, Giussani, G, Gnedovskaya, E, Goharinezhad, S, Gopalani, S, Gorini, G, Goudarzi, H, Goulart, A, Greaves, F, Grivna, M, Grosso, G, Gubari, M, Gugnani, H, Guimaraes, R, Guled, R, Guo, G, Guo, Y, Gupta, R, Gupta, T, Haddock, B, Hafezi-Nejad, N, Hafiz, A, Haj-Mirzaian, A, Hall, B, Halvaei, I, Hamadeh, R, Hamidi, S, Hammer, M, Hankey, G, Haririan, H, Haro, J, Hasaballah, A, Hasan, M, Hasanpoor, E, Hashi, A, Hassanipour, S, Hassankhani, H, Havmoeller, R, Hay, S, Hayat, K, Heidari, G, Heidari-Soureshjani, R, Henrikson, H, Herbert, M, Herteliu, C, Heydarpour, F, Hird, T, Hoek, H, Holla, R, Hoogar, P, Hosgood, H, Hossain, N, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hsairi, M, Hsieh, V, Hu, G, Hu, K, Huda, T, Humayun, A, Huynh, C, Hwang, B, Iannucci, V, Ibitoye, S, Ikeda, N, Ikuta, K, Ilesanmi, O, Ilic, I, Ilic, M, Inbaraj, L, Ippolito, H, Iqbal, U, Irvani, S, Irvine, C, Islam, M, Islam, S, Iso, H, Ivers, R, Iwu, C, Iyamu, I, Jaafari, J, Jacobsen, K, Jafari, H, Jafarinia, M, Jahani, M, Jakovljevic, M, Jalilian, F, James, S, Janjani, H, Javaheri, T, Javidnia, J, Jeemon, P, Jenabi, E, Jha, R, Jha, V, Ji, J, Johansson, L, John, O, John-Akinola, Y, Johnson, C, Jonas, J, Joukar, F, Jozwiak, J, Jurisson, M, Kabir, A, Kabir, Z, Kalani, H, Kalani, R, Kalankesh, L, Kalhor, R, Kanchan, T, Kapoor, N, Matin, B, Karch, A, Karim, M, Kassa, G, Katikireddi, S, Kayode, G, Kazemi Karyani, A, Keiyoro, P, Keller, C, Kemmer, L, Kendrick, P, Khalid, N, Khammarnia, M, Khan, E, Khan, M, Khatab, K, Khater, M, Khatib, M, Khayamzadeh, M, Khazaei, S, Kieling, C, Kim, Y, Kimokoti, R, Kisa, A, Kisa, S, Kivimaki, M, Knibbs, L, Knudsen, A, Kocarnik, J, Kochhar, S, Kopec, J, Korshunov, V, Koul, P, Koyanagi, A, Kraemer, M, Krishan, K, Krohn, K, Kromhout, H, Kuate Defo, B, Kumar, G, Kumar, V, Kurmi, O, Kusuma, D, La Vecchia, C, Lal, D, Lalloo, R, Lallukka, T, Lami, F, Landires, I, Lang, J, Langan, S, Larsson, A, Lasrado, S, Lauriola, P, Lazarus, J, Lee, P, Lee, S, Legrand, K, Leigh, J, Leonardi, M, Lescinsky, H, Leung, J, Levi, M, Li, S, Lim, L, Linn, S, Liu, S, Liu, Y, Lo, J, Lopez, A, Lopez, J, Lopukhov, P, Lorkowski, S, Lotufo, P, Lu, A, Lugo, A, Maddison, E, Mahasha, P, Mahdavi, M, Mahmoudi, M, Majeed, A, Maleki, A, Maleki, S, Malekzadeh, R, Malta, D, Mamun, A, Manda, A, Manguerra, H, Mansour-Ghanaei, F, Mansouri, B, Mansournia, M, Mantilla Herrera, A, Maravilla, J, Marks, A, Martin, R, Martini, S, Martins-Melo, F, Masaka, A, Masoumi, S, Mathur, M, Matsushita, K, Maulik, P, Mcalinden, C, Mcgrath, J, Mckee, M, Mehndiratta, M, Mehri, F, Mehta, K, Memish, Z, Mendoza, W, Menezes, R, Mengesha, E, Mereke, A, Mereta, S, Meretoja, A, Meretoja, T, Mestrovic, T, Miazgowski, B, Miazgowski, T, Michalek, I, Miller, T, Mills, E, Mini, G, Miri, M, Mirica, A, Mirrakhimov, E, Mirzaei, H, Mirzaei, M, Mirzaei, R, Mirzaei-Alavijeh, M, Misganaw, A, Mithra, P, Moazen, B, Mohammad, D, Mohammad, Y, Mohammad Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadifard, N, Mohammadpourhodki, R, Mohammed, A, Mohammed, H, Mohammed, J, Mohammed, S, Mokdad, A, Molokhia, M, Monasta, L, Mooney, M, Moradi, G, Moradi, M, Moradi-Lakeh, M, Moradzadeh, R, Moraga, P, Morawska, L, Morgado-Da-Costa, J, Morrison, S, Mosapour, A, Mosser, J, Mouodi, S, Mousavi, S, Khaneghah, A, Mueller, U, Mukhopadhyay, S, Mullany, E, Musa, K, Muthupandian, S, Nabhan, A, Naderi, M, Nagarajan, A, Nagel, G, Naghavi, M, Naghshtabrizi, B, Naimzada, M, Najafi, F, Nangia, V, Nansseu, J, Naserbakht, M, Nayak, V, Negoi, I, Ngunjiri, J, Nguyen, C, Nguyen, H, Nguyen, M, Nigatu, Y, Nikbakhsh, R, Nixon, M, Nnaji, C, Nomura, S, Norrving, B, Noubiap, J, Nowak, C, Nunez-Samudio, V, Oancea, B, Odell, C, Ogbo, F, Oh, I, Okunga, E, Oladnabi, M, Olagunju, A, Olusanya, B, Olusanya, J, Omer, M, Ong, K, Onwujekwe, O, Orpana, H, Ortiz, A, Osarenotor, O, Osei, F, Ostroff, S, Otoiu, A, Otstavnov, N, Otstavnov, S, Overland, S, Owolabi, M, Mahesh, P, Padubidri, J, Palladino, R, Panda-Jonas, S, Pandey, A, Parry, C, Pasovic, M, Pasupula, D, Patel, S, Pathak, M, Patten, S, Patton, G, Toroudi, H, Peden, A, Pennini, A, Pepito, V, Peprah, E, Pereira, D, Pesudovs, K, Pham, H, Phillips, M, Piccinelli, C, Pilz, T, Piradov, M, Pirsaheb, M, Plass, D, Polinder, S, Polkinghorne, K, Pond, C, Postma, M, Pourjafar, H, Pourmalek, F, Poznanska, A, Prada, S, Prakash, V, Pribadi, D, Pupillo, E, Syed, Z, Rabiee, M, Rabiee, N, Radfar, A, Rafiee, A, Raggi, A, Rahman, M, Rajabpour-Sanati, A, Rajati, F, Rakovac, I, Ram, P, Ramezanzadeh, K, Ranabhat, C, Rao, P, Rao, S, Rashedi, V, Rathi, P, Rawaf, D, Rawaf, S, Rawal, L, Rawassizadeh, R, Rawat, R, Razo, C, Redford, S, Reiner, R, Reitsma, M, Remuzzi, G, Renjith, V, Renzaho, A, Resnikoff, S, Rezaei, N, Rezapour, A, Rhinehart, P, Riahi, S, Ribeiro, D, Rickard, J, Rivera, J, Roberts, N, Rodriguez-Ramirez, S, Roever, L, Ronfani, L, Room, R, Roshandel, G, Roth, G, Rothenbacher, D, Rubagotti, E, Rwegerera, G, Sabour, S, Sachdev, P, Saddik, B, Sadeghi, E, Sadeghi, M, Saeedi, R, Saeedi Moghaddam, S, Safari, Y, Safi, S, Safiri, S, Sagar, R, Sahebkar, A, Sajadi, S, Salam, N, Salamati, P, Salem, H, Salem, M, Salimzadeh, H, Salman, O, Salomon, J, Samad, Z, Samadi Kafil, H, Sambala, E, Samy, A, Sanabria, J, Sanchez-Pimienta, T, Santomauro, D, Santos, I, Santos, J, Santric-Milicevic, M, Saraswathy, S, Sarmiento-Suarez, R, Sarrafzadegan, N, Sarveazad, A, Sathian, B, Sathish, T, Sattin, D, Saxena, S, Schaeffer, L, Schiavolin, S, Schlaich, M, Schmidt, M, Schutte, A, Schwebel, D, Schwendicke, F, Senbeta, A, Senthilkumaran, S, Sepanlou, S, Serdar, B, Serre, M, Shadid, J, Shafaat, O, Shahabi, S, Shaheen, A, Shaikh, M, Shalash, A, Shams-Beyranvand, M, Shamsizadeh, M, Sharafi, K, Sheikh, A, Sheikhtaheri, A, Shibuya, K, Shield, K, Shigematsu, M, Shin, J, Shin, M, Shiri, R, Shirkoohi, R, Shuval, K, Siabani, S, Sierpinski, R, Sigfusdottir, I, Sigurvinsdottir, R, Silva, J, Simpson, K, Singh, J, Singh, P, Skiadaresi, E, Skou, S, Skryabin, V, Smith, E, Soheili, A, Soltani, S, Soofi, M, Sorensen, R, Soriano, J, Sorrie, M, Soshnikov, S, Soyiri, I, Spencer, C, Spotin, A, Sreeramareddy, C, Srinivasan, V, Stanaway, J, Stein, C, Stein, D, Steiner, C, Stockfelt, L, Stokes, M, Straif, K, Stubbs, J, Sufiyan, M, Suleria, H, Suliankatchi Abdulkader, R, Sulo, G, Sultan, I, Tabares-Seisdedos, R, Tabb, K, Tabuchi, T, Taherkhani, A, Tajdini, M, Takahashi, K, Takala, J, Tamiru, A, Taveira, N, Tehrani-Banihashemi, A, Temsah, M, Tesema, G, Tessema, Z, Thurston, G, Titova, M, Tohidinik, H, Tonelli, M, Topor-Madry, R, Topouzis, F, Torre, A, Touvier, M, Tovani-Palone, M, Tran, B, Travillian, R, Tsatsakis, A, Tudor Car, L, Tyrovolas, S, Uddin, R, Umeokonkwo, C, Unnikrishnan, B, Upadhyay, E, Vacante, M, Valdez, P, van Donkelaar, A, Vasankari, T, Vasseghian, Y, Veisani, Y, Venketasubramanian, N, Violante, F, Vlassov, V, Vollset, S, Vos, T, Vukovic, R, Waheed, Y, Wallin, M, Wang, Y, Watson, A, Wei, J, Wei, M, Weintraub, R, Weiss, J, Werdecker, A, West, J, Westerman, R, Whisnant, J, Whiteford, H, Wiens, K, Wolfe, C, Wozniak, S, Wu, A, Wu, J, Wulf Hanson, S, Xu, G, Xu, R, Yadgir, S, Yahyazadeh Jabbari, S, Yamagishi, K, Yaminfirooz, M, Yano, Y, Yaya, S, Yazdi-Feyzabadi, V, Yeheyis, T, Yilgwan, C, Yilma, M, Yip, P, Yonemoto, N, Younis, M, Younker, T, Yousefi, B, Yousefi, Z, Yousefinezhadi, T, Yousuf, A, Yu, C, Yusefzadeh, H, Moghadam, T, Zamani, M, Zamanian, M, Zandian, H, Zastrozhin, M, Zhang, Y, Zhang, Z, Zhao, J, Zhao, X, Zhao, Y, Zheng, P, Zhou, M, Ziapour, A, Zimsen, S, Lim, S, Murray, C, GBD 2019 Risk Factors Collaborator, Violante FS, Biosciences, Department of Public Health, Clinicum, Department of Neurosciences, HUS Comprehensive Cancer Center, Environmental Sciences, Sub Foundations&PhilosophyofNaturSc begr, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Public Health, Bin Sayeed, M. S. B., Caetano Dos Santos, F. L., Camera, L. A., Elyazar, I. R. F., Ayalew Gebreslassie, A. A. A., Ginindza, T. G., Matin, B. K., Morgado-Da-Costa, J., Khaneghah, A. M., Mahesh, P. A., Toroudi, H. P., Syed, Z. Q., Salem, M. R., Skou, S. T., Tovani-Palone, M. R., Tudor Car, L. T., and Moghadam, T. Z.

Subjects
Male, Nutritional Sciences, Specific risk, Contaminación del Aire Interior, 030204 cardiovascular system & hematology, Socioeconomic Factor, systematic analysis, Global Health, Body Mass Index, Global Burden of Disease, Health Risk Behavior, Health Risk Behaviors, Disease studies, 0302 clinical medicine, Risk Factors, METABOLIC RISKS, 030212 general & internal medicine, 11 Medical and Health Sciences, Factores de Riesgo, 2. Zero hunger, education.field_of_study, Public health, Injuries, Public Health, Global Health, Social Medicine and Epidemiology, General Medicine, GBD, risck factors, attributable burden of disease, 3142 Public health care science, environmental and occupational health, 3. Good health, Relative risk, Environmental health, Health, Hypertension, Global Burden of Diseases, Injuries, Risk Factors, A990 Medicine and Dentistry not elsewhere classified, Female, Leading risk factors, Global Health Metrics, Cohort study, Human, medicine.medical_specialty, Substance-Related Disorders, Population, UNITED-STATES, Risk Assessment, DIET, ITC-HYBRID, 03 medical and health sciences, Life Expectancy, MORTALITY, DISABILITY, POLLUTION, CLUSTERS, SDG 3 - Good Health and Well-being, General & Internal Medicine, medicine, Humans, Global Burden of Disease Study, Risk factor, education, Global burden, business.industry, Risk Factor, Malnutrition, Klinisk medicin, Global Burden of Diseases, Environmental Exposure, medicine.disease, Enfermedades, purl.org/pe-repo/ocde/ford#3.02.00 [https], Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, Years of potential life lost, Socioeconomic Factors, Risk factors, Disease study, Hyperglycemia, ITC-ISI-JOURNAL-ARTICLE, NA, Clinical Medicine, business, RA
Abstract

Background Rigorous analysis of levels and trends in exposure to leading risk factors and quantification of their effect on human health are important to identify where public health is making progress and in which cases current efforts are inadequate. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a standardised and comprehensive assessment of the magnitude of risk factor exposure, relative risk, and attributable burden of disease. Methods GBD 2019 estimated attributable mortality, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 87 risk factors and combinations of risk factors, at the global level, regionally, and for 204 countries and territories. GBD uses a hierarchical list of risk factors so that specific risk factors (eg, sodium intake), and related aggregates (eg, diet quality), are both evaluated. This method has six analytical steps. (1) We included 560 risk-outcome pairs that met criteria for convincing or probable evidence on the basis of research studies. 12 risk-outcome pairs included in GBD 2017 no longer met inclusion criteria and 47 risk-outcome pairs for risks already included in GBD 2017 were added based on new evidence. (2) Relative risks were estimated as a function of exposure based on published systematic reviews, 81 systematic reviews done for GBD 2019, and meta-regression. (3) Levels of exposure in each age-sex-location-year included in the study were estimated based on all available data sources using spatiotemporal Gaussian process regression, DisMod-MR 2.1, a Bayesian meta-regression method, or alternative methods. (4) We determined, from published trials or cohort studies, the level of exposure associated with minimum risk, called the theoretical minimum risk exposure level. (5) Attributable deaths, YLLs, YLDs, and DALYs were computed by multiplying population attributable fractions (PAFs) by the relevant outcome quantity for each age-sex-location-year. (6) PAFs and attributable burden for combinations of risk factors were estimated taking into account mediation of different risk factors through other risk factors. Across all six analytical steps, 30 652 distinct data sources were used in the analysis. Uncertainty in each step of the analysis was propagated into the final estimates of attributable burden. Exposure levels for dichotomous, polytomous, and continuous risk factors were summarised with use of the summary exposure value to facilitate comparisons over time, across location, and across risks. Because the entire time series from 1990 to 2019 has been re-estimated with use of consistent data and methods, these results supersede previously published GBD estimates of attributable burden. Findings The largest declines in risk exposure from 2010 to 2019 were among a set of risks that are strongly linked to social and economic development, including household air pollution; unsafe water, sanitation, and handwashing; and child growth failure. Global declines also occurred for tobacco smoking and lead exposure. The largest increases in risk exposure were for ambient particulate matter pollution, drug use, high fasting plasma glucose, and high body-mass index. In 2019, the leading Level 2 risk factor globally for attributable deaths was high systolic blood pressure, which accounted for 10.8 million (95% uncertainty interval [UI] 9.51-12.1) deaths (19.2% [16.9-21.3] of all deaths in 2019), followed by tobacco (smoked, second-hand, and chewing), which accounted for 8.71 million (8.12-9.31) deaths (15.4% [14.6-16.2] of all deaths in 2019). The leading Level 2 risk factor for attributable DALYs globally in 2019 was child and maternal malnutrition, which largely affects health in the youngest age groups and accounted for 295 million (253-350) DALYs (11.6% [10.3-13.1] of all global DALYs that year). The risk factor burden varied considerably in 2019 between age groups and locations. Among children aged 0-9 years, the three leading detailed risk factors for attributable DALYs were all related to malnutrition. Iron deficiency was the leading risk factor for those aged 10-24 years, alcohol use for those aged 25-49 years, and high systolic blood pressure for those aged 50-74 years and 75 years and older. Interpretation Overall, the record for reducing exposure to harmful risks over the past three decades is poor. Success with reducing smoking and lead exposure through regulatory policy might point the way for a stronger role for public policy on other risks in addition to continued efforts to provide information on risk factor harm to the general public. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.

Published
2020

146. Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017

Author

Giulio Castelpietra, Feng Sha, Khalid A Altirkawi, Seyedeh Zahra Masoumi, Gebreamlak Gebremedhn Gebremeskel, Ahmad Daryani, Ibrahim Abdollahpour, Simon I. Hay, Deborah Carvalho Malta, Erin B Hamilton, Kate E. LeGrand, Nikolay Ivanovich Briko, Ana-Laura Manda, Aziz Eftekhari, Irfan Ullah, Seth Christopher Yaw Appiah, Zichen Liu, Maida Umar, Shaimaa I. El-Jaafary, Marina Pinheiro, Farhad Ghamari, Milad Mohammadoo-Khorasani, Rajaram Yadav, Syed Mohamed Aljunid, Ramesh Holla, Farzad Jalilian, Jacek Jerzy Jozwiak, Omar Mukhtar Salman, Bayew Kelkay, Tanuj Kanchan, Irina Filip, Michael R. Phillips, Hamid Reza Tohidinik, Demelash Abewa Elemineh, Reza Malekzadeh, Tomasz Miazgowski, Diana Silva, Samath D Dharmaratne, Eleonora Dubljanin, Fatemeh Zare, Jasvinder A. Singh, Hagazi Gebremedhin Kassaye, Nathaniel J Henry, Venkatesh Maled, Girikumar Kumaresh, Alireza Rafiei, Zhi-Jiang Zhang, Arielle Wilder Eagan, Merhawi Gebremedhin Tekle, Gholamreza Roshandel, Jeevan Pereira, Tinuke O Olagunju, Olatunde Aremu, Mohammad Zamani, Mu'awiyyah Babale Sufiyan, Lidia Morawska, Bayisa Abdissa Baye, Eduarda Fernandes, Feleke Mekonnen Demeke, Beriwan Abdulqadir Ali, Ibrahim A Khalil, Hafte Kahsay Kebede, Songhomitra Panda-Jonas, Yuichiro Yano, Haileab Fekadu Wolde, Antonio Maria Borzì, Delia Hendrie, Azeem Majeed, Vahid Rashedi, Mehran Shams-Beyranvand, Ilais Moreno Velásquez, Derrick A Bennett, Roba Khundkar, Mohammed Madadin, Biniyam Sahiledengle Geberemariyam, Parul Puri, Lidia Sanchez Riera, Yetunde O. John-Akinola, Jennifer Rickard, Saeed Shahabi, Tiffany K. Gill, Jemal Abdu Mohammed, Alessandra C. Goulart, Mohiuddin Ahsanul Kabir Chowdhury, Roya Safari-Faramani, Pawan Faris, Farhad Moradpour, Guilherme Borges, Sadia Bibi, Bartosz Miazgowski, Wubalem Fekadu, Rakhi Dandona, Ali Reza Soltanian, Alaa Badawi, Amir Hasanzadeh, Hassan Haghparast Bidgoli, Carlos A Castañeda-Orjuela, Morteza Arab-Zozani, Vinay Nangia, Gaurav Gupta, Farkhonde Salehi, Isabela M. Benseñor, Rekha Thapar, Yasser S. Amer, Naohiro Yonemoto, Ahmad Ghashghaee, Amanda J. Mason-Jones, Marcela Agudelo-Botero, Ashraf Nabhan, Saeed Safari, Lorainne Tudor Car, Ayman Grada, Stanislav S. Otstavnov, Keyvan Pakshir, Nefsu Awoke, Ahamarshan Jayaraman Nagarajan, Adnan Kisa, Ghasem Azarian, Yogesh Sabde, Soufiane Boufous, Fatemeh Khosravi Shadmani, Ketema Bizuwork Gebremedhin, Heather Orpana, Narayan Bahadur Mahotra, Tripti Khanna, Peter Nyasulu, Tommi Vasankari, Reza Mohammadpourhodki, Peter Njenga Keiyoro, Andrea Werdecker, Sanghamitra Pati, Rajan Nikbakhsh, Sorin Hostiuc, Prateek Rastogi, Xuefeng Liu, Manasi Kumar, Josip Car, Chuanhua Yu, Aziz Rezapour, Narayana Manjunatha, Ritesh G. Menezes, Michael K. Hole, Asadollah Gholamian, Pascual R. Valdez, Lorenzo Monasta, Amit Arora, Marek Majdan, Abraham Getachew Kelbore, Irini Chatziralli, Rafael Alves Guimarães, Mohammad Hassan Emamian, Filippo Ariani, Jeadran N. Malagón-Rojas, Jae Il Shin, Aziz Sheikh, Garumma Tolu Feyissa, Ahmed Abdelalim, Babak Moazen, Smita Pakhale, Bija Soleymani, Mehdi Hosseinzadeh, Young Eun Kim, Yunquan Zhang, Guoqing Hu, Yousef Khader, Suzanne Barker-Collo, Rizwan Suliankatchi Abdulkader, Mahdi Safdarian, Arash Sarveazad, Maria Magdalena Constantin, Dhirendra N Sinha, Alireza Ansari-Moghaddam, Khezar Hayat, Ferrán Catalá-López, Shaun Wen Huey Lee, Susan M Sawyer, Soosanna Kumary Chattu, Salman Rawaf, Seyed Sina Naghibi Irvani, Eun-Kee Park, Nauman Khalid, Marwa Rashad Salem, Duduzile Ndwandwe, Carl Abelardo T. Antonio, Morteza Abdullatif Khafaie, Borhan Mansouri, Faramarz Shaahmadi, Rovshan Khalilov, Milena M Santric Milicevic, Pankaj Singh, Ashish Badiye, Ai Koyanagi, Priya Rathi, Sanni Yaya, Ali Bijani, Shanshan Li, Onome Bright Oghenetega, Manoochehr Karami, Huong Lan Thi Nguyen, Soheil Hassanipour, Chukwudi A Nnaji, Obinna Onwujekwe, Swayam Prakash, Animut Tagele Tamiru, Ted R. Miller, Rebecca Ivers, Paulo A. Lotufo, Tomislav Mestrovic, Bhaskaran Unnikrishnan, Morteza Shamsizadeh, Abdollah Mohammadian-Hafshejani, Savita Lasrado, Amir Almasi-Hashiani, Burcu Kucuk Bicer, Samad Azari, Degena Bahrey Tadesse, Ziad El-Khatib, Ashish Pathak, Kebreab Paulos, Krittika Bhattacharyya, Animut Alebel, Rupak Desai, Rafael Tabarés-Seisdedos, Melkamu Merid Mengesha, Ayenew Kassie Tesema, Amir Radfar, Shane D. Morrison, Inga Dora Sigfusdottir, Hamid Yimam Hassen, Miloud Taki Eddine Aichour, Getnet Gedefaw, Hamed Zandian, Chi Linh Hoang, Seyedmojtaba Seyedmousavi, Desalegn Getnet Demsie, Fares Alahdab, Vafa Rahimi-Movaghar, Atalay Goshu Muluneh, Leeberk Raja Inbaraj, Muluken Bekele Sorrie, Olayinka Stephen Ilesanmi, Om P Kurmi, Subramanian Senthilkumaran, Ahmed Omar Bali, Wagaye Fentahun Chanie, Abadi Kahsu Gebre, Neha Chaudhary, Endang Indriasih, Neeraj Bedi, Ghobad Moradi, Pankaj Bhardwaj, Erkin M. Mirrakhimov, Daniel Y. Cho, Karen M. Tabb, Elham Ehsani-Chimeh, Kamarul Imran Musa, Mustafa Z. Younis, Meresa Berwo Mengesha, Veincent Christian Filipino Pepito, Jalal Arabloo, Mukhammad David Naimzada, Ingan Ukur Tarigan, Eleni Bagli, Prasanna Mithra, Masood Ali Shaikh, Siamak Sabour, Theo Vos, Van C. Lansingh, Cuong Tat Nguyen, Dennis Odai Laryea, Tuomo J. Meretoja, Ireneous N. Soyiri, Mariam Molokhia, Biruk Wogayehu Taddele, Robert C. Reiner, Till Bärnighausen, Walter Mendoza, Maciej Banach, Justin J. Lang, Maysaa El Sayed Zaki, Martha Híjar, Farahnaz Joukar, João Mauricio Castaldelli-Maia, R V Polibin, Sudha Jayaraman, S. Mohammad Sajadi, Cyrus Alinia, Nicholas L S Roberts, Aso Mohammad Darwesh, Akine Eshete Abosetugn, Mostafa Dianati Nasab, Samar Al-Hajj, Jagadish Rao Padubidri, Gebretsadkan Hintsa Tekulu, Kidanemaryam Berhe, Mehdi Mirzaei-Alavijeh, Hasan Yusefzadeh, Felix Akpojene Ogbo, Mahesh P A, Amir Manafi, Berhe Gebremichael, Carlos Miguel Rios González, Rahman Shiri, Girmay Teklay Weldesamuel, Pallab K. Maulik, Suresh Jungari, Ali Yadollahpour, Ali H. Mokdad, Alan D. Lopez, Masoud Behzadifar, Naho Morisaki, Nithin Kumar, Corina Benjet, Seyed-Mohammad Fereshtehnejad, Nikita Otstavnov, Vahid Yazdi-Feyzabadi, Serge Resnikoff, Inbal Salz, Muhammed Magdy Abd El Razek, Taweewat Wiangkham, Vinod C. Nayak, Niguse Meles Alema, G Anil Kumar, Mohammed Ibrahim Mohialdeen Gubari, Yoshan Moodley, Amir Kasaeian, Nitin Joseph, Mihajlo Jakovljevic, Farnam Mohebi, Navid Rabiee, Ali Kabir, Hossein Poustchi, Gebrekiros Gebremichael Meles, Asres Bedaso Tilahune, Yonatal Mesfin Tefera, Abdur Razzaque Sarker, Zoubida Zaidi, Hung Chak Ho, Andre M. N. Renzaho, Vahid Alipour, Sowmya J. Rao, Francesco Saverio Violante, Monika Sawhney, Daniel N. Kiirithio, Josephine W. Ngunjiri, Muhammad Aziz Rahman, Amin Soheili, Félix Carvalho, Hafiz Ansar Rasul Suleria, Saleh Salehi Zahabi, Benjamin B. Massenburg, Yun Jin Kim, Tomas Y Ferede, Saqib Ali, Yousef Mohammad, Getinet Ayano, Zabihollah Yousefi, Neeti Kapoor, Lope H Barrero, Hosni Salem, Sharareh Eskandarieh, Hai Quang Pham, Zahra Sadat Dibaji Forooshani, Erika Ota, Srikanta Banerjee, Babak Asghari, Arash Tehrani-Banihashemi, Dina Nur Anggraini Ningrum, Tauseef Ahmad, Giovanni Damiani, Hamidreza Komaki, Catalina Liliana Andrei, Karzan Abdulmuhsin Mohammad, Rosario Cárdenas, Richard C. Franklin, Naznin Hossain, Miriam Levi, Hayimro Edemealem Merie, Kavitha Ranganathan, Anwar Rafay, Srinivas Murthy, Engida Yisma, Mehdi Sayyah, Bruno Ramos Nascimento, Lalit Dandona, Ahmad Zarei, Kwaku Oppong Asante, Masoud Moradi, Luca Ronfani, Berhe Etsay Tesfay, Prabhat Lamichhane, Juan Sanabria, Brijesh Sathian, Daniel Kim, Yoosik Youm, Kewal Krishan, Maryam Zamanian, Christian Lycke Ellingsen, Dawit Habte Woldeyes, Josep Maria Haro, Gebre Teklemariam Demoz, Zahiruddin Quazi Syed, Hamid Sharifi, Dinh-Toi Chu, Vasily Vlassov, Emmanuel Wandera Okunga, Sanjay Zodpey, Birhanu Geta, Amaha Kahsay, Mark A. Stokes, Faris Lami, Yousef Fatahi, Moritz U. G. Kraemer, Anusha Ganapati Bhat, Naser Mohammad Gholi Mezerji, Samantha M. Colquhoun, Louisa Degenhardt, Ivo Rakovac, Saeed Amini, Sadaf G. Sepanlou, Claudio Alberto Dávila-Cervantes, Asmamaw Demis, Samer Hamidi, Teshome Abegaz Kamil, Muhammad Shahdaat Bin Sayeed, In-Hwan Oh, Afshin Derakhshani, Sojib Bin Zaman, Peter Memiah, Andreea Mirica, Dawit Zewdu Wondafrash, Sheikh Mohammed Shariful Islam, Oluwatosin Kuti, Shivakumar K.M. Kondlahalli, Soraya Seedat, Mohammad Ali Jahani, Bereket Duko Adema, Paul S. F. Yip, Gurudatta Naik, Ali Rajabpour-Sanati, Farid Najafi, Kebede Deribe, Ionut Negoi, Malke Asaad, Mehedi Hasan, Tim Driscoll, Reza Rawassizadeh, Vishnu Renjith, Taras Kavetskyy, Masoud Foroutan, Akbar Barzegar, Mohsen Bayati, Mohammad Ali Mansournia, Zohreh Arefi, Saif Ullah, Fatemeh Heydarpour, Joemer C. Maravilla, Masoud Moghadaszadeh, Rasmus Havmoeller, Pietro Ferrara, Vijay Kumar Chattu, Rohollah Kalhor, Amrit Banstola, Payman Salamati, Genet Melak Alamene, George C Patton, André Faro, Rushdia Ahmed, Era Upadhyay, Vivek Kumar, Mahmood Moosazadeh, Temesgen Gebeyehu Wondmeneh, Vladimir Andreevich Korshunov, Soraya Siabani, Shyam Sundar Budhathoki, Alexander C. Tsai, Suliman Alghnam, Irena Ilic, Tsegaye Lolaso Lenjebo, Andrew T Olagunju, Mohan Bairwa, Amy E. Peden, Catalin-Gabriel Smarandache, Ejaz Ahmad Khan, Spencer L. James, Ronan A Lyons, Seok Jun Yoon, Siavash Rahimi, Kathryn H. Jacobsen, Morenike Oluwatoyin Folayan, Zachary V Dingels, Florian Fischer, Joht Singh Chandan, Amir Abdoli, Takeshi Fukumoto, Tariku Tesfaye Bekuma, Efat Mohamadi, David C. Schwebel, Milena Ilic, Daniel Adane Endalew, Mahdi Sharif-Alhoseini, Jost B. Jonas, Mahtab Alikhani, Fariborz Mansour-Ghanaei, Bach Xuan Tran, Lal B. Rawal, Lyn March, Ester Cerin, Martin Amogre Ayanore, Morteza Naserbakht, Hamid Safarpour, Sangram Kishor Patel, Vera Marisa Costa, Ai-Min Wu, Raimundas Lunevicius, Suzanne Polinder, Mika Shigematsu, Bryan L. Sykes, Zeleke Aschalew Melketsedik, Nuworza Kugbey, M. Mofizul Islam, Atif Amin Baig, Ana Isabel Ribeiro, Joel M. Francis, Alexandra Brazinova, Nader Jahanmehr, Yuming Guo, Sonia Saxena, Nima Hafezi-Nejad, Khanh Bao Tran, Mansour Ghafourifard, Navid Manafi, Chris D Castle, Brian J. Hall, Ravi Prakash Jha, Joan B. Soriano, Rajendra Kadel, Beatriz Paulina Ayala Quintanilla, Oladimeji Adebayo, Arianna Maever L. Amit, Kerrie E. Doyle, Olalekan A. Uthman, Farshad Farzadfar, Janet L Leasher, Shafiu Mohammed, Paolo Lauriola, Tilahun Belete Mossie, Nihad A. Almasri, Fakher Rahim, Dillon O Sylte, Emma Smith, Palash Chandra Banik, Muktar Beshir Ahmed, Achala Upendra Jayatilleke, Arman Latifi, Carlo La Vecchia, Randah R. Hamadeh, G. K. Mini, Kenean Getaneh Tlaye, Dan J. Stein, Leila R Kalankesh, Abdelrahman Ibrahim Abushouk, Mikk Jürisson, Habte Belete, Atte Meretoja, Yasir Waheed, Fahad Alanezi, Hadi Hassankhani, Shai Linn, Anas M. Saad, Yong Yu, Aidin Abedi, Mohammad Rabiee, Jaya Prasad Tripathy, Jack T Fox, Abdallah M. Samy, Roman Topor-Madry, Michal Grivna, Adam Belay Wondmieneh, Narayanaswamy Venketasubramanian, Addisu Melese, Mohammad Khammarnia, Fatemeh Rajati, Arun Balachandran, Juanita A. Haagsma, Segun Emmanuel Ibitoye, Telma Zahirian Moghadam, Maseer Khan, Sezer Kisa, Basema Saddik, Ahad Bakhtiari, Maziar Moradi-Lakeh, Dimas Ria Angga Pribadi, Habibolah Khazaie, Ghulam Mustafa, Ata Rafiee, Benn Sartorius, HUS Comprehensive Cancer Center, Clinicum, University of Helsinki, Helsinki University Hospital Area, HUS Neurocenter, Public Health, Instituto de Saúde Pública da Universidade do Porto, James SL, Violante FS, Vos T., Sálfræðideild (HR), Department of Psychology (RU), Samfélagssvið (HR), School of Social Sciences (RU), Háskólinn í Reykjavík, Reykjavik University, James, S, Castle, C, Dingels, Z, Fox, J, Hamilton, E, Liu, Z, S Roberts, N, Sylte, D, Henry, N, Legrand, K, Abdelalim, A, Abdoli, A, Abdollahpour, I, Abdulkader, R, Abedi, A, Abosetugn, A, Abushouk, A, Adebayo, O, Agudelo-Botero, M, Ahmad, T, Ahmed, R, Ahmed, M, Eddine Aichour, M, Alahdab, F, Alamene, G, Alanezi, F, Alebel, A, Alema, N, Alghnam, S, Al-Hajj, S, Ali, B, Ali, S, Alikhani, M, Alinia, C, Alipour, V, Aljunid, S, Almasi-Hashiani, A, Almasri, N, Altirkawi, K, Abdeldayem Amer, Y, Amini, S, Loreche Amit, A, Andrei, C, Ansari-Moghaddam, A, T Antonio, C, Yaw Appiah, S, Arabloo, J, Arab-Zozani, M, Arefi, Z, Aremu, O, Ariani, F, Arora, A, Asaad, M, Asghari, B, Awoke, N, Ayala Quintanilla, B, Ayano, G, Ayanore, M, Azari, S, Azarian, G, Badawi, A, Badiye, A, Bagli, E, Baig, A, Bairwa, M, Bakhtiari, A, Balachandran, A, Banach, M, Banerjee, S, Banik, P, Banstola, A, Barker-Collo, S, Barnighausen, T, Barrero, L, Barzegar, A, Bayati, M, Baye, B, Bedi, N, Behzadifar, M, Bekuma, T, Belete, H, Benjet, C, Bennett, D, Bensenor, I, Berhe, K, Bhardwaj, P, Bhat, A, Bhattacharyya, K, Bibi, S, Bijani, A, Bin Sayeed, M, Borges, G, Borzi, A, Boufous, S, Brazinova, A, Briko, N, Budhathoki, S, Car, J, Cardenas, R, Carvalho, F, Castaldelli-Maia, J, Castaneda-Orjuela, C, Castelpietra, G, Catala-Lopez, F, Cerin, E, Chandan, J, Chanie, W, Chattu, S, Chattu, V, Chatziralli, I, Chaudhary, N, Cho, D, Kabir Chowdhury, M, Chu, D, Colquhoun, S, Constantin, M, Costa, V, Damiani, G, Daryani, A, Davila-Cervantes, C, Demeke, F, Demis, A, Demoz, G, Demsie, D, Derakhshani, A, Deribe, K, Desai, R, Nasab, M, Da Silva, D, Dibaji Forooshani, Z, Doyle, K, Driscoll, T, Dubljanin, E, Adema, B, Eagan, A, Eftekhari, A, Ehsani-Chimeh, E, Sayed Zaki, M, Elemineh, D, El-Jaafary, S, El-Khatib, Z, Ellingsen, C, Emamian, M, Endalew, D, Eskandarieh, S, Faris, P, Faro, A, Farzadfar, F, Fatahi, Y, Fekadu, W, Ferede, T, Fereshtehnejad, S, Fernandes, E, Ferrara, P, Feyissa, G, Filip, I, Fischer, F, Folayan, M, Foroutan, M, Francis, J, Franklin, R, Fukumoto, T, Geberemariyam, B, Gebre, A, Gebremedhin, K, Gebremeskel, G, Gebremichael, B, Gedefaw, G, Geta, B, Ghafourifard, M, Ghamari, F, Ghashghaee, A, Gholamian, A, Gill, T, Goulart, A, Grada, A, Grivna, M, Mohialdeen Gubari, M, Guimaraes, R, Guo, Y, Gupta, G, Haagsma, J, Hafezi-Nejad, N, Bidgoli, H, Hall, B, Hamadeh, R, Hamidi, S, Haro, J, Hasan, M, Hasanzadeh, A, Hassanipour, S, Hassankhani, H, Hassen, H, Havmoeller, R, Hayat, K, Hendrie, D, Heydarpour, F, Hijar, M, Ho, H, Hoang, C, Hole, M, Holla, R, Hossain, N, Hosseinzadeh, M, Hostiuc, S, Hu, G, Ibitoye, S, Ilesanmi, O, Ilic, I, Ilic, M, Inbaraj, L, Indriasih, E, Naghibi Irvani, S, Shariful Islam, S, Islam, M, Ivers, R, Jacobsen, K, Jahani, M, Jahanmehr, N, Jakovljevic, M, Jalilian, F, Jayaraman, S, Jayatilleke, A, Jha, R, John-Akinola, Y, Jonas, J, Joseph, N, Joukar, F, Jozwiak, J, Jungari, S, Jurisson, M, Kabir, A, Kadel, R, Kahsay, A, Kalankesh, L, Kalhor, R, Kamil, T, Kanchan, T, Kapoor, N, Karami, M, Kasaeian, A, Kassaye, H, Kavetskyy, T, Kebede, H, Keiyoro, P, Kelbore, A, Kelkay, B, Khader, Y, Khafaie, M, Khalid, N, Khalil, I, Khalilov, R, Khammarnia, M, Khan, E, Khan, M, Khanna, T, Khazaie, H, Shadmani, F, Khundkar, R, Kiirithio, D, Kim, Y, Kim, D, Kisa, A, Kisa, S, Komaki, H, M Kondlahalli, S, Korshunov, V, Koyanagi, A, G Kraemer, M, Krishan, K, Bicer, B, Kugbey, N, Kumar, V, Kumar, N, Kumar, G, Kumar, M, Kumaresh, G, Kurmi, O, Kuti, O, Vecchia, C, Lami, F, Lamichhane, P, Lang, J, Lansingh, V, Laryea, D, Lasrado, S, Latifi, A, Lauriola, P, Leasher, J, Huey Lee, S, Lenjebo, T, Levi, M, Li, S, Linn, S, Liu, X, Lopez, A, Lotufo, P, Lunevicius, R, Lyons, R, Madadin, M, El Razek, M, Mahotra, N, Majdan, M, Majeed, A, Malagon-Rojas, J, Maled, V, Malekzadeh, R, Malta, D, Manafi, N, Manafi, A, Manda, A, Manjunatha, N, Mansour-Ghanaei, F, Mansouri, B, Mansournia, M, Maravilla, J, March, L, Mason-Jones, A, Masoumi, S, Massenburg, B, Maulik, P, Meles, G, Melese, A, Melketsedik, Z, N Memiah, P, Mendoza, W, Menezes, R, Mengesha, M, Meretoja, T, Meretoja, A, Merie, H, Mestrovic, T, Miazgowski, B, Miazgowski, T, Miller, T, Mini, G, Mirica, A, Mirrakhimov, E, Mirzaei-Alavijeh, M, Mithra, P, Moazen, B, Moghadaszadeh, M, Mohamadi, E, Mohammad, Y, Mohammad, K, Darwesh, A, Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammadpourhodki, R, Mohammed, S, Mohammed, J, Mohebi, F, Molokhia, M, Monasta, L, Moodley, Y, Moosazadeh, M, Moradi, M, Moradi, G, Moradi-Lakeh, M, Moradpour, F, Morawska, L, Velasquez, I, Morisaki, N, Morrison, S, Mossie, T, Muluneh, A, Murthy, S, Musa, K, Mustafa, G, Nabhan, A, Nagarajan, A, Naik, G, Naimzada, M, Najafi, F, Nangia, V, Nascimento, B, Naserbakht, M, Nayak, V, Ndwandwe, D, Negoi, I, Ngunjiri, J, Nguyen, C, Thi Nguyen, H, Nikbakhsh, R, Anggraini Ningrum, D, Nnaji, C, Nyasulu, P, Ogbo, F, Oghenetega, O, Oh, I, Okunga, E, Olagunju, A, Olagunju, T, Bali, A, Onwujekwe, O, Asante, K, Orpana, H, Ota, E, Otstavnov, N, Otstavnov, S, Mahesh, P, Padubidri, J, Pakhale, S, Pakshir, K, Panda-Jonas, S, Park, E, Patel, S, Pathak, A, Pati, S, Patton, G, Paulos, K, Peden, A, Filipino Pepito, V, Pereira, J, Pham, H, Phillips, M, Pinheiro, M, Polibin, R, Polinder, S, Poustchi, H, Prakash, S, Angga Pribadi, D, Puri, P, Syed, Z, Rabiee, M, Rabiee, N, Radfar, A, Rafay, A, Rafiee, A, Rafiei, A, Rahim, F, Rahimi, S, Rahimi-Movaghar, V, Rahman, M, Rajabpour-Sanati, A, Rajati, F, Rakovac, I, Ranganathan, K, Rao, S, Rashedi, V, Rastogi, P, Rathi, P, Rawaf, S, Rawal, L, Rawassizadeh, R, Renjith, V, N Renzaho, A, Resnikoff, S, Rezapour, A, Ribeiro, A, Rickard, J, Rios Gonzalez, C, Ronfani, L, Roshandel, G, Saad, A, Sabde, Y, Sabour, S, Saddik, B, Safari, S, Safari-Faramani, R, Safarpour, H, Safdarian, M, Sajadi, S, Salamati, P, Salehi, F, Zahabi, S, Rashad Salem, M, Salem, H, Salman, O, Salz, I, Samy, A, Sanabria, J, Riera, L, Santric Milicevic, M, Sarker, A, Sarveazad, A, Sathian, B, Sawhney, M, Sawyer, S, Saxena, S, Sayyah, M, Schwebel, D, Seedat, S, Senthilkumaran, S, Sepanlou, S, Seyedmousavi, S, Sha, F, Shaahmadi, F, Shahabi, S, Shaikh, M, Shams-Beyranvand, M, Shamsizadeh, M, Sharif-Alhoseini, M, Sharifi, H, Sheikh, A, Shigematsu, M, Shin, J, Shiri, R, Siabani, S, Sigfusdottir, I, Singh, P, Singh, J, Sinha, D, Smarandache, C, R Smith, E, Soheili, A, Soleymani, B, Soltanian, A, Soriano, J, Sorrie, M, Soyiri, I, Stein, D, Stokes, M, Sufiyan, M, Rasul Suleria, H, Sykes, B, Tabares-Seisdedos, R, Tabb, K, Taddele, B, Tadesse, D, Tamiru, A, Tarigan, I, Tefera, Y, Tehrani-Banihashemi, A, Tekle, M, Tekulu, G, Tesema, A, Tesfay, B, Thapar, R, Tilahune, A, Tlaye, K, Tohidinik, H, Topor-Madry, R, Tran, B, Tran, K, Tripathy, J, Tsai, A, Car, L, Ullah, S, Ullah, I, Umar, M, Unnikrishnan, B, Upadhyay, E, Uthman, O, Valdez, P, Vasankari, T, Venketasubramanian, N, Violante, F, Vlassov, V, Waheed, Y, Weldesamuel, G, Werdecker, A, Wiangkham, T, Wolde, H, Woldeyes, D, Wondafrash, D, Wondmeneh, T, Wondmieneh, A, Wu, A, Yadav, R, Yadollahpour, A, Yano, Y, Yaya, S, Yazdi-Feyzabadi, V, Yip, P, Yisma, E, Yonemoto, N, Yoon, S, Youm, Y, Younis, M, Yousefi, Z, Yu, Y, Yu, C, Yusefzadeh, H, Moghadam, T, Zaidi, Z, Zaman, S, Zamani, M, Zamanian, M, Zandian, H, Zarei, A, Zare, F, Zhang, Z, Zhang, Y, Zodpey, S, Dandona, L, Dandona, R, Degenhardt, L, Dharmaratne, S, Hay, S, Mokdad, A, Reiner Jr, R, Sartorius, B, Vos, T, James, S. L., Castle, C. D., Dingels, Z. V., Fox, J. T., Hamilton, E. B., Liu, Z., Roberts, N. L. S., Sylte, D. O., Henry, N. J., Legrand, K. E., Abdelalim, A., Abdoli, A., Abdollahpour, I., Abdulkader, R. S., Abedi, A., Abosetugn, A. E., Abushouk, A. I., Adebayo, O. M., Agudelo-Botero, M., Ahmad, T., Ahmed, R., Ahmed, M. B., Aichour, M. T. E., Alahdab, F., Alamene, G. M., Alanezi, F. M., Alebel, A., Alema, N. M., Alghnam, S. A., Al-Hajj, S., Ali, B. A., Ali, S., Alikhani, M., Alinia, C., Alipour, V., Aljunid, S. M., Almasi-Hashiani, A., Almasri, N. A., Altirkawi, K., Amer, Y. S. A., Amini, S., Amit, A. M. L., Andrei, C. L., Ansari-Moghaddam, A., Antonio, C. A. T., Appiah, S. C. Y., Arabloo, J., Arab-Zozani, M., Arefi, Z., Aremu, O., Ariani, F., Arora, A., Asaad, M., Asghari, B., Awoke, N., Quintanilla, B. P. A., Ayano, G., Ayanore, M. A., Azari, S., Azarian, G., Badawi, A., Badiye, A. D., Bagli, E., Baig, A. A., Bairwa, M., Bakhtiari, A., Balachandran, A., Banach, M., Banerjee, S. K., Banik, P. C., Banstola, A., Barker-Collo, S. L., Barnighausen, T. W., Barrero, L. H., Barzegar, A., Bayati, M., Baye, B. A., Bedi, N., Behzadifar, M., Bekuma, T. T., Belete, H., Benjet, C., Bennett, D. A., Bensenor, I. M., Berhe, K., Bhardwaj, P., Bhat, A. G., Bhattacharyya, K., Bibi, S., Bijani, A., Sayeed, M. S. B., Borges, G., Borzi, A. M., Boufous, S., Brazinova, A., Briko, N. I., Budhathoki, S. S., Car, J., Cardenas, R., Carvalho, F., Castaldelli-Maia, J. M., Castaneda-Orjuela, C. A., Castelpietra, G., Catala-Lopez, F., Cerin, E., Chandan, J. S., Chanie, W. F., Chattu, S. K., Chattu, V. K., Chatziralli, I., Chaudhary, N., Cho, D. Y., Chowdhury, M. A. K., Chu, D. -T., Colquhoun, S. M., Constantin, M. -M., Costa, V. M., Damiani, G., Daryani, A., Davila-Cervantes, C. A., Demeke, F. M., Demis, A. B., Demoz, G. T., Demsie, D. G., Derakhshani, A., Deribe, K., Desai, R., Nasab, M. D., Dias da Silva, D., Forooshani, Z. S. D., Doyle, K. E., Driscoll, T. R., Dubljanin, E., Adema, B. D., Eagan, A. W., Eftekhari, A., Ehsani-Chimeh, E., El Sayed Zaki, M., Elemineh, D. A., El-Jaafary, S. I., El-Khatib, Z., Ellingsen, C. L., Emamian, M. H., Endalew, D. A., Eskandarieh, S., Faris, P. S., Faro, A., Farzadfar, F., Fatahi, Y., Fekadu, W., Ferede, T. Y., Fereshtehnejad, S. -M., Fernandes, E., Ferrara, P., Feyissa, G. T., Filip, I., Fischer, F., Folayan, M. O., Foroutan, M., Francis, J. M., Franklin, R. C., Fukumoto, T., Geberemariyam, B. S., Gebre, A. K., Gebremedhin, K. B., Gebremeskel, G. G., Gebremichael, B., Gedefaw, G. A., Geta, B., Ghafourifard, M., Ghamari, F., Ghashghaee, A., Gholamian, A., Gill, T. K., Goulart, A. C., Grada, A., Grivna, M., Gubari, M. I. M., Guimaraes, R. A., Guo, Y., Gupta, G., Haagsma, J. A., Hafezi-Nejad, N., Bidgoli, H. H., Hall, B. J., Hamadeh, R. R., Hamidi, S., Haro, J. M., Hasan, M. M., Hasanzadeh, A., Hassanipour, S., Hassankhani, H., Hassen, H. Y., Havmoeller, R., Hayat, K., Hendrie, D., Heydarpour, F., Hijar, M., Ho, H. C., Hoang, C. L., Hole, M. K., Holla, R., Hossain, N., Hosseinzadeh, M., Hostiuc, S., Hu, G., Ibitoye, S. E., Ilesanmi, O. S., Ilic, I., Ilic, M. D., Inbaraj, L. R., Indriasih, E., Irvani, S. S. N., Islam, S. M. S., Mofizul Islam, M., Ivers, R. Q., Jacobsen, K. H., Jahani, M. A., Jahanmehr, N., Jakovljevic, M., Jalilian, F., Jayaraman, S., Jayatilleke, A. U., Jha, R. P., John-Akinola, Y. O., Jonas, J. B., Joseph, N., Joukar, F., Jozwiak, J. J., Jungari, S. B., Jurisson, M., Kabir, A., Kadel, R., Kahsay, A., Kalankesh, L. R., Kalhor, R., Kamil, T. A., Kanchan, T., Kapoor, N., Karami, M., Kasaeian, A., Kassaye, H. G., Kavetskyy, T., Kebede, H. K., Keiyoro, P. N., Kelbore, A. G., Kelkay, B., Khader, Y. S., Khafaie, M. A., Khalid, N., Khalil, I. A., Khalilov, R., Khammarnia, M., Khan, E. A., Khan, M., Khanna, T., Khazaie, H., Shadmani, F. K., Khundkar, R., Kiirithio, D. N., Kim, Y. -E., Kim, D., Kim, Y. J., Kisa, A., Kisa, S., Komaki, H., Kondlahalli, S. K. M., Korshunov, V. A., Koyanagi, A., Kraemer, M. U. G., Krishan, K., Bicer, B. K., Kugbey, N., Kumar, V., Kumar, N., Anil Kumar, G., Kumar, M., Kumaresh, G., Kurmi, O. P., Kuti, O., Vecchia, C. L., Lami, F. H., Lamichhane, P., Lang, J. J., Lansingh, V. C., Laryea, D. O., Lasrado, S., Latifi, A., Lauriola, P., Leasher, J. L., Lee, S. W. H., Lenjebo, T. L., Levi, M., Li, S., Linn, S., Liu, X., Lopez, A. D., Lotufo, P. A., Lunevicius, R., Lyons, R. A., Madadin, M., El Razek, M. M. A., Mahotra, N. B., Majdan, M., Majeed, A., Malagon-Rojas, J. N., Maled, V., Malekzadeh, R., Malta, D. C., Manafi, N., Manafi, A., Manda, A. -L., Manjunatha, N., Mansour-Ghanaei, F., Mansouri, B., Mansournia, M. A., Maravilla, J. C., March, L. M., Mason-Jones, A. J., Masoumi, S. Z., Massenburg, B. B., Maulik, P. K., Meles, G. G., Melese, A., Melketsedik, Z. A., Memiah, P. T. N., Mendoza, W., Menezes, R. G., Mengesha, M. B., Mengesha, M. M., Meretoja, T. J., Meretoja, A., Merie, H. E., Mestrovic, T., Miazgowski, B., Miazgowski, T., Miller, T. R., Mini, G. K., Mirica, A., Mirrakhimov, E. M., Mirzaei-Alavijeh, M., Mithra, P., Moazen, B., Moghadaszadeh, M., Mohamadi, E., Mohammad, Y., Mohammad, K. A., Darwesh, A. M., Mezerji, N. M. G., Mohammadian-Hafshejani, A., Mohammadoo-Khorasani, M., Mohammadpourhodki, R., Mohammed, S., Mohammed, J. A., Mohebi, F., Molokhia, M., Monasta, L., Moodley, Y., Moosazadeh, M., Moradi, M., Moradi, G., Moradi-Lakeh, M., Moradpour, F., Morawska, L., Velasquez, I. M., Morisaki, N., Morrison, S. D., Mossie, T. B., Muluneh, A. G., Murthy, S., Musa, K. I., Mustafa, G., Nabhan, A. F., Nagarajan, A. J., Naik, G., Naimzada, M. D., Najafi, F., Nangia, V., Nascimento, B. R., Naserbakht, M., Nayak, V., Ndwandwe, D. E., Negoi, I., Ngunjiri, J. W., Nguyen, C. T., Nguyen, H. L. T., Nikbakhsh, R., Ningrum, D. N. A., Nnaji, C. A., Nyasulu, P. S., Ogbo, F. A., Oghenetega, O. B., Oh, I. -H., Okunga, E. W., Olagunju, A. T., Olagunju, T. O., Bali, A. O., Onwujekwe, O. E., Asante, K. O., Orpana, H. M., Ota, E., Otstavnov, N., Otstavnov, S. S., Mahesh, P. A., Padubidri, J. R., Pakhale, S., Pakshir, K., Panda-Jonas, S., Park, E. -K., Patel, S. K., Pathak, A., Pati, S., Patton, G. C., Paulos, K., Peden, A. E., Pepito, V. C. F., Pereira, J., Pham, H. Q., Phillips, M. R., Pinheiro, M., Polibin, R. V., Polinder, S., Poustchi, H., Prakash, S., Pribadi, D. R. A., Puri, P., Syed, Z. Q., Rabiee, M., Rabiee, N., Radfar, A., Rafay, A., Rafiee, A., Rafiei, A., Rahim, F., Rahimi, S., Rahimi-Movaghar, V., Rahman, M. A., Rajabpour-Sanati, A., Rajati, F., Rakovac, I., Ranganathan, K., Rao, S. J., Rashedi, V., Rastogi, P., Rathi, P., Rawaf, S., Rawal, L., Rawassizadeh, R., Renjith, V., Renzaho, A. M. N., Resnikoff, S., Rezapour, A., Ribeiro, A. I., Rickard, J., Gonzalez, C. M. R., Ronfani, L., Roshandel, G., Saad, A. M., Sabde, Y. D., Sabour, S., Saddik, B., Safari, S., Safari-Faramani, R., Safarpour, H., Safdarian, M., Mohammad Sajadi, S., Salamati, P., Salehi, F., Zahabi, S. S., Rashad Salem, M. R., Salem, H., Salman, O., Salz, I., Samy, A. M., Sanabria, J., Riera, L. S., Santric Milicevic, M. M., Sarker, A. R., Sarveazad, A., Sathian, B., Sawhney, M., Sawyer, S. M., Saxena, S., Sayyah, M., Schwebel, D. C., Seedat, S., Senthilkumaran, S., Sepanlou, S. G., Seyedmousavi, S., Sha, F., Shaahmadi, F., Shahabi, S., Shaikh, M. A., Shams-Beyranvand, M., Shamsizadeh, M., Sharif-Alhoseini, M., Sharifi, H., Sheikh, A., Shigematsu, M., Shin, J. I., Shiri, R., Siabani, S., Sigfusdottir, I. D., Singh, P. K., Singh, J. A., Sinha, D. N., Smarandache, C. -G., Smith, E. U. R., Soheili, A., Soleymani, B., Soltanian, A. R., Soriano, J. B., Sorrie, M. B., Soyiri, I. N., Stein, D. J., Stokes, M. A., Mu'Awiyyah, B. S., Suleria, H. A. R., Sykes, B. L., Tabares-Seisdedos, R., Tabb, K. M., Taddele, B. W., Tadesse, D. B., Tamiru, A. T., Tarigan, I. U., Tefera, Y. M., Tehrani-Banihashemi, A., Tekle, M. G., Tekulu, G. H., Tesema, A. K., Tesfay, B. E., Thapar, R., Tilahune, A. B., Tlaye, K. G., Tohidinik, H. R., Topor-Madry, R., Tran, B. X., Tran, K. B., Tripathy, J. P., Tsai, A. C., Car, L. T., Ullah, S., Ullah, I., Umar, M., Unnikrishnan, B., Upadhyay, E., Uthman, O. A., Valdez, P. R., Vasankari, T. J., Venketasubramanian, N., Violante, F. S., Vlassov, V., Waheed, Y., Weldesamuel, G. T., Werdecker, A., Wiangkham, T., Wolde, H. F., Woldeyes, D. H., Wondafrash, D. Z., Wondmeneh, T. G., Wondmieneh, A. B., Wu, A. -M., Yadav, R., Yadollahpour, A., Yano, Y., Yaya, S., Yazdi-Feyzabadi, V., Yip, P., Yisma, E., Yonemoto, N., Yoon, S. -J., Youm, Y., Younis, M. Z., Yousefi, Z., Yu, Y., Yu, C., Yusefzadeh, H., Moghadam, T. Z., Zaidi, Z., Zaman, S. B., Zamani, M., Zamanian, M., Zandian, H., Zarei, A., Zare, F., Zhang, Z. -J., Zhang, Y., Zodpey, S., Dandona, L., Dandona, R., Degenhardt, L., Dharmaratne, S. D., Hay, S. I., Mokdad, A. H., Reiner, R. C., Sartorius, B., Vos, T., James, Spencer L, Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Adema, Bereket Duko, Yisma, Engida, and Vos, Theo

Subjects
Dánarmein, Fötlun, Dánartíðni, Lífslíkur, Life expectancy, 1106 Human Movement and Sports Sciences, burden of disease, Global Health, Global Burden of Disease, 0302 clinical medicine, Quality-Adjusted Life Year, Global health, Medicine, LIFE EXPECTANCY, 030212 general & internal medicine, POPULATION, Cause of death, Original Research, RISK, education.field_of_study, Global disease burdens, Injuries, Sjúkdómar, Incidence (epidemiology), Incidence, Population health, Burden of disease, Global, global, 3142 Public health care science, environmental and occupational health, 3. Good health, Descriptive epidemiology, Lýðheilsa, Quality-Adjusted Life Years, Public Health, TERRITORIES, descriptive epidemiology, Human, Population, 195 COUNTRIES, Humans, Life Expectancy, Morbidity, Wounds and Injuries, 1117 Public Health and Health Services, 03 medical and health sciences, AGE, SYSTEMATIC ANALYSIS, Mortality, education, Disability, SEX-SPECIFIC MORTALITY, business.industry, Faraldsfræði, DISABILITY, Public Health, Environmental and Occupational Health, Quality-adjusted life year, Years of potential life lost, Áverkar, 1701 Psychology, Human medicine, business, 030217 neurology & neurosurgery, Demography
Abstract

Publisher's version (útgefin grein), Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care., Bill and Melinda Gates Foundation OPP1152504, "Peer Reviewed"

Published
2020

147. Acne Keloidalis Nuchae and the Metabolic Syndrome: A Population-Based Study

Author

Khalaf, Kridin, Arieh, Solomon, Dana, Tzur-Bitan, Giovanni, Damiani, Doron, Comaneshter, and Arnon D, Cohen

Subjects
Adult, Aged, 80 and over, Male, Metabolic Syndrome, Adolescent, Acne Keloid, Comorbidity, Middle Aged, Young Adult, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Child, Preschool, Hypertension, Prevalence, Humans, Female, Obesity, Israel, Child, Aged, Retrospective Studies
Abstract

The association between acne keloidalis nuchae (AKN) and the metabolic syndrome (MS) has been reported anecdotally. However, it is yet to be investigated in the setting of controlled studies, leaving this topic inconclusive in the current literature.The aim was to estimate the association between AKN and the MS and its components, utilizing one of the largest cohorts of patients with AKN.A retrospective, population-based, cross-sectional study was performed between 2005 and 2018. We utilized the database of Clalit Health Services, the largest public healthcare provider organization in Israel. The current study encompassed data collected from general community clinics, primary care, and referral centers, as well as from ambulatory and hospital care.A total of 2677 patients with AKN and 13,190 controls were included. The prevalence of the MS was greater in patients with AKN than in control subjects (16.1% vs. 6.6%, respectively; odds ratio [OR] 2.72; 95% confidence interval [CI] 2.40-3.08; P 0.001). Obesity demonstrated the strongest association with AKN (OR 3.00; 95% CI 2.75-3.28), followed by type 2 diabetes mellitus (OR 2.47; 95% CI 2.20-2.77), hypertension (OR 1.82; 95% CI 1.63-2.05), and dyslipidemia (OR 1.60; 95% CI 1.46-1.75). Estimates were not altered significantly after controlling for putative confounding factors.A strong association was observed between AKN and the MS on the one hand, and with every one of its four components on the other. Physicians treating patients with AKN should be aware of this possible comorbidity. Patients with AKN should be carefully assessed for comorbid metabolic disorders.

Published
2020

148. Efficacy and tolerability of bevacizumab in patients with severe Covid -19

Author

Yihai Cao, Yuan Zhang, Attila Kovacs, Margherita Canesi, Dexin Yu, Wenhai Sui, Jie Wei, Hao Wang, Alberto Fumagalli, Gianmarco Aondio, Jiaojiao Pang, Shuo Wu, Yu Li, Xiang Ji, Giuseppe Valmadre, Bailu Wang, Ming Lu, Miriam Revera, Feng Xu, Yuguo Chen, Ying Zhang, Giovanni Damiani, Jun Chen, and Yuan Bian

Subjects
Coronavirus disease 2019 (COVID-19), Bevacizumab, Respiratory rate, business.industry, Oxygenation, medicine.disease, Pneumonia, Tolerability, Anesthesia, medicine, business, Pathological, medicine.drug, Oxygen saturation (medicine)
Abstract

On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate ≥ 30 times/min, oxygen saturation ≤ 93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and ≤ 300 mmHg, and diffuse pneumonia confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], ppTRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT04275414, URL: https://clinicaltrials.gov/ct2/show/NCT04275414.

Published
2020

149. Estimating the Odds of Ulcerative Colitis-Associated Pyoderma Gangrenosum: A Population-Based Case-Control Study

Author

Khalaf Kridin, Giovanni Damiani, Dana Tzur Bitan, Arnon D. Cohen, and Ralf Ludwig

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Time Factors, Population, Dermatology, Logistic regression, Odds, Risk Factors, Internal medicine, medicine, Odds Ratio, Prevalence, Humans, education, Aged, education.field_of_study, business.industry, Case-control study, Middle Aged, medicine.disease, Comorbidity, Ulcerative colitis, Pyoderma Gangrenosum, Logistic Models, Case-Control Studies, Colitis, Ulcerative, Female, business, Pyoderma gangrenosum
Abstract

Background: Ulcerative colitis (UC) is a well-known underlying comorbidity of pyoderma gangrenosum (PG). However, the risk conferred by UC for the subsequent development of PG is yet to be elucidated. We aimed to estimate the magnitude of the association between UC and the subsequent occurrence of PG, which would enable us to assess the odds of PG developing in individuals with a history of UC. Methods: A population-based case-control study was conducted to compare PG patients (n = 302) and age-, sex- and ethnicity-matched control subjects (n = 1,497) regarding the presence of UC. Logistic regression models were utilized for univariate and multivariate analyses. Results: The prevalence of preexisting UC was greater in patients with PG than in controls (7.3 vs. 0.5%; p < 0.001). A 15-fold increase in the odds of PG in individuals with preexisting UC was observed (OR 14.62, 95% CI 6.45–33.18). The greatest risk of developing PG occurred in the first years following the diagnosis of UC (OR 35.50, 95% CI 4.35–289.60), and decreased thereafter to 10.03 (95% CI 1.83–55.03), 6.69 (95% CI 1.49–30.02), and 10.03 (95% CI 1.83–55.03) at 1–5, 5–10, and 10–15 years after the diagnosis of UC, respectively. This association retained its statistical significance following the adjustment for confounding factors (adjusted OR 10.78, 95% CI 4.55–25.52). Patients with both PG and UC were younger and had a lower prevalence of smoking than the remaining patients with PG. Conclusions: UC increases the odds of developing PG by 15-fold, with the highest probability of developing PG occurring within the first year after the diagnosis of UC. Patients with UC may be advised to avoid additional precipitating factors for the development of PG.

Published
2020

150. Phototherapeutic approach to dermatology patients during the 2019 coronavirus pandemic: real‐life data from the Italian red zone

Author

Pasquale Frascione, Giovanni Damiani, Alessia Pacifico, Marco Ardigò, and Aldo Morrone

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Hospitalized patients, viruses, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Dermatology, Hair Removal, medicine.disease_cause, Virus, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pandemic, Research Letter, medicine, Humans, Pandemics, Coronavirus, business.industry, COVID-19, Phototherapy, Real life data, Research Letters, Italy, Coronavirus Infections, business
Abstract

Since the novel Coronavirus 2019, also known as COVID‐19 or SARS CoV‐2, crossed the Chinese borders and became pandemic, Italy has rapidly become the country with the highest number of patient deaths as well as confirmed and/or hospitalized patients, after China [1‐2]. On March 12th Italy was declared a red‐zone and special protocols were enacted to limit the spread of the virus. Although COVID‐19 does not have epidermotropism, cutaneous manifestations in Cov‐19 positive patients have been reported [3] and departments of dermatology are considered at high risk [4] and were ordered to admit only patients needing urgent treatments or undergoing chronic immunosuppressive therapy in order to minimize nosocomial virus spread.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results